WO1996013262A1 - Muscarine antagonists - Google Patents

Muscarine antagonists Download PDF

Info

Publication number
WO1996013262A1
WO1996013262A1 PCT/US1995/013710 US9513710W WO9613262A1 WO 1996013262 A1 WO1996013262 A1 WO 1996013262A1 US 9513710 W US9513710 W US 9513710W WO 9613262 A1 WO9613262 A1 WO 9613262A1
Authority
WO
WIPO (PCT)
Prior art keywords
piperidin
dihydro
benzimidazol
pyrimidinecarbonyl
ethyl
Prior art date
Application number
PCT/US1995/013710
Other languages
French (fr)
Inventor
Wayne J. Thompson
Michael F. Sugrue
Richard W. Ransom
Pierre J. Mallorga
Ian M. Bell
Anthony M. Smith
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/329,757 external-priority patent/US5574044A/en
Priority claimed from US08/440,153 external-priority patent/US5691323A/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU39674/95A priority Critical patent/AU701127B2/en
Priority to EP95937615A priority patent/EP0786997A4/en
Priority to JP51469196A priority patent/JP2002515008A/en
Publication of WO1996013262A1 publication Critical patent/WO1996013262A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to control of ocular development in general and, more particularly, to the treatment of the eye to prevent and/or arrest the development of myopia (nearsightedness).
  • myopia nearsightedness
  • myopia Approximately one of every four persons suffer from myopia, i.e., an elongation of the eye along the visual axis.
  • myopia afflicts 10% to 75% of the youth of the world, depending upon race, geographic distribution and level of education.
  • Myopia is not a trivial maldevelopment of the eye. In its pathologic form, the sclera continues to grow and as result the retina stretches and degenerates resulting in permanent blindness.
  • Cycloplegics are topically administered drugs that relax the ciliary muscle of the eye, which is the muscle that focuses the eye by controlling lens dimensions.
  • the classic cycloplegic drug is the belladonna alkaloid atropine, available for over a century.
  • Atropine is a long-acting non-specific
  • ACh neurotransmitter acetylcholine
  • Atropine is impractical in that it causes mydriasis (increase of pupil size) and its action on the ciliary muscle to inhibit ocular focusing impairs near visual work like reading.
  • the receptors in the iris and ciliary muscle responsible for the side effects of atropine are of the M3 subtype.
  • studies have shown that muscarinic receptors in the retina of a variety of non-human species are comprised of m1 , m2 and m4 subtypes. Accordingly, a muscarinic antagonist with low m3 activity would be efficacious in prevention of the development of myopia without the undesirable side effects associated with the use of atropine.
  • retinal concentrations of dopamine were found to be reduced during such image deprivation and the ocular administration of a dopamine-related agent, e.g., apomorphine, a dopamine agonist, was found to inhibit or actually prevent the axial enlargement of the eye under conditions ordinarily leading to such enlargement.
  • a dopamine-related agent e.g., apomorphine, a dopamine agonist
  • Cholinergic receptors are proteins embedded in the wall of a cell that respond to the chemical acetylcholine. Particularly, it is now known that the cholinergic receptors are subdivided into nicotinic and muscarinic receptors and that the muscarinic receptors are not all of the same type. Recent literature indicates that there are at least five types of cholinergic muscarinic receptors (types ml through m5). Receptors of type ml are those present in abundance and thought to be enriched in the brain neural tissue and neural ganglia. The other receptors are concentrated in other tissues such as the heart, smooth muscle tissue or glands. While many others are at least five types of cholinergic muscarinic receptors (types ml through m5). Receptors of type ml are those present in abundance and thought to be enriched in the brain neural tissue and neural ganglia. The other receptors are concentrated in other tissues such as the heart, smooth muscle tissue or glands. While many others
  • pharmacological agents interacting with muscarinic receptors influence several types, some agents are known to have a major effect on a single type of receptor with relative selectivity and other agents can have a relatively selective effect on a different single receptor. Still other agents may have a significant effect on more than one or even all types of receptors.
  • dihydrochloride are anticholinergic, antimuscarinic, and relatively selective for Ml receptors. See U.S. Pat. No. 5,122,522. It is also known that 4-DAMP (4-diphenylacetoxy-N-methylpiperadine methiodide) is a relatively selective antagonist for smooth muscle (ordinarily called M3 type but variously called type M2 or M3, as the current classification of receptors is in flux). Pirenzepine, being primarily an M1 antagonist, inhibits axial elongation, but is far less effective at pupil dilation than atropine or another cycloplegic agent. This makes it possible to suppress the development of myopia
  • This invention is concerned with novel 1,3-dihydro-1 - ⁇ 1 -[piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-ones and 1,3-dihydro-1 - ⁇ 4-amino-1 -cyclohexyl ⁇ -2H-benzimidazol-2-ones, their compositions and method of use.
  • the novel compounds are selective muscarinic antagonists of the m1 , m2, and m4 subtypes with low activity at the m3 subtype.
  • the compounds have good ocular
  • the compounds are effective for the treatment and/or prevention of myopia.
  • novel compounds of this invention are represented by the structural formula: wherein:
  • N is nitrogen
  • O oxygen
  • NBCONB2 CB 2 COCB 2 , CB 2 CONB, NBCOCB 2 , or OB
  • W is O or H 2 ;
  • B is H, Me, Et, Pr, iPr, CH 2 OH, CO 2 Me, CO 2 Et,
  • Q is phenyl or heterocycle ring unsubstimted or
  • R is independently taken from H, small alkyl , branched alkyl, halo, alkoxy, OH, amino, dialkylamino, or alkyla
  • heterocycle or heterocyclic as used herein except where noted, represents a stable 5- to 7- membered
  • heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocyclic rings include pyridine, pyrazine, pyrimidine, pyridazine, triazine, imidazole, pyrazole, triazole, quinoline.
  • alkyl is intended to include both branched and straight chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl).
  • alkoxy represents an alkyl group of indicated carbon atoms attached through an oxygen linkage.
  • alkylamino represents an alkyl group of indicated carbon atoms attached through a nitrogen atom linkage.
  • dialkylamino represents two alkyl groups of indicated carbon atoms attached through a nitrogen atom linkage.
  • small alkyl is intended to indicate those alkyls with C1 to C4 carbon atoms, either branched or linear in connection.
  • alkylsulfonyl represents an alkyl group of indicated carbon atoms attached through an sulfonyl (SO 2 ) linkage.
  • halo represents fluoro, chloro, bromo or iodo.
  • the pharmaceutically acceptable salts of the compounds of formula I include the conventional non-toxic salts or the quarternary ammonium salts of the compounds of formula I formed e.g. from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic,
  • phosphoric, nitric and the like and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
  • the compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.
  • novel compounds of this invention are prepared by the following non-limiting procedures:
  • the reaction is preferably carried out at room temperature (20- 30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid.
  • the reaction is preferably carried out at room temperature (20-30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid.
  • NHCO 2 CH 2 Ph NHCO 2 C(CH 3 ) 3 , NHCO 2 CH 3 , NHCO 2 CH 2 CH 3 or N 3 can be used as an intermediate.
  • Deprotection by the usual methods hydrogenation or acidic hydrolysis followed by basification
  • the preferred compounds can be obtained after isolation and purification.
  • the more preferred trans -isomer is either formed selectively by control of the reaction
  • novel starting materials of the formula (IV) can be obtained by conventional procedures such as those described in the Examples section.
  • the starting materials of the formula (V) are either
  • the reaction is preferably carried out at room temperature (20- 30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid.
  • CO 2 CH 2 CH 3 can be used as an intermediate.
  • Deprotection by the usual methods hydrogenation or acidic hydrolysis followed by basification
  • the more preferred trans -isomer is either formed selectively by control of the reaction conditions, or separated by chromatography.
  • novel starting materials of the formula (IV) can be obtained by conventional procedures such as those described in the Examples section.
  • the starting materials of the formula (VI) are either commercially available or can be obtained by conventional
  • the reaction is preferably carried out at room temperature (20- 30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid.
  • Deprotection by the usual methods hydrogenation or acidic hydrolysis followed by basification
  • the more preferred transisomer is either formed selectively by control of the reaction conditions, or separated by chromatography.
  • novel starting materials of the formula (VII) can be obtained by conventional procedures such as those described in the Examples section.
  • the starting materials of the formula (III) are either
  • the compounds of the present invention include, but are not limited by the following Tables (1-4).
  • the selectivity of the compounds can be measured by radioligand displacement from ml-m5 receptors expressed in Chinese hamster ovary cells (CKO) as described in the Examples section.
  • the functional activity of the compounds can be assessed by measuring the agonist induced contractile response on muscle tissue from rabbit vas deferens (M 1 ), the guinea pig left atria (M2), or the guinea pig ileum (M3) as described in the Examples section.
  • the functional activity at the human muscarinic receptors can be assessed by measuring agonist induced phosphoinositide hydrolysis in CHO cells expressing the human ml and m3 receptors or agonist inhibition of foskolin-stimulated adenylate cyclase activity in CHO cells expressing the human m2 receptor as described in the Examples section.
  • the instant compounds of this invention are useful in treating and/or preventing the development of myopia. Therapy to inhibit axial-elongation myopia during maturation can be
  • Eye drops are typically made up at a concentration of active agent between about 0.1 and 2% in the ophthalmic medium.
  • a 0.5%-2% solution of the instant muscarinic antagonist in water would be a likely concentration for clinical use.
  • a pH of about 4.5 to about 7.5 is expected to be acceptable as an ophthalmic drop and practical in terms of known solubility and stability of piperidines.
  • Phosphate buffering is also common for eye drops and is compatible with the instant muscarinic antagonist.
  • a common regimen for application of eye drops is one to three times a day spaced evenly throughout waking hours. More effective agents may require fewer applications or enable the use of more dilute solutions.
  • ointments and solid inserts are now coming into increased use in clinical practice. These aid the ocular
  • muscarinic antagonist might prevent or inhibit the development of permanent or persistent amblyopia in maturing humans with decreased likelihood of sensitization of the eye. It is also possible that humans who have already developed amblyopia from other or even unknown causes might be aided by similar therapeutic treatment with the aforementioned agents.
  • Step 1 A mixture of 100 g 4-piperidone hydrochloride hydrate, 1 L ether, 300 mL of water, 500 mL of saturated aqueous
  • Step 2 A mixture of 20.6 g N-t-butyloxycarbonyl-4-piperidone, 15 g of 4-(2-oxo-1-benzimidazolinyl)piperidine, 300 mL of 1 ,2-dichloroethane, 4.2 mL of glacial acetic acid and 24 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na 2 CO 3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated under reduced pressure.
  • Step 3 A stirred solution of 4 g of 1,3-dihydro-1- ⁇ 1 -[ 1 -(t-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one in 150 mL of 1N HCl was heated to reflux for 4 h, cooled and
  • Step 4 To a stirred solution of 6 g of 1,3-dihydro-1 - ⁇ 1 -[ 1 -piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one dihydrochloride salt and 20 mL of triethylamine in 500 mL of dichloromethane was added 3 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 50 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two additional 200 mL portions of chloroform and the combined organic extracts dried over MgS O 4 and concentrated under reduced pressure.
  • Step 1 A mixture of 69 g of 4-chloro-3-nitro-toluene, 50 g of ethyl 4-amino-1 -piperidinecarboxylate, 24 g of sodium carbonate, 0.1 g of sodium iodide and 120 mL of cyclohexanol was heated to 150°C for 72 h. After cooling the cyclohexanol was distilled off under reduced pressure and the residue partitioned between 1 L of ethyl acetate and 1 L of water. The organic extract was dried over MgSO 4 and
  • Step 2 A mixture of 8.23 g of ethyl 4-(4-methyl-2-nitroanilino)-1-piperidinecarboxylate, 200 mL of tetrahydrofuran , 225 mL of ethanol and 2 g of 5% platinum on carbon was stirred under an atmosphere of hydrogen for 7 h. The catalyst was filtered off and the filtrate concentrated to to a thick oil.
  • Step 3 A mixture of 5 g of ethyl 4-(5-methyl-2-oxo-1 -benzimidazolinyl)piperidine-1 -carboxylate and 20 mL of 2N NaOH was heated under reflux for 12 h. The resulting solution is cooled and stirred for for 30 minutes with 5 g of ammonium chloride and extracted with three 200 mL portions of chloroform. The combined organic extracts were dried over MgSO 4 , concentrated under reduced pressure and triturated with ether. The solid product 4-(5-methyl-2-oxo-1-benzimidazolinyl)piperidine weighed 3.5 g after drying.
  • Step 4 A mixture of 4.5 g N-t-butyloxycarbonyl-4-piperidone, 4.7 g of 4-(5-methyl-2-oxo-1 -benzimidazolinyl)piperidine, 65 mL of 1 ,2-dichloroethane, 1.3 mL of glacial acetic acid and 6.4 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h.
  • the reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na 2 CO 3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated under reduced pressure.
  • Step 5 A stirred solution of 6.18 g of 5-methyl-1,3-dihydro-1 - ⁇ 1 -[ 1 -(t-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one in 200 mL of 1N HCl was heated to reflux for 4 h, cooled and concentrated to dryness. After drying overnight under vacuum, there was obtained 6 g of 5-methyl-1 ,3-dihydro-1 - ⁇ 1-[ 1 -piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one dihydrochloride salt as a white solid.
  • Step 6 To a stirred solution of 6 g of 5-methyl-1,3-dihydro-1 - ⁇ 1 -[ 1 -piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one
  • Step 1 A mixture of 10 g of 1 ,4-cyclohexanedione mono-ethyleneketal, 13.8 g of 1,2-phenylenediamine, 180 mL of 1 ,2-dichloroethane, 4 mL of glacial acetic acid and 19 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 200 mL chloroform and 200 mL saturated 1N NaOH and the layers separated. The aqueous layer was extracted with 2 X 50 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated to dryness under reduced pressure.
  • Step 2 A mixture of 7 g of the ethylene ketal of 1 ,3-dihydro- 1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 100 mL of glacial acetic acid, 50 mL of water and 50 mL of cone. HCl was heated under reflux for 12 h. The mixture was concentrated under reduced pressure, diluted with 100 mL of water and extracted into 3 X 200 mL of CHCl 3 . The combined organic extracts were washed with 100 mL of water, 100 mL of saturated Na 2 CO 3 . dried over MgSO 4 and concentrated under reduced pressure.
  • Step 3 A mixture of 1.5 g of 1,3-dihydro-1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 1.21 g of tert-butyl-1 -piperazinecarboxylate, 20 mL of 1,2-dichloroethane, 0.4 mL of acetic acid and 1.8 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na 2 CO 3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated under reduced pressure.
  • Step 4 A stirred solution of 0.52 g of trans -1 ,3-dihydro-1 - ⁇ 4-[4-(tert -butyloxycarbonyl)piperazin-1-yl]-1-cyclohexyl ⁇ -2H-benzimidazol-2-one in 15 mL of 1N HCl was heated to reflux for 1 h, cooled, basified to pH 10 with 6N NaOH and extracted 2 ⁇ 50 mL of CHCl 3 . The combined extracts were dried over MgSO 4 and concentrated under reduced pressure.
  • Step 5 To a stirred solution of 0.044 g of trans -1,3-dihydro-1 - ⁇ 4-(1 -piperazinyl)-1 -cyclohexyl ⁇ -2H-benzimidazol-2-one and 20 mL of triethylamine in 3 mL of dichloromethane was added 0.03 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 5 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two addtional 20 mL portions of chloroform and the combined organic extracts dried over MgSO 4 and concentrated under reduced pressure.
  • Step 1 To a stirred solution of 2.0 g of ethyl 4-amino- 1 -piperidinecarboxylate and 2 mL of triethylamine in 50 mL of
  • Step 2 A mixture of 1.2 g of the ethylene ketal of 4-(3-pyridinecarbonylamino)- 1 -piperidinecarboxylate and 20 mL of 6N HCl was heated under reflux for 6 h. The mixture was cooled, extracted with 20 mL of dichloromethane, then basified with 6N NaOH and extracted with 3 X 50 mL of chloroform.
  • Step 3 A mixture of 0.13 g of 1 ,3-dihydro-1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 0.12 g of 4-(3-pyridinecarbonylamino)piperidine, 5 mL of 1 ,2-dichloroethane, 0.04 mL of glacial acetic acid and 0.161 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na 2 CO 3 and the layers separated.
  • Step 1 To a stirred solution of 0.108 g of 3-aminomethylpyridine and 0.280 g of di-2-pyridylcarbonate in 5 mL of dichloromethane was added 0.209 mL of triethylamine. After 12 h, the mixture was diluted with 50 mL of dichloromethane and washed with 50 mL of satutrated sodium bicarbonate, dried over MgSO 4 and concentrated under reduced pressure. The residue was filtered through a short column of silica gel , eluting with ethyl acetate ( 100 mL) and the eluate concentrated to dryness.
  • Step 2 A mixture of 0.108 g of 1 ,3-dihydro- 1- ⁇ 1-[ 1-piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one, 0.070 g of N-(3-pyridylmethyl)-O-2-pyridylurethane and 0.062 mL of triethylamine in 5 mL of dichloromethane was added 2.07 g of nicotinoyl chloride hydrochloride.
  • Step 1 A mixture of 1.5 g of 1 ,3-dihydro-1 -(4-oxocyclohexyl)- 2H-benzimidazol-2-one, 1.21 g of tert-butyl 1 -piperazinecarboxylate, 20 mL of 1 ,2-dichloroethane, 0.40 mL of glacial acetic acid and 1.79 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na 2 CO 3 and the layers separated.
  • Step 2 A stirred solution of 0.52 g of 1 ,3-dihydro-l - ⁇ trans -4-[4-(tert -butylcarbonyl)piperazin-1 -yl]-1 -cyclohexyl ⁇ -2H-benzimidazol-2-one in 15 mL of 1N HCl was heated to reflux for 1 h, cooled and basified with 6N NaOH. The basic mixture was extracted with 2 X 50 mL portions of chloroform. The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
  • Step 3 To a stirred solution of 0.044 g of 1,3-dihydro-1-[trans-4-[ 1-piperazinyl]-1 -cyclohexyl ⁇ -2H-benzimidazol-2-one and 0.2 mL of triethylamine in 3 mL of dichloromethane was added 0.030 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 5 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two addtional 20 mL portions of chloroform and the combined organic extracts dried over MgSC ⁇ t and concentrated under reduced pressure.
  • Step 1 A mixture of 1.5 g of 1,3-dihydro- 1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 1.12 g of ethyl 4-amino-1 -piperidinecarboxylate, 20 mL of 1 ,2-dichloroethane, 0.40 mL of glacial acetic acid and 1.79 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na 2 CO 3 and the layers separated.
  • Step 2 A stirred solution of 1.2 g of 1,3-dihydro-1 - ⁇ trans -4-[ 1-ethoxycarbonyl-4-piperidinylamino]-1-cyclohexyl ⁇ -2H-benzimidazol-2- one in 20 mL of 6N HCl was heated to reflux for 12 h, cooled and basified with 6N NaOH. The basic mixture was extracted with 2 X 50 mL portions of chloroform. The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
  • Step 3 To a stirred solution of 0.050 g of 1,3-dihydro-1- ⁇ trans-4-[4-piperidinylamino]-1-cyclohexyl ⁇ -2H-benzimidazol-2-one and 0.023 mL of triethylamine in 1.5mL of dichloromethane was added 0.024 g of nicotinoyl chloride hydrochloride. After 12 h, 20 mL of saturated sodium carbonate was added, the organic layer was separated, and the aqueous layer extracted with two addtional 20 mL portions of chloroform. The combined organic extracts dried over MgSO 4 and concentrated under reduced pressure. Chromatography over silica gel eluting with 10% methanol/10% cone.
  • Step 1 A mixture of trans -4-aminocyclohexanol hydrochloride
  • Step 2 To a stirred solution of oxalyl chloride (0.83 g) in dry dichloromethane (15 mL) at -60 °C was added dimethylsulfoxide (1.0 mL) in dichloromethane (3 mL) dropwise. The reaction mixture was stirred at -60 °C for 10 min, then N-tert -butyloxycarbonyl-trans -4- aminocyclohexanol (1.28 g) in dichloromethane (70 mL) was added over 15 min. The resulting mixture was stirred at -60 °C for a further 15 min, then triethylamine (4.2 mL) was added and the solution was allowed to warm to room temperature.
  • Step 3 A mixture of N-tert -butyloxycarbonyl-4-aminocyclohexanone (1.32 g), 4-(2-keto-1-benzimidazolinyl)piperidine ( 1.48 g), sodium triacetoxyborohydride (1.97 g), acetic acid (0.35 mL), 1 ,2-dichloroethane (50 mL) and tetrahydrofuran (60 mL) was stirred at room temperature for 3 days. Saturated aqueous Na 2 CO 3 (30 mL) and H 2 O (30 mL) were added and the mixture was extracted with
  • Step 4 The mixture of cis and trans isomers isolated in Step 3 (0.85 g) was stirred in ethyl acetate (100 mL) at 0 °C and gaseous HCl was bubbled in until the mixture was saturated with the acid. Stirring was continued for 20 min, then the reaction mixture was concentrated in vacuo. The residue was dissolved in chloroform, washed with saturated aqueous Na 2 CO 3 , and the organic layer was dried over MgSO 4 and evaporated under reduced pressure.
  • Step 5 To the mixture of cis and trans isomers isolated in Step 4 (90 mg) was added tetrahydrofuran (3 mL), dimethylformamide (2 mL), triethylamine (0.12 mL) and nicotinoyl chloride hydrochloride (76 mg). The reaction mixture was stirred at room temperature for 18 h then concentrated to dryness under reduced pressure.
  • Step 1 To 1 mL of benzyl alcohol cooled in an ice bath was added 0.1 g of 60% sodium hydride oil dispersion. After 15 min., 0.1 g of 6-chloro-2-pyrazinoic acid was added. The mixture was stirred at room temperature forl h, then acidified with 2 mL of 1 N HCl. The mixture was cooled in an ice bath and the white precipitate collected by filtration.
  • Step 2 From 1,3-dihydro-1- ⁇ 1-[1 -piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one dihydrochloride salt and 6-benzyloxy-2- pyrazinoic acid using the procedure described for Example 3, there was obtained 1 ,3-dihydro-1- ⁇ 1-[ 1-(6-benzyloxy-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one as a white solid: 1 H NMR (400 MHz, CDCI 3 ) 9.98 (s, 1H), 8.46 (m, 1H), 8.36 (m, 1H), 7.47-7.05 (m, 9H), 5.43 (m, 2H), 4.81 (br s, 1H), 4.39 (br s, 1H), 3.9 (br s, 1H), 2.85 (m, 1H), 2.65 (m, 1H), 2.46 (m, 4
  • Step 1 A mixture of 0.15 g of 1,3-dihydro-1- ⁇ 1-[1-(6-chloro-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one, 0.26 g of sodium azide and 5 mL of anhydrous N,N-dimethylformamide was stirred for 24 h, then concentrated to dryness under reduced pressure. The residue was partitioned between 50 mL of chloroform and 5 mL of saturated sodium carbonate and the organic extracts dried over MgSO 4 .
  • Step 2 The crude 1 ,3-dihydro-1- ⁇ 1 -[1-(6-azido-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one was hydrogenated under 1 atm. of hydrogen in 20 mL of ethanol over 0.05 g of 5% palladium on carbon. The catalyst was removed by filtration and the filtrate concentrated to dryness under reduced pressure. Preparative thin layer chromatography using 20%
  • CDCI 3 9.25 (s, 1H), 8.90 (s, 2H), 7.98 (s, 1H), 7.61 (s, 1H), 7.3 (m, 1H), 7.1 -7.05 (m, 3H), 4.8 (m, 1H), 4.4 (m, 1H), 4.1 (m, 1H), 3.1 (m, 2H), 2.9 (m, 2H), 2.77-2.35 (m, 4H), 2.0-1.5 (m, 7H).
  • CDCI 3 9.52 (s, 1H), 9.33 (s, 1H), 9.22 (m, 1H), 7.5 (m, 1H), 7.27 (m, 1H), 7.12-7.04 (m, 3H), 4.77 (m, 1H), 4.35 (br s, 1H), 3.6 (m, 1H), 3.1 (m. 2H), 2.9 (m, 1H), 2.65 (m, 1H), 2.44 (m, 4H), 2.1 (br s, 1H), 1.87 (m, 4H), 1.6 (m, 2H).
  • the dihydrochloride salt was precipitated from ethanol/ether: Analysis calculated for C 22 H 26 N 6 O 2 ⁇ 0.62
  • the dihydrochloride salt was precipitated from ethanol/toluene: Analysis calculated for C 24 H 30 N 6 O 2 ⁇ 1.6 H 2 O ⁇ 0.4 CH 3 C 6 H 5 : C: 56.16, H: 6.77, N: 14.66; found C: 56.18, H: 6.37, N: 14.69.
  • Step 1 A mixture of 45 g of 2-aminomethylaniline, 60 g of di-tert -butyldicarbonate, 1000 mL of dichloromethane was stirred for 18 h and washed with 500 mL of 2N NaOH. The organic extract was dried over MgSO 4 and concentrated under reduced pressure. Drying under vacuum gave 47 g of 2-(tert -butoxycarbonylaminomethyl)aniline as a white crystalline solid.
  • Step 2 A mixture of 15.5 g of 1- ⁇ tert -butoxycarbonyl
  • Step 3 To a stirred solution of 27.1 g of tert -butyl 4-(2-tert-butoxycarbonylaminomethylanilino)-1 -piperidinecarboxylate and 30 mL of triethylamine in 400 mL of dichloromethane was added dropwise 60 mL of a 1.93 M solution of phosgene in toluene. After stirring for 12 h, 200 mL of 1N NaOH was added. The mixture was shaken, and the organic layer separated, dried over MgSO 4 and concentrated under reduced pressure.
  • Step 4 A stirred solution of 25 g of 1 ,3-dihydro-1 -[1 -tert
  • Step 5 A mixture of 0.52 g of 1 ,3-dihydro-1-[piperidin-4-yl]-1H-3,4-dihydroquinazolin-2-one, 0.65 g of N-t-butyloxycarbonyl-4-piperidone, 10 mL of 1 ,2-dichloroethane, 0.3 mL of glacial acetic acid and 1 g of sodium triacetoxyborohydride was stirred at room
  • Step 6 A stirred solution of 0.9 g of 1 ,3-dihydro- 1 - ⁇ 1 -[1-(tert-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ - 1 H-3,4-dihydroquinazolin-2-one in 40 mL of 1N HCl was heated to reflux for 6 h, cooled and concentrated to dryness. After drying overnight under vacuum, there was obtained 0.58 g of 1,3-dihydro-1 - ⁇ 1-[piperidin-4-yl]piperidin-4-yl ⁇ -1H-3,4-dihydroquinazolin-2-one dihydrochloride salt as a white solid.
  • Step 7 To a stirred solution of 0.58 g of 1 ,3-dihydro-1- ⁇ 1- [piperidin-4-yl]piperidin-4-yl ⁇ -1H-3,4-dihydroquinazolin-2-one dihydrochloride salt and lmL of triethylamine in 50 mL of
  • dichloromethane was added 0.3 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 50 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two additional 50 mL portions of chloroform and the combined organic extracts dried over MgSO 4 and concentrated under reduced pressure.
  • Step 1 To a stirred mixture of 1.1 g of 5-(1 -aminoethyl)pyrimidine (O. Cervinska and P. Malon, Coll. Czechoslov. Chem. Commun. 1977, 42 , 3464-72.), 17 mL of ethanol and 1.36 g of K 2 CO 3 heated to reflux was added dropwise over 30 min, a solution of 4 g of 1 ,1 -dimethyl-4oxopiperidinium iodide in 70 mL of water. When the addition was complete, the mixture was heated under reflux for an additional 2 h, cooled, basified to pH 9 with K 2 CO 3 and extracted with 5 times with 50 mL portions of methylene chloride. The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
  • 5-(1 -aminoethyl)pyrimidine O. Cervinska and P. Malon, Coll. Czechoslov. Chem. Commun. 1977, 42 , 3464-72.
  • Step 2 A mixture of 0.24 g of 1 -( 1-(5-pyrimidinyl)-ethyl)-4-oxopiperidine, 0.24 g of 1-(4-piperidinyl) benzimidazol-2H-one, 4 mL of 1 ,2-dichloroethane, 0.12 mL of glacial acetic acid and 0.45 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 100 mL dichloromethane and 25 mL saturated aqueous Na 2 CO 3 and the layers separated.
  • the bis-maleate salt Analysis calculated for C 23 H 29 ClN 6 O ⁇ 2 C 4 H 4 O 4 : C:55.31, H: 5.54, N: 12.49; found C: 55.41, H: 5.54, N: 12.60.
  • Step 1 A mixture of 5 g of 1 ,4-cyclohexanedione mono-ethyleneketal, 4.3 g of 1 ,3-dihydro-1 -(4-piperidinyl)-benzimidazol-2H-one, 75 mL of 1 ,2-dichloroethane, 1.2 mL of acetic acid and 5.45 g of sodium
  • triacetoxyborohydride was stirred at room temperature for 48 h.
  • the reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na 2 CO 3 and the layers separated.
  • the aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated under reduced pressure.
  • Step 2 A mixture of 7.0 g of the ethylene ketal of 1 ,3-dihydro-1 - ⁇ 1 -[4-oxocyclohex-1-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one, 80 mL of glacial acetic acid, 80 mL of water and 20 mL of cone. HCl was heated under reflux for 2 h, then allowed to cool ovemight. The mixture was concentrated under reduced pressure, diluted with 100 mL of saturated Na 2 CO 3 and extracted into 3 X 200 mL of CHCl 3 . The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
  • Step 1 A mixture of 0.10 g of trans -1 ,3-dihydro-1 - ⁇ 4-(1 - piperazinyl)-1 -cyclohexyl ⁇ -2H-benzimidazol-2-one, 0.037 mL of 3-pyridinecarboxaldehyde, 15 mL of 1 ,2-dichloroethane, 0.10 mL of glacial acetic acid and 0.1 1 g of sodium triacetoxyborohydride was stirred at room temperature for 24 h. The reaction mixture was poured into 10 mL dichloromethane and 10 mL saturated aqueous NaHCO 3 and the layers separated.
  • Step 1 A mixture of ethyl 4-oxocyclohexanecarboxylate (1.86 g), 4-(2-oxo-1 -benzimidazolinyl)piperidine ( 1.98 g), 1 ,2-dichloroethane (40 mL), glacial acetic acid (0.52 mL) and sodium triacetoxyborohydride (3.47 g) was stirred at room temperature for 72 h. The reaction mixture was poured into dichloromethane (50 mL) and saturated
  • Step 2 To a stirred solution of the cis and trans isomers of ethyl 1-[4-(2-keto-1 -benzimidazolinyl)piperidin- 1-yl]cyclohexane-4-carboxylate (2.16 g) in dry toluene (150 mL) at -90 °C under argon, was added diisobutylaluminum hydride (1 1.6 mL of a 1.5 M solution in toluene). The reaction mixture was stirred at -90 °C for 1h, then quenched with methanol (1 mL) followed by saturated sodium potassium tartrate (50 mL).
  • Step 3 To a stirred solution of 5-bromopyrimidine (3.98 g) in 1 : 1 diethyl ether; tetrahydrofuran (120 mL) at -1 10 °C under argon, was added n-butyllithium (10.4 mL of a 1.6 M solution in hexanes) at such a rate that the temperature was maintained at -1 10 °C.
  • Step 1 To a stirred solution of oxalyl chloride (68 mg) in dry
  • Step 1 A mixture of 1 ,3-dihydro-1 - ⁇ 1 -[4-oxocyclohex-1 -yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one (200 mg), 3-aminopyridine (29 mg), 1 ,2-dichloroethane (1.5 mL), acetic acid (0.087 mL) and sodium
  • Step 1 Sodium borohydride (0.69 g) was added in portions to a stirred solution of acetylpyrazine (1.49 g) in ethanol (300 mL) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 20 min, then water (100 mL) was added and the mixture adjusted to pH 7 with 1 N hydrochloric acid. The neutralized solution was concentrated in vacua to a volume of 200 mL, saturated with sodium chloride, and extracted with ethyl acetate (3 X 500 mL). The organic extracts were dried (Na 2 SO 4 ) and concentrated to give a solid which was washed with dichloromethane (4 X 100 mL). The dichloromethane washings were concentrated to give 2-(1 -hydroxyethyl)pyrazine (1.38 g) as a colorless oil.
  • Step 2 To a stirred solution of 2-( 1 -hydroxyethyl)pyrazine (0.859 g) and diphenylphosphoryl azide (2.48 g) in dry toluene (12 mL) at 0 °C, under argon, was added 1 ,8-diazabicyclo[5.4.0]undec-7-ene ( 1.35 mL) dropwise. The resulting mixture was allowed to warm slowly to room temperature and stirred for 22 h then quenched with water (8 mL). The organic layer was removed and the aqueous phase extracted with 10 mL ethyl acetate.
  • Step 3 2-(1-Azidoethyl)pyrazine (0.77 g) and 10% palladium on carbon (0.075 g) were stirred in ethanol (40 mL) under an atmosphere of hydrogen at room temperature for 2 h. The mixture was filtered through a pad of celite and the filtrate concentrated under reduced pressure to yield 2-(1-aminoethyl)pyrazine (0.56 g) as a pale oil
  • Step 4 To a stirred mixture of 2-(1 -aminoethyl)pyrazine (225 mg), ethanol (10 mL) and K 2 CO 3 (72 mg) heated to reflux was added dropwise over 30 min, a solution of 4 g of 1 ,1 -dimethyl-4-oxopiperidinium iodide (2.1 g) in water (36 mL). When the addition was complete, the mixture was heated under reflux for an additional 2 h, cooled, basified to pH 10 with Na 2 CO 3 and extracted with ethyl acetate (3 X 100 mL). The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
  • Step 5 A mixture of 1 -(1-(2-pyrazinyl)-ethyl)-4-oxopiperidine (37 mg), 4-(2-oxo-1 -benzimidazolinyl)piperidine (41 mg), 1 ,2-dichloroethane (0.75 mL), glacial acetic acid (0.01 1 mL) and sodium triacetoxyborohydride (60 mg) was stirred at room temperature for 48 h. The reaction mixture was poured into dichloromethane (5 mL) and saturated aqueous Na 2 CO 3 (3 mL) and the layers separated.
  • Step 1 Sodium borohydride (1.75 g) was added in portions to a stirred solution of ace tylpyri dine (12.1 g) in ethanol (100 mL) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 20 min, then concentrated under reduced pressure to remove ethanol. The thick residue was diluted with 300 mL of dichloromethane, 25 mL of water and 5 mL of 20% NaOH. Thed aqueous layer was saturated with sodium chloride,and extracted with ethyl acetate (4 X 150 mL). The combined organic extracts were dried (MgSO 4 ) and concentrated.
  • Step 2 A mixture of 5 g of 3-( 1-hydroxyethyl)pyridine, 80 mL of t-butylmethylether, 0.85 g of lipase from Pseudom ⁇ nas fluorescens on Celite® (30 wt%, prepared as described by D. Bianchi, P. Cesti and E. Battistel, J. Org. Chem. 1988, 53 , 5531 -34) and 2.0 mL of acetic anhydride was allowed to stir in a stoppered flask for 24 h. The mixture was filtered and concentrated under reduced pressure.
  • Step 3 To a stirred solution of 1.7 g of 3-(1 'S-hydroxyethyl)pyridine and 4.7 g of diphenylphosphoryl azide 20 mL of dry tetrahydrofuran cooled to 0 °C, was added 3.4 g of 1 ,8-diazabicyclo[5.4.0]undec-7-ene. The resulting mixture was allowed to warm to room temperature for 48 h., then loaded on a 10 ⁇ 15 cm column of silica gel.
  • Step 5 To a stirred mixture of 1.5 g of 3-( 1 'R-aminoethyl)pyridine, 50 mL of ethanol and 1.54 g of K 2 CO 3 heated to reflux was added dropwise over 40 min a solution of 4.5 g of 1 -ethyl-1 -methyl-4-oxopiperidinium iodide in water (80 mL). When the addition was complete, the mixture was heated under reflux for an additional 30 min, cooled and extracted with 3 X 100 mL portions of chloroform. The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
  • Step 6 A mixture of 1 -( 1'R-(3"-pyridinyl)-ethyl)-4-oxopiperidine (250 mg), 4-(2-oxo-1 -benzimidazolinyl)piperidine (530 mg), 1 ,2-dichloroethane (7 mL), glacial acetic acid (0.2 mL) and sodium
  • the citrate salt Analysis calculated for C 24 H 31 N 5 O ⁇ 1.5 C 6 H 8 O 7 : C: 57.13, H: 6.25, N: 10.10 found C: 57.48, H: 6.39, N: 10.35.
  • Step 1 To a stirred solution of 4.06 g of 5-pyrimidineacetic acid (F. Zymalkowski and E. Reimann, Arch. Pharm. 1966 299 362-7) and triethylamine (6.55 g) in methylene chloride (150 mL) at 0 °C was added ethyl chloroformate (6.38 g) followed by 4-dimethylaminopyridine (0.72 g). The mixture was stirred at 0 °C for 1 h, then the solution was diluted with methylene chloride (200 mL) and saturated ammonium chloride ( 150 mL) was added. After removal of the organic phase, the aqueous layer was extracted with methylene chloride (2 X 200 mL) and the combined organic extracts were dried over MgSO 4 and concentrated to give 7.33 g of a crude oil.
  • 5-pyrimidineacetic acid F. Zymalkowski and E. Reimann, Arch. Pharm. 1966 299 362-7
  • Step 3 A mixture of ethyl 2-methyl-2-(5-pyrimidinyl)propionate (4.64 g), 1.0 N lithium hydroxide (26 mL) and THF ( 100 mL) was heated to reflux under argon for 26 h. The mixture was allowed to cool, adjusted to pH 7 with acetic acid, and concentrated to dryness to give 4.1 1 g of lithium 2-methyl-2-(5-pyrimidinyl)propionate as a pale solid.
  • Step 4 A mixture of lithium 2-methyl-2-(5-pyrimidinyl)propionate (4.1 1 g), diphenylphosphoryl azide (13.2 g), triethylamine (4.86 g) and anhydrous tert-butyl alcohol (100 mL) was heated to reflux for 6 h, then allowed to cool and concentrated in vacuo. The residue was partitioned between chloroform (250 mL) and water ( 100 mL), and the chloroform was extracted, dried (MgSO 4 ) and evaporated under reduced pressure. Chromatography on silica gel, eluting with
  • Step 5 The crude 2-(5-pyrimidinyl)-2-propylisocyanate was treated with a mixture of 1.0 N sodium hydroxide (26 mL), water (20 mL) and THF ( 100 mL) at 0 °C for 30 min, then the mixture was poured into ethyl acetate (200 mL) and water (100 mL). The aqueous layer was acidified to pH 5 with 10% citric acid, extracted twice with ethyl acetate, and then adjusted to pH 1 1 , saturated with sodium chloride, and extracted with methylene chloride (3 X 250 mL). The combined methylene chloride extracts were dried (Na 2 SO 4 ) and concentrated in vacuo to give 2-(5-pyrimidinyl)-2-propylamine (950 mg) as a colorless oil.
  • Step 6 To a stirred mixture of 2-(5-pyrimidinyl)-2-propylamine (660 mg), ethanol (9 mL) and K 2 CO 3 (665 mg) heated to reflux was added dropwise over 30 min, a solution of 1 ,1-dimethyl-4-oxopiperidinium iodide (1.9 g) in water (36 mL). When the addition was complete, the mixture was heated under reflux for an additional 2 h, cooled, basified to pH 10 with Na 2 CO 3 and extracted with ethyl acetate (3 ⁇ 100 mL). The combined organic extracts were dried over MgSO 4 and
  • Step 7 A mixture of 1 -(2-(5-pyrimidinyl)-prop-2-yl)-4-oxopiperidine ( 1 17 mg), 4-(2-oxo-1 -benzimidazolinyl)piperidine ( 128 mg), 1 ,2-dichloroethane (2.5 mL), glacial acetic acid (0.031 mL) and sodium triacetoxyborohydride ( 170 mg) was stirred at room temperature for 48 h. The reaction mixture was poured into dichloromethane (15 mL) and saturated aqueous Na 2 CO 3 (8 mL) and the layers separated.
  • the dihydrochloride salt Analysis calculated for C 22 H 29 CI 2 N 5 O 3 S ⁇ 2 HCl ⁇ 0.8 C 7 H 8 ⁇ 2.0 H 2 O C: 53.10, H: 6.36, N: 11.22 found C: 53.02, H: 6.40, N: 11.15.
  • Step 1 A mixture of 0.65 g of ethyl 2-amino-5-pyrimidinecarboxylate (P. Schenone, L. Sansebastiano and L. Mosti, J. Heterocyclic Chem., 1990, 27 , 295-305) , 1.7 g of di-tert-butyldicarbonate and 50 mL of dichloromethane was allowed to stir overnight then concentrated under reduced pressure.
  • ethyl 2-amino-5-pyrimidinecarboxylate P. Schenone, L. Sansebastiano and L. Mosti, J. Heterocyclic Chem., 1990, 27 , 295-305
  • 1.7 g of di-tert-butyldicarbonate and 50 mL of dichloromethane was allowed to stir overnight then concentrated under reduced pressure.
  • Step 3 From 1,3-dihydro-1 - ⁇ 1 -[ 1-piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one dihydrochloride salt and 2-tert-butoxycarbonylamino-5-pyrimidinecarboxylic acid using the procedure described for Example 3, there was obtained 1 ,3-dihydro- 1 - ⁇ 1 -[ 1 -(2-tert-butoxycarbonylamino-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one as a solid: 1 H NMR (400 MHz, CDCl 3 ) 9.95 (m, 1H), 8.81 (s, 2H), 7.28 (m, 2H), 7.08 (m, 2H), 4.77 (s, 1H), 4.35 (m, 1H), 3.80 (s, 1H), 3.12 (m, 4H). 2.88 (m, 1H), 2.68 (m, 1
  • Step 4 The 1 ,3-dihydro-1- ⁇ 1 -[ 1 -(2-tert-butoxycarbonylamino-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one was dissolved in ethyl acetate, cooled to -50°C and treated with a stream of HCl gas for 2 min. The reaction mixture was allowed to warm to room temperature and stir for several hours, and then concentrated to dryness under reduced pressure.
  • Step 1 To a stirred solution of 1,3-dihydro-1- ⁇ 1-[4-oxocyclohex-1-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one (100 mg) in methanol (4 mL) at 0°C, under nitrogen, was added tert-butylamine-borane (28 mg). The reaction mixture was stirred at 0°C for 1 h, then quenched with water (2 mL) and concentrated to remove the methanol.
  • the resulting oil was dissolved in ethyl acetate (50 mL) and the organic solution was washed with saturated sodium carbonate (10 mL), then water (10 mL), then brine (10 mL) and then dried over sodium sulfate.
  • hydrochloride salt was precipitated from diethyl ether/chloroform:
  • Step 1 To a stirred solution of 1,3-dihydro-1- ⁇ 1-[4-oxocyclohex-1-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one (100 mg) in dry
  • CHO cells When 80- 100% confluent, CHO cells were harvested, and transferred to centrifuge tubes containing CHO buffer (20 mM HEPES at pH 7.4 containing 5mM MgCl 2 ). The cells were
  • the homogenate was centrifuged at 40,000 ⁇ g for 15 minutes at 4°C in a Beckman J2-21 M centrifuge.
  • membranes were resuspended in CHO buffer to a concentration of one flask harvested (75 cm 2 ) per mL of buffer, mixed well and aliquoted in cryovials ( 1mL/vial). The vials were stored at -70°C until used in the assay. The binding incubation was done in
  • polypropylene macrowell tube strips in a final volume of 0.5 mL of HEPES buffer (20 mM; pH 7.4 containing 5 mM MgCl 2 ) containing 0.1 mL of cell membrane suspension, 3H-N-methylscopolamine (NEN Corporation, NET-636, 70-87 C i /mmole) at a final volume of 0.5 mL of HEPES buffer (20 mM; pH 7.4 containing 5 mM MgCl 2 ) containing 0.1 mL of cell membrane suspension, 3H-N-methylscopolamine (NEN Corporation, NET-636, 70-87 C i /mmole) at a final
  • K i values were calculated using the program LIGAND.
  • Compounds displayed K i values at m1 , m2 and m4 in the range of InM to 5,000 nM. All compounds described herein displayed typically greater than 300-fold less potency at the m3 receptor subtype, in the range of 300 nM to 1 14,000 nM.
  • tissue segments are attached to platinum electrodes with 4-0 surgical silk and placed in a 10 mL jacketed tissue bath containing Krebs buffer at 30°C, bubbled with 5% CO 2 / 95% O 2 .
  • the tissues are connected to a Statham-Gould force transducer; 0.75 gram of tension is applied and the tissues are electrically stimulated.
  • EFS parameters are 0.05 Hz; 0.5 ms duration; voltage is set to 30% of 50 V at 25 ohms and increased until a supramaximal voltage is achieved.
  • the contractions are recorded on a Gould strip chart recorder. The tissues are washed every 20 minutes and allowed to equilibrate.
  • a concentration response curve to the selective ml receptor agonist McN-A-343 is determined. Tissues are washed every 20 minutes for 60 minutes. The vehicle or compound is added to the bath and the tissues are incubated for 30 minutes, then the McN-A-343 concentration response is repeated. EC 50 values are determined for both vehicle and tissues treated with the compound before and after treatment. Antagonist dissociation constants (K b ) are calculated by the dose-ratio method. Compounds displayed K b values at m l generally consistent with the radioligand binding assay described in Example 30 in the range of 5 to 100 nM.
  • dextrose 1 1 mM warmed to 37°C.
  • Each atria is attached to platinum electrodes with 4-0 surgical silk and placed in a 10 mL jacketed tissue bath containing Krebs buffer at 37°C, bubbled with 5% CO 2 / 95% O 2 .
  • the tissues are connected to a Statham-Gould force transducer; 0.75 gram of tension is applied and the tissues are electrically stimulated. [EFS parameters are 3 Hz; 4 ms duration; voltage is set to 5 V.]
  • the contractions are recorded on a Gould strip chart recorder.
  • the tissues are washed every 20 minutes and allowed to equilibrate.
  • a concentration response curve to the agonist carbachol is determined. Tissues are washed every 20 minutes for 60 minutes. The vehicle or compound is added to the bath and the tissues are incubated for 30 minutes, then the carbachol
  • Antagonist dissociation constants are calculated by the dose-ratio method.
  • Compounds displayed K b values at M2 generally consistent with the radioligand binding assay described in Example 30 in the range of 5 to 100 nM.
  • the lumen of the remainder is flushed with oxygenated Krebs solution [NaCl, 1 18 mM; KCl, 4.7 mM; CaCl 2 , 2.5 mM: KH 2 PO 4 , 1.2 mM; MgSO 4 , 1.2 mM; NaHCO 3 , 25 mM; dextrose, 1 1 mM] warmed to 30°C.
  • the ileum is cut into 2.5 cm segments and each segment is mounted on a glass pipette.
  • a scalpel is used to lightly cut the surface of the tissue and a cotton swab used to tease the longitudinal muscle free from the underlying circular muscle.
  • EC 50 values are determined for both vehicle and tissues treated with the compound before and after treatment.
  • Antagonist dissociation constants (K b ) are calculated by the dose-ratio method.
  • Compounds displayed K b values at M3 generally consistent with the radioligand binding assay described in Example 30 in the range of 3900 to 24000 nM.
  • EXAMPLE 72 ml and m3 receptor antagonist activity on the human muscarinic receptors expressed in CHO cells
  • Preconfluent CHO cells were labeled for 24 hours with 4 ⁇ Ci/mL of [ 3 H] myo-inositol (specific activity 15-20 Ci /mmole).
  • the cells were detached from flasks using 1 mM EDTA in phosphate buffer saline, centrifuged for 5 minutes at 200x g, and resuspended in assay buffer (1 16 mM NaCl; 10 mM LiCl; 4.7 mM KCl; 1.2 mM MgSO 4 ; 2.5 mM CaCl 2 ; 1.2 mM KH 2 PO 4 ; 5 mM NaHCO 3 ; 1 1 mM dextrose, 20 mM HEPES; pH 7.4 at 37°C) to the desired volume.
  • K b values were generated by performing carbachol concentration-response curves in the absence and presence of a fixed concentration of compound.
  • Compounds displayed K b values at ml and m3 generally consistent with the radioligand binding assay described in Example 30 in the range of 1 to 100 nM at m 1 and 4,000 to 20,000 at m3.
  • Preconfluent CHO cells were harvested using 1 mM
  • Muscarinic agonist 50 microliters of carbachol; 1 micromolar final concentration
  • 20 microliters of 200 ⁇ M forskolin was then added followed by 20 microliters of 200 ⁇ M forskolin and the tubes were incubated at 30°C for an additional 15 minutes.
  • the reaction was stopped by placing the tubes in boiling water for 5 minutes.
  • the tubes were cooled on ice and then centrifuged at 12,000 xg for 10 minutes. Fifty microliters of each supernatant was then analyzed for cAMP using a commercially available radioimmunoassay kit following the manufacturer's instructions.
  • K b values were generated by performing carbachol concentration-response curves in the absence and presence of a fixed concentration of compound.
  • Compounds displayed K b values at m2 generally consistent with the radioligand binding assay described in Example 30 in the range of 1 to 100 nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds, 1,3-dihydro-1-{1-[piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-ones and 1,3-dihydro-1-{4-amino-1-cyclohexyl}-2H-benzimidazol-2-ones and derivatives thereof, their preparation, method of use and pharmaceutical compositions are described. These compounds are endowed with antimuscarinic activity and are useful in the treatment and/or prevention of myopia (commonly known as nearsightedness).

Description

TITLE OF THE INVENTION
MUSCARINE ANTAGONISTS
BACKGROUND OF THE INVENTION
This invention relates to control of ocular development in general and, more particularly, to the treatment of the eye to prevent and/or arrest the development of myopia (nearsightedness). Approximately one of every four persons suffer from myopia, i.e., an elongation of the eye along the visual axis. In particular, myopia afflicts 10% to 75% of the youth of the world, depending upon race, geographic distribution and level of education. Myopia is not a trivial maldevelopment of the eye. In its pathologic form, the sclera continues to grow and as result the retina stretches and degenerates resulting in permanent blindness.
Inheritance, environmental forces such as diet, sun intake, and substantial eye use, etc., are but a few theories that have been postulated to explain the on-set of myopia. In that regard, preventive measures such as eye rest, eye exercise, eye glasses, contact lens and drug and surgical therapies have been proposed. However, these measures are neither ideal nor risk-free. The surgical therapies (e.g. corneal surgery using excimer lasers or conventional knives) attempted for this condition are drastic and often unsuccessful. Moreover, neither of the therapies (excimer lasers or conventional knives) are easily reversed or sufficiently predictable in their results. Complications from contact lens wear range from allergic reactions to permanent loss of vision due to corneal ulceration. Even with the complications associated with contact lens wear, there are roughly 24 million wearers in the United States, with the number expected to double in the next 3 years.
While eyeglasses eliminate most of the medical risks listed above, they are not an acceptable option as evidenced by the contact lens wearers who tolerate the frustration of contact lens wear.
One particular drug therapy utilized in the treatment of myopia involves the use of cycloplegics. Cycloplegics are topically administered drugs that relax the ciliary muscle of the eye, which is the muscle that focuses the eye by controlling lens dimensions. The classic cycloplegic drug is the belladonna alkaloid atropine, available for over a century. Atropine is a long-acting non-specific
antimuscarinic agent that antagonizes the action of the
neurotransmitter acetylcholine (ACh) at autonomic effector cells innervated by postganglionic cholinergic nerves of the
parasympathetic nervous system. However, use of atropine, is impractical in that it causes mydriasis (increase of pupil size) and its action on the ciliary muscle to inhibit ocular focusing impairs near visual work like reading. There is strong evidence that the receptors in the iris and ciliary muscle responsible for the side effects of atropine are of the M3 subtype. Additionally, studies have shown that muscarinic receptors in the retina of a variety of non-human species are comprised of m1 , m2 and m4 subtypes. Accordingly, a muscarinic antagonist with low m3 activity would be efficacious in prevention of the development of myopia without the undesirable side effects associated with the use of atropine.
There is now substantial evidence to link the posterior part of the eye, specifically image quality at the retina and hence an extension of the nervous system, to the postnatal regulation of ocular growth. There is significant evidence of myopia in an eye that is subjected to retinal image impairment. It has been shown that axial myopia can be experimentally induced, in either birds or primates, in an eye in which the retina is deprived of formed images, e.g., by suturing the eyelids or wearing an image diffusing goggle. The experimental myopia induced in birds or primates such as monkeys mimics, in many respects, the axial myopia of humans.
Thus, the phenomenon of an animal's vision process apparently contributes to the feedback mechanism by which postnatal ocular growth is normally regulated and refractive error is determined. This indicates that this mechanism is neural and likely originates in the retina. R. A. Stone, et al. have found a method of controlling the abnormal postnatal growth of the eye of a maturing animal, which comprises controlling the presence of a neurochemical, its agonist or antagonist, which neurochemical is found to be changed under conditions during maturation leading to abnormal axial length. See U.S. Pat. No. 4,066,772 and 5,284,843. Therein it is disclosed that retinal concentrations of dopamine were found to be reduced during such image deprivation and the ocular administration of a dopamine-related agent, e.g., apomorphine, a dopamine agonist, was found to inhibit or actually prevent the axial enlargement of the eye under conditions ordinarily leading to such enlargement.
There have also been recent advances made in the understanding of the cholinergic nervous system and the receptors thereto. Cholinergic receptors are proteins embedded in the wall of a cell that respond to the chemical acetylcholine. Particularly, it is now known that the cholinergic receptors are subdivided into nicotinic and muscarinic receptors and that the muscarinic receptors are not all of the same type. Recent literature indicates that there are at least five types of cholinergic muscarinic receptors (types ml through m5). Receptors of type ml are those present in abundance and thought to be enriched in the brain neural tissue and neural ganglia. The other receptors are concentrated in other tissues such as the heart, smooth muscle tissue or glands. While many
pharmacological agents interacting with muscarinic receptors influence several types, some agents are known to have a major effect on a single type of receptor with relative selectivity and other agents can have a relatively selective effect on a different single receptor. Still other agents may have a significant effect on more than one or even all types of receptors.
It is known, for example, that pirenzepine, (Gastrozepin, LS 519) 5, 11 -Dihydro-1 1-[4-methyl-1 -piperazinyl)acetyl]-6H-pyrido[2,3-b] benzodiazepin-6-one, and its
dihydrochloride are anticholinergic, antimuscarinic, and relatively selective for Ml receptors. See U.S. Pat. No. 5,122,522. It is also known that 4-DAMP (4-diphenylacetoxy-N-methylpiperadine methiodide) is a relatively selective antagonist for smooth muscle (ordinarily called M3 type but variously called type M2 or M3, as the current classification of receptors is in flux). Pirenzepine, being primarily an M1 antagonist, inhibits axial elongation, but is far less effective at pupil dilation than atropine or another cycloplegic agent. This makes it possible to suppress the development of myopia
without dilating the pupil and paralyzing the accommodation activity of the ciliary muscle. Additionally, the administration of a drug topically into the eye of a developing child for a long period of time makes it desirable to have a minimal likelihood of sensitization of the eye. Pirenzepine and atropine test positive in sensitization assays and this is an undesirable side effect.
SUMMARY OF THE INVENTION
This invention is concerned with novel 1,3-dihydro-1 -{ 1 -[piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-ones and 1,3-dihydro-1 -{4-amino-1 -cyclohexyl }-2H-benzimidazol-2-ones, their compositions and method of use. The novel compounds are selective muscarinic antagonists of the m1 , m2, and m4 subtypes with low activity at the m3 subtype. The compounds have good ocular
penetration (bioavailability) when dosed as a 0.1 - 2% aqueous solution, preferably a 0.5-2% solution. The compounds are effective for the treatment and/or prevention of myopia.
DETAILED DESCRIPTION OF THE INVENTION
The novel compounds of this invention are represented by the structural formula:
Figure imgf000007_0001
wherein:
C is carbon
H is hydrogen
N is nitrogen
O is oxygen
S is sulfur
P is phosphorus X, Y, and Z are independently = N, or CH;
J is independently = NB or CB2;
K is independently = NB, CB2, O, carbonyl,
thiocarbonyl, sulfonyl, phosphonyl, NBCO, NBCO2, NBCB2, COCB2 , CONB, CO2, CO2B, NB2,
NBCONB2, CB2COCB2, CB2CONB, NBCOCB2, or OB; W is O or H2;
A is (CH2)n, (CBH)n, (CB2)n, C=O, or C=S, wherein n is 0, 1 or 2; m, o & k are 0, 1 or 2;
B is H, Me, Et, Pr, iPr, CH2OH, CO2Me, CO2Et,
CH2 CH2OH, CONH2, OH, NH2, NHMe, NMe2, OMe, OEt, CONHMe, or CONMe2
Q is phenyl or heterocycle ring unsubstimted or
substituted with Me, Et, Pr, Bu, hydroxyl, alkoxy, F, Cl, Br, I. alkylsulfonyl, phenyl or heterocyclic;
D. E. F & G are chosen from:
Figure imgf000008_0001
Figure imgf000009_0001
where:
R is independently taken from H, small alkyl , branched alkyl, halo, alkoxy, OH, amino, dialkylamino, or alkyla
The term heterocycle or heterocyclic, as used herein except where noted, represents a stable 5- to 7- membered
monocyclic heterocyclic ring, which is either saturated or
unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and including any bicyclic group in which any of the above defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic rings include pyridine, pyrazine, pyrimidine, pyridazine, triazine, imidazole, pyrazole, triazole, quinoline. isoquinoline, quinazoline, quinoxaline, phthalazine, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, oxadiazole, pyrrole, furan. thiophene, hydrogenated derivatives of these heterocyles such as piperidine, pyrrolidine, azetidine, tetrahydrofuran. and N-oxide derivatives of heterocyles containing basic nitrogen. Any fused combinations of any of these above-defined heterocyclic rings is also a part of this definition.
The term alkyl is intended to include both branched and straight chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl).
The term alkoxy represents an alkyl group of indicated carbon atoms attached through an oxygen linkage.
The term alkylamino represents an alkyl group of indicated carbon atoms attached through a nitrogen atom linkage.
The term dialkylamino represents two alkyl groups of indicated carbon atoms attached through a nitrogen atom linkage.
The term small alkyl is intended to indicate those alkyls with C1 to C4 carbon atoms, either branched or linear in connection.
The term alkylsulfonyl represents an alkyl group of indicated carbon atoms attached through an sulfonyl (SO2) linkage.
The term halo as used herein, represents fluoro, chloro, bromo or iodo.
A preferred embodiment of the novel compounds of this invention is realized when,
1 ) X=N, Y=CH, m=0;
2) X=CH, Y=CH, J= NH, m=1 ; or
3) X=CH, Y=N, m=0.
A more preferred embodiment of the novel compounds of this invention is realized when,
1 ) X=N, Y=CH, m=0, A is not present, and D,E,F and G are CR where R is defined as above.
The pharmaceutically acceptable salts of the compounds of formula I include the conventional non-toxic salts or the quarternary ammonium salts of the compounds of formula I formed e.g. from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic,
phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.
Examples of the novel compounds of this
invention are as follows: 1,3-dihydro-1-{ 1 -[ 1-(4-nitrobenzoyl)piperidin-4-yl]piperidin-4-y1}-2H-benzimidazol-2-one, 1,3-dihydro-1 -{ 1 -[ 1 -(3-nitrobenzoyl)piperidin-4-yl]piperidin-4-yl } -2H-benzimidazol-2-one, 1 ,3-dihydro-1-{ 1-[ 1 -benzyl-4-piperidinyl]piperidin-4-yl } -2H-benzimidazol-2-one, 1,3-dihydro-1 -{ 1 -[ 1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-benzoylpiperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridinecarbonyl)-4-piperidinylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyridinecarbonyl)-4-piperidinylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-furoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(2,3,4,5,6-pentafluorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-benzo[b]thiophenecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5,6-dichloro-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-benzofurancarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[trans-1-benzyloxycarbonylamino-4-cyclohexylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-(1-[trans-1-phthalimido-4-cyclohexylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[trans-4-phthalimidomethyl-1-cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-napthyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-methoxybenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-chloro-2-benzo[b]thiophenecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2,4,6-trichlorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-isoxazolyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(3,5-dimethyl-4-isoxazolyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[trans-1-(4-nitrobenzamido)-4-cyclohexylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[trans-4-ethoxycarbonyl-1-cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-nitrobenzyl)-4-piperidinyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(benzyloxycarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[trans-4-hydroxymethyl-1-cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-fluorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-bromobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-iodobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3,4-dimethoxybenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-nitro-2-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[trans-1-phthalimido-4-cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-methoxy-4-amino-5-chlorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-dimethylaminobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-nitrobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-cyanobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-methoxycarbonylbenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-(3-pyridyl)acrylyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-nitro-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-methyl-2-pyrazolin-1-yl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-quinolinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-acetylbenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-methoxybenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-phenylbenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-methyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-amino-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-quinolinecarbonyl)piperidin-4-yI]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-phenyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-methyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(6-(4-morpholinyl)-3-pyridinecarbonyl)piperidin¬4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridylmethyloxycarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridylacetyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-methyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyridylacetyl)piperidin-4-yl]piperidin-4-y1}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-methyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridylmethylaminocarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2R-(1,1-dimethylethoxycarbonylamino)-3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2S-(1,1-dimethylethoxycarbonylamino)-3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-y1}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyridylthioacetyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, (4'''R,5'''S) and (4"'S,5'''R) 1,3-dihydro-1-(1'-(1''-(1'''-methyl-2'''-oxo-5"'-(3""-pyridyl)-4"'-pyrrolidinecarbonyl)piperidin-4"-yl)piperidin-4'-yl)-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2S-amino-3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(2R-amino-3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridyloxyacetyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-[trans-4-[4-(3-pyridinecarbonyl)piperazin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yI]piperidin-4-yl}-1H-3,4-dihydroquinazolin-2-one, 1,3-dihydro-1-{1-[1-(4-pyridylsulfonyl)acetyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-amino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-imidazolecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{trans-4-[4-(4-nitrobenzoyl)piperazin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{trans-4-11-(3-pyridinecarbonyl)-4-piperidinylamino]-1-cyclohexyl}-2H-benzimidazol-2-one,
5-methyl-1,3-dihydro-1-{1-[1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{trans-4-[4-(5-pyrimidinecarbonyl)piperazin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-amino-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridinemethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-methoxy-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-methyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 5-fluoro-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-chloro-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one.
4-fluoro-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
6-fluoro-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
7-fluoro-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
6-methyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(2-amino-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-methylamino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-dimethylamino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-piperidino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(6-pyrrolidinyl-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-methyl-1,3-dihydro-1-{1-[1-(5-pyrimidinemethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-[trans-4-[4-(5-pyridinecarbonylamino)piperidin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one. 1,3-dihydro-1-{1-[1-(4-pyridazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-benzyloxy-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-chloro-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
4-methyl-1,3-dihydro-1-{1-[1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-ethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-methoxy-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-hydroxy-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-ethoxy-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl)-2H-benzimidazol-2-one,
5-(2-hydroxyethoxy)-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-amino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-3-{1-[1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-2-oxo-imidazo[4,5-b]pyridine, 1,3-dihydro-1-{1-[trans-4-(3-pyridinecarbonylamino)cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[4-(1,3-dihydro-2-oxo-2H-benzimidazolin-1-yl)cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[cis-4-(3-pyridinecarbonylamino)cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 5-propyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-butyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 5-(1-methylethyl)-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-(1-hydroxyethyl)-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
4-methyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
4-ethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5,6-dimethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
4,5-dimethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[1-(5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-1H-3,4-dihydroquinazolin-2-one,
(±)-1,3-Dihydro-1-{1-[1-(1-(5-pyrimidinyl)-ethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
(1,''S) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one, (1'''R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'''S) 1,3-Dihydro-1-{1'-[1''-(1'''-(5'"'-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one,
(1'"R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one,
(1"S) 1,3-Dihydro-1-{1'-[1''-(1"'-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one,
(1'''R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[4-oxocyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one, cis-1,3-Dihydro-1-{1-[1-(5-pyrimidinylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[1-(5-pyrimidinylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{4-[4-(3-pyridinylmethyl)piperazin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[1-(2-pyrazinylmethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
(±)-cis-1,3-Dihydro-1-(1-{4-[(5-pyrimidinyl)hydroxymethyl]cyclohex-1-yl}piperidin-4-yl)-2H-benzimidazol-2-one,
(±)-trans-1,3-Dihydro-1-(1-{4-[(5-pyrimidinyl)hydroxymethyl]cyclohex-1-yl}piperidin-4-yl)-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[4-(5-pyrimidinylcarbonyl)cyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one, cis-1,3-Dihydro-1-{1-[1-(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[1-(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
(±)-1,3-Dihydro-1-(1-{1-[1-(2-pyrazinyl)-ethyl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one,
(±) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one, (1"'R) 1,3-Dihydro-1-{1'-[1''-(1"'-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'''R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one,
(1"'R) 1,3-Dihydro-1-{1'-[1''-(1"'-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one,
(±)-1,3-Dihydro-1-(1-{1-[1-(2-pyrazinyl)-1-ethyl]piperidin-4-yl}piperidin-4-yl)-5-methyl-2H-benzimidazol-2-one,
(±)-1,3-Dihydro-1-(1-{1-[1-(2-pyrazinyl)-1-ethyl]piperidin-4-yl}piperidin-4-yl)-5-chloro-2H-benzimidazol-2-one, 1,3-dihydro-1-(1-{1-[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one, 1,3-dihydro-1-(1-{1-[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-5-methyl-2H-benzimidazol-2-one, 1,3-dihydro-1-(1-{1-[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-5-chloro-2H-benzimidazol-2-one, 1,3-dihydro-5-methyl-1-(1-{1-[2-(3-pyridyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one, 1 ,3-dihydro-(1-{1-[2-(3-pyridyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one, 1 ,3-dihydro-1-{1-[1-(2-phenyl-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[1-(3-pyridinesulfonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-methyl-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[1-(5-pyrimidinylmethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[1-(4-imidazolylmethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-amino-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
(1'''R)-1,3-Dihydro-1-{1'-[1''-(1"'-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1"'S)-1,3-Dihydro-1-{1'-[1''-(1'"-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'''R)-1,3-Dihydro-1-{1'-[1''-(2"'-hydroxy-1'"-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one, (1'''S)-1,3-Dihydro-1-{1'-[1''-(2"'-hydroxy-1'"-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[4-hydroxycyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one, or cis-1,3-Dihydro-1-{1-[4-hydroxycyclohex-1-yl]piperidin-4-y1}-2H-benzimidazol-2-one.
The most preferred compounds are as follows:
5-methyl-1,3-dihydro-1-{1-[1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one 1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one 1,3-dihydro-1-{1-[1-(2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one 1,3-dihydro-1-{1-[1-(3-pyridinemethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
5-methoxy-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one 5-methyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
5-ethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one (1'"R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one
( 1"'R) 1,3-Dihydro-1-{1'-[1''-(1"'-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one (1'''R) 1,3-Dihydro-1-{l'-[1''-(1"'-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one 1,3-Dihydro-1-{1-[4-oxocyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one trans-1,3-Dihydro-1-{1-[1-(5-pyrimidinylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one trans-1,3-Dihydro-1-{1-[1-(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
(1'"R) 1,3-Dihydro-1-{1'-[1''-(1"'-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one (1'"R) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one
(1'''R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one
The novel compounds of this invention are prepared by the following non-limiting procedures:
Compounds of the formula I, where X= N, Y = CH and m = 0, can be prepared by a number of routes, including the following:
Figure imgf000026_0001
The reaction is preferably carried out at room temperature (20- 30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid. For the preferred examples where Z = N; and o = 1 , a suitably protected piperidone of formula III such as where o = 1, k = 0 and K = CO2CH2Ph, CO2C(CH3)3, CO2CH3 or CO2CH2CH3 can be used as an intermediate. Similiarly, for the examples where Z = CH, K = NH, o = 1 and k = 1 a suitably protected 4-aminocyclohexanone of formula III such as where o=l , k = 0, K = NHCO2CH2Ph, NHCO2C(CH3)3, NHCO2CH3, NHCO2CH2CH3 or N3 can be used as an intermediate. Deprotection by the usual methods (hydrogenation or acidic hydrolysis followed by basification) provides the free amine compound which can be acylated or alkylated by standard procedures. By this route the most preferred compounds can be obtained after isolation and purification.
The starting materials of the formula (II) and (III) are either commercially available or can be obtained by conventional
procedures such as those described in the Examples section. Compounds of the formula I, where X= CH, Y = N and m=0 can be prepared by a number of routes, including the following:
T
Figure imgf000027_0001
The reaction is preferably carried out at room temperature (20-30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid. For the preferred examples where Z = N and o = 1 , a suitably protected piperazine of formula V such as where k = 0 and K = CO2CH2Ph, CO2C(CH3)3, CO2CH3 or CO2CH2CH3 can be used as an intermediate. Similiarly, for the preferred examples where Z = CH, K = NH, and o = 1 , a suitably protected 4-aminopiperidine such as formula V where o = 1 , k = 0 and K =
NHCO2CH2Ph, NHCO2C(CH3)3, NHCO2CH3, NHCO2CH2CH3 or N3 can be used as an intermediate. Deprotection by the usual methods ( hydrogenation or acidic hydrolysis followed by basification) provides the free amine compound which can be acylated or alkylated by standard procedures. By this route the preferred compounds can be obtained after isolation and purification. The more preferred trans -isomer is either formed selectively by control of the reaction
conditions, or separated by chromatography.
The novel starting materials of the formula (IV) can be obtained by conventional procedures such as those described in the Examples section. The starting materials of the formula (V) are either
commercially available or can be obtained by conventional
procedures such as those described in the Examples section.
Compounds of the formula I, where X= CH, Y =CH, J = NH and m=1 can be prepared by a number of routes, including the following:
Figure imgf000028_0001
The reaction is preferably carried out at room temperature (20- 30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid. For the preferred examples where Z = N a suitably protected 4-aminopiperidine of formula VI such as where o = 1 and k = 0 and K = CO2CH2Ph, CO2C(CH3)3 , CO2CH3 or
CO2CH2CH3 can be used as an intermediate. Similiarly, for the preferred examples where Z = CH and k = 1 , a suitably monoprotected 1 ,4-diaminocyclohexane of formula VI such as where o = 1 , k = 0 and K = NHCO2CH2Ph, NHCO2C(CH3)3, NHCO2CH3, NHCO2CH2CH3 or N3 can be used as an intermediate. Deprotection by the usual methods (hydrogenation or acidic hydrolysis followed by basification) provides the free amine compound which can be acylated or alkylated by standard procedures. By this route the preferred compounds can be obtained after isolation and purification. The more preferred trans -isomer is either formed selectively by control of the reaction conditions, or separated by chromatography.
The novel starting materials of the formula (IV) can be obtained by conventional procedures such as those described in the Examples section. The starting materials of the formula (VI) are either commercially available or can be obtained by conventional
procedures such as those described in the Examples section.
Compounds of the formula I, where X= CH, Y =CH, J = NH and m=1 can also be prepared by the following:
Figure imgf000030_0001
The reaction is preferably carried out at room temperature (20- 30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid. For the preferred examples where Z = N, a suitably protected piperidone of formula III such as where o = 1 , k = 0, and K = CO2CH2Ph, CO2C(CH3)3, CO2CH3 or CO2CH2CH3 can be used as an intermediate. Simiharly, for the preferred examples where Z = CH, o = 1, and J = NH, a suitably mono-protected 4- aminocyclohexanone of formula III such as where o = 1 and k = 0 and K = NHCO2CH2Ph, NHCO2C(CH3)3, NHCO2CH3, NHCO2CH2CH3 or N3 can be used as an intermediate. Deprotection by the usual methods ( hydrogenation or acidic hydrolysis followed by basification) provides the free amine compound which can be acylated or alkylated by standard procedures. By this route the preferred compounds can be obtained after isolation and purification. The more preferred transisomer is either formed selectively by control of the reaction conditions, or separated by chromatography.
The novel starting materials of the formula (VII) can be obtained by conventional procedures such as those described in the Examples section. The starting materials of the formula (III) are either
commercially available or can be obtained by conventional
procedures such as those described in the Examples section. The compounds of the present invention include, but are not limited by the following Tables (1-4).
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
The selectivity of the compounds can be measured by radioligand displacement from ml-m5 receptors expressed in Chinese hamster ovary cells (CKO) as described in the Examples section. The functional activity of the compounds can be assessed by measuring the agonist induced contractile response on muscle tissue from rabbit vas deferens (M 1 ), the guinea pig left atria (M2), or the guinea pig ileum (M3) as described in the Examples section. The functional activity at the human muscarinic receptors can be assessed by measuring agonist induced phosphoinositide hydrolysis in CHO cells expressing the human ml and m3 receptors or agonist inhibition of foskolin-stimulated adenylate cyclase activity in CHO cells expressing the human m2 receptor as described in the Examples section. The instant compounds of this invention are useful in treating and/or preventing the development of myopia. Therapy to inhibit axial-elongation myopia during maturation can be
administered by the use of the agent in eye drops. Indeed, in the vast majority of cases, treatment agents are administered to human eyes by the application of eye drops. Eye drops are typically made up at a concentration of active agent between about 0.1 and 2% in the ophthalmic medium. A 0.5%-2% solution of the instant muscarinic antagonist in water would be a likely concentration for clinical use. A pH of about 4.5 to about 7.5 is expected to be acceptable as an ophthalmic drop and practical in terms of known solubility and stability of piperidines. Phosphate buffering is also common for eye drops and is compatible with the instant muscarinic antagonist. A common regimen for application of eye drops is one to three times a day spaced evenly throughout waking hours. More effective agents may require fewer applications or enable the use of more dilute solutions. Alternatively, ointments and solid inserts are now coming into increased use in clinical practice. These aid the ocular
penetration of the drug. It is, of course, also possible to administer the above-described active agents in therapeutically effective amounts and dosages in pills, capsules, or other preparations of systemic administration.
In experiments in animals where axial myopia has been experimentally induced by depriving the retina of formed images, it has been noted by others in primates that amblyopia was also experimentally and coincidentally induced. Amblyopia is evidenced by poor visual acuity in the eye resulting in poor visual
performance. Normally, visual acuity improves during maturation. It is known that amblyopia may occur in humans from unknown causes or as part of strabismus. It is possible that administration of therapeutically effective amounts and dosages of the instant
muscarinic antagonist might prevent or inhibit the development of permanent or persistent amblyopia in maturing humans with decreased likelihood of sensitization of the eye. It is also possible that humans who have already developed amblyopia from other or even unknown causes might be aided by similar therapeutic treatment with the aforementioned agents.
The following examples are provided in order that this invention might be more fully understood; they are not to be construed as limitative of the invention. The compounds are characterized analytically using techniques such as nuclear magnetic resonance, mass spectrometry, chromatography and the like.
EXAMPLE 1
1,3-dihydro-1 -{1 -[1 -(5-pyrimidine-carbonyl)piperidin -4 -yl]piperidin-4-yl}-2H-benzimidazol-2-one
Step 1 : A mixture of 100 g 4-piperidone hydrochloride hydrate, 1 L ether, 300 mL of water, 500 mL of saturated aqueous
Na2CO3 solution and 140 g di-t-butyldicarbonate was vigorously stirred for 5 days. The layers were separated and the aqueous layer was extracted with 500 mL of ether. The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. The product N-t-butyloxycarbonyl-4-piperidone, 127 g, crystallized as a white solid.
Step 2: A mixture of 20.6 g N-t-butyloxycarbonyl-4-piperidone, 15 g of 4-(2-oxo-1-benzimidazolinyl)piperidine, 300 mL of 1 ,2-dichloroethane, 4.2 mL of glacial acetic acid and 24 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Recrystallization of the crude product from 200 mL of ethyl acetate gave in two crops 28.7 g of pure 1 ,3-dihydro-1 -{ 1 -[ 1 -(t-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl } -2H-benzimidazol-2-one as a white solid.
Step 3: A stirred solution of 4 g of 1,3-dihydro-1-{ 1 -[ 1 -(t-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl } -2H-benzimidazol-2-one in 150 mL of 1N HCl was heated to reflux for 4 h, cooled and
concentrated to dryness. After drying overnight under vacuum, there was obtained 4.0 g of 1,3-dihydro-1 -{ 1-[ 1 -piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one dihydrochloride salt as a white solid.
Step 4: To a stirred solution of 6 g of 1,3-dihydro-1 -{ 1 -[ 1 -piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one dihydrochloride salt and 20 mL of triethylamine in 500 mL of dichloromethane was added 3 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 50 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two additional 200 mL portions of chloroform and the combined organic extracts dried over MgS O4 and concentrated under reduced pressure. Recrystallization of the crude product from 200 mL of ethyl acetate gave in two crops 6 g of pure 1,3-dihydro-1 -{ 1 -[ 1 -(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 10.4 (s, 1H), 9.28 (s, 1H), 8.82 (s, 2H), 7.4-6.9 (m, 4H), 4.8 (br m, 1H), 4.4 (br m, 1H), 3.8 (br m. 1H), 3.1 (br m, 4H), 2.88 (br m. 1H), 2.74 (br m, 1H). 2.44 (br m, 4H), 2.0 (br m, 1H), 1.88 (br m, 2H), 1.58 (br m, 2H). The dihydrochloride salt was recystallized from ethanol: Analysis calculated for C22H26N6O2●2HCl●1.3 C2H7O C: 54.79, H: 6.69, N: 15.58 found C: 54.85, H: 6.67, N: 15.55.
EXAMPLE 2
5-methyl-1,3-dihydro-1 -{1 -[1 -(5-pyrimidine
carbonyl)piperidin-4-yl]piperidin-4-yl)-2H-benzimidazol-2-one
Step 1 : A mixture of 69 g of 4-chloro-3-nitro-toluene, 50 g of ethyl 4-amino-1 -piperidinecarboxylate, 24 g of sodium carbonate, 0.1 g of sodium iodide and 120 mL of cyclohexanol was heated to 150°C for 72 h. After cooling the cyclohexanol was distilled off under reduced pressure and the residue partitioned between 1 L of ethyl acetate and 1 L of water. The organic extract was dried over MgSO4 and
concentrated under reduced pressure. Chromatography over silica gel, eluting with 20% ethyl acetate in cyclohexane gave 38.5 g (42.3%) of ethyl 4-(4-methyl-2-nitroanilino)-1 -piperidinecarboxylate as an orange crystalline solid. 1H NMR (400 MHz, CDCl3) 8.0 (s, 1H), 7.27 (t, J = 9 Hz, 1H), 6.8 (d, J = 9 Hz, 1H), 4.15 (q, J = 7 Hz, 2H), 4.05 (br m, 2H), 3.67 (br m, 1H), 3.10 (br t, J = 1 1 Hz, 2H), 2.27 (s, 3H), 2.06 (br d, J = 1 1 Hz, 2H), 1.6 (m, 2H), 1.27 (t, J = 7 Hz, 4H).
Step 2: A mixture of 8.23 g of ethyl 4-(4-methyl-2-nitroanilino)-1-piperidinecarboxylate, 200 mL of tetrahydrofuran , 225 mL of ethanol and 2 g of 5% platinum on carbon was stirred under an atmosphere of hydrogen for 7 h. The catalyst was filtered off and the filtrate concentrated to to a thick oil. To an ice cold, vigorously stirred solution of the resulting crude ethyl 4-(4-methyl-2-aminoanilino)-1 -piperidinecarboxylate in 500 mL of ethyl acetate was added 500 mL of saturated sodium carbonate followed by 20 mL of 1.9 M phosgene in toluene dropwise over 30 min. After stirring overnight at room temperature, the layers were separated and the organic layer dried over MgSO4 and concentrated to dryness. Trituration of the residue with ether-hexane gave 8 g of ethyl 4-(5-methyl-2-oxo-1 -benzimidazolinyl)piperidine-1-carboxylate as a white crystalline solid.
Step 3: A mixture of 5 g of ethyl 4-(5-methyl-2-oxo-1 -benzimidazolinyl)piperidine-1 -carboxylate and 20 mL of 2N NaOH was heated under reflux for 12 h. The resulting solution is cooled and stirred for for 30 minutes with 5 g of ammonium chloride and extracted with three 200 mL portions of chloroform. The combined organic extracts were dried over MgSO4, concentrated under reduced pressure and triturated with ether. The solid product 4-(5-methyl-2-oxo-1-benzimidazolinyl)piperidine weighed 3.5 g after drying.
Step 4: A mixture of 4.5 g N-t-butyloxycarbonyl-4-piperidone, 4.7 g of 4-(5-methyl-2-oxo-1 -benzimidazolinyl)piperidine, 65 mL of 1 ,2-dichloroethane, 1.3 mL of glacial acetic acid and 6.4 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Recrystallization of the crude product from 50 mL of ethyl acetate gave in two crops 6.18 g of pure 5-methyl-1 ,3-dihydro-1 -{ 1-[ 1 -(t-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one as a white solid: mp 210-21 1°C.
Step 5: A stirred solution of 6.18 g of 5-methyl-1,3-dihydro-1 -{ 1 -[ 1 -(t-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one in 200 mL of 1N HCl was heated to reflux for 4 h, cooled and concentrated to dryness. After drying overnight under vacuum, there was obtained 6 g of 5-methyl-1 ,3-dihydro-1 - { 1-[ 1 -piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one dihydrochloride salt as a white solid.
Step 6: To a stirred solution of 6 g of 5-methyl-1,3-dihydro-1 - { 1 -[ 1 -piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one
dihydrochloride salt and 20 mL of triethylamine in 500 mL of dichloromethane was added 3 g of pyrimidine-5-carboxylic acid chloride. After 2 h. 50 mL of dilute aqueous ammonia was added and the mixture stirred for an additional30 min. The organic layer was separated, the aqueous layer extracted with two addtional 200 mL portions of chloroform and the combined organic extracts dried over MgSO4 and concentrated under reduced pressure. Recrystallization of the crude product from 200 mL of ethyl acetate gave in two crops 6 g of pure 5-methyl-1 ,3-dihydro- 1 -{ 1 -[ 1 -(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.6 (br s, 1H), 9.28 (s, 1H), 8.82 (s, 2H), 7.14 (d, J = 7.4 Hz, 1H), 6.93 (s, 1H), 6.84 (d, J = 7.4 Hz, 1H), 4.8 (br m, 1H), 4.3 (br m, 1H), 3.8 (br m, 1H), 3.2 (br m, 1H), 3.1 (br m, 4H), 2.74 (br m, 1H), 2.41 (br m, 4H), 2.36 (s, 3H), 2.0 (br m, 1H), 1.88 (br m, 2H), 1.58 (br m, 2H). The dihydrochloride salt was recystallized from toluene-ethanol: Analysis calculated for C23H28N6O2●2HCl●0.2
C7H8●0.75 H2O C: 55.78, H: 6.35, N: 16.00 found C: 55.82, H: 6.61 , N: 16.04.
EXAMPLE 3
1,3-dihydro-1-{1 -[1 -(2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzitnidazol-2-one
To a stirred, ice cold solution of 25 mg of pyrazine-2-carboxylic acid and 0.1 1 mL of triethylamine in 5 mL of tetrahydrofuran was added 0.040 mL of diphenylphosphoryl chloride. After stirring for 1 h at 0°C, 100 mg 1,3-dihydro- 1 -{ 1 -[ 1-piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one dihydrochloride salt was added and the reagents were allowed to warm and stir overnight. The reaction mixture was diluted with 100 mL of chloroform and the resulting solution was washed with 10 mL of saturated Na2CO3, dried over MgSO4 and concentrated under reduced pressure. Preparative thin layer
chromatography on silica gel eluting with 90:10:5 CHCl3:CH3OH: conc. NH4OH gave 90 mg of 1 ,3-dihydro-1 -{ 1 -[ 1 -(2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl } -2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 10.0 (s, 1H), 8.94 (s, 1H), 8.65 (s, 1H), 8.57 (s. 1H), 7.3-6.9 (m. 4H). 4.8 (br d, J= 12.5 Hz, 1H), 4.4 (br m, 1 H), 4.0 (br d. J= 12.5 Hz. 1H), 3.1 (br m. 4H), 2.88 (br m. 1H), 2.71 (br m, 1H), 2.47 (br m, 4H), 2.0 (br d, J= 12 Hz, 1H), 1.88 (br m, 2H), 1.68 (br t, J= 12 Hz. 2H). The dihydrochloride salt was recystallized from ethanol: Analysis calculated for
C22H26N6O2●2CCl●0.5 C2H7O C: 59.28, H: 6.49, N: 18.04 found C: 59.18, H: 6.36, N: 17.99.
EXAMPLE 4
1,3-dihydro-1 -{1 -[1 -(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 1,3-dihydro-1 -{ 1 -[ 1-piperidin-4-yl]piperidin-4-yl } -2H-benzimidazol-2-one dihydrochloride salt and nicotinoylchloride hydrochloride using the procedure described for Example 1 , Step 4 there was obtained 1 ,3-dihydro-1 -{ 1 -[ 1 -(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.8 (s, 1H), 8.68 (m, 2H), 7.77 (m, 1H), 7.37 (m, 1H), 7.27 (m, 1H), 7.12-7.0 (m, 3H), 4.8 (br m, 1H), 4.38 (br m, 1H), 3.8 (br m, 1H), 3.1 (br m, 4H), 2.88 (br m, 1H), 2.65 (br m, 1H), 2.44 (br m, 4H), 2.0 (br m, 1H), 1.88 (br m, 2H), 1.60 (br m, 2H). The dihydrochloride salt was recystallized from ethanol: Analysis calculated for C23H27N5O2●2HCl●0.5 C2H 7O C: 57.32, H: 6.43, N: 13.97 found C: 57.32, H: 6.57, N: 13.77.
EXAMPLE 5
5-methyl-1 ,3-dihydro-1 -{1 -[1 -(3-pyridine
carbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 5-methyl-1,3-dihydro- 1 -{ 1 -[ 1 -piperidin-4-yl]piperidin-4-yl } -2H-benzimidazol-2-one dihydrochloride salt and nicotinoylchloride hydrochloride using the procedure described for Example 1 , Step 4 there was obtained 5-methyl-1 ,3-dihydro-1 -{ 1 -[ 1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 9.45 (s, 1H), 8.68 (m, 2H), 7.77 (m, 1H), 7.37 (m, 1H), 7.14 (d. J = 7.4 Hz, 1H), 6.93 (s, 1H). 6.84 (d, J = 7.4 Hz, 1H), 4.8 (br m, 1H), 4.38 (br m, 1H), 3.8 (br m, 1H), 3.1 (br m, 4H), 2.88 (br m, 1H), 2.65 (br m, 1H), 2.44 (br m, 4H), 2.38 (s, 3H), 2.0 (br m, 1H), 1.88 (br m, 2H), 1.60 (br m, 2H). Analysis calculated for C24H29N5O2●0.5CH2Cl2●0.8 CH3CO2CH2CH3 C:
64.91 , H: 7.12, N: 13.81 found C: 65.04, H: 7.10, N: 13.52.
EXAMPLE 6 trans -1,3-Dihydro-1-{4-[4-(5-pyrimidinecarbonyl)piperazin-1 -yl]-1 -cyclohexyl}-2H-benzimidazol-2-one
Step 1 : A mixture of 10 g of 1 ,4-cyclohexanedione mono-ethyleneketal, 13.8 g of 1,2-phenylenediamine, 180 mL of 1 ,2-dichloroethane, 4 mL of glacial acetic acid and 19 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 200 mL chloroform and 200 mL saturated 1N NaOH and the layers separated. The aqueous layer was extracted with 2 X 50 mL of chloroform and the combined organic layers dried over MgSO4 and concentrated to dryness under reduced pressure. To an ice cold, vigorously stirred solution of the resulting crude 4-(2-aminoanilino)-cyclohexan-1 -one ethylene ketal in 200 mL of ethyl acetate was added 200 mL of saturated sodium carbonate followed by 10 mL of 1.9 M phosgene in toluene dropwise over 30 min. After stirring overnight at room temperature, the layers were separated and the organic layer dried over MgSO4 and concentrated to dryness. Chromatography over silica gel, eluting with 5% methanol in dichloromethane gave 7 g of the ethylene ketal of 1 ,3-dihydro-1-(4-oxocyclohexyl)-2H-benzimidazol-2-one as a solid. 1H NMR (400 MHz, CDCI3) 9.58 (s, 1H), 7.28 (m, 1H), 7.07-7.15 (m, 3H), 4.5 (m, 1H), 4.03 (m, 4H), 2.5 (m, 2H), 1.8-1.93 (m, 6H).
Step 2: A mixture of 7 g of the ethylene ketal of 1 ,3-dihydro- 1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 100 mL of glacial acetic acid, 50 mL of water and 50 mL of cone. HCl was heated under reflux for 12 h. The mixture was concentrated under reduced pressure, diluted with 100 mL of water and extracted into 3 X 200 mL of CHCl3. The combined organic extracts were washed with 100 mL of water, 100 mL of saturated Na2CO3. dried over MgSO4 and concentrated under reduced pressure. Drying under vacuum gave 5 g of 1 ,3-dihydro-1-(4-oxocyclohexyl)-2H-benzimidazol-2-one as a tan solid: 1H NMR (400 MHz, CDCl3) 9.52 (s, 1H), 7.14-7.03 (m, 4H), 4.82 (m, 1H), 2.8-2.6 (m, 4H), 2.2 (m, 2H).
Step 3: A mixture of 1.5 g of 1,3-dihydro-1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 1.21 g of tert-butyl-1 -piperazinecarboxylate, 20 mL of 1,2-dichloroethane, 0.4 mL of acetic acid and 1.8 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Chromatography of the crude product on silica gel, eluting with 90: 10 CHCl3: MeOH gave 0.631 g of cis -1 ,3-dihydro-1 -{4-[4-(tert-butyloxycarbonyl)piperazin-1 -yl]-1-cyclohexyl}-2H-benzimidazol-2-one as white solid: mp = 228-30°C; 1H NMR (400 MHz, CDCl3 ) 7.45 (m, 1H), 7.14 (m, 1H), 7.05 (m, 2H), 3.55 (br s, 4H), 2.49 (br s, 6H), 2.27 (s, 1H), 2.15 (br d, J= 15.1 , 2H), 1.58 (br d, J = 10.6, 4H), 1.49 (s, 9H): followed by 0.52 g of trans -1 ,3-dihydro-1 -{4-[4-(tert
-butyloxycarbonyl)piperazin- 1-yl]-1-cyclohexyl }-2H-benzimidazol-2-one as white solid: mp = 195-6°C; 1H NMR (400 MHz, CDCl3 ) 7.14 (m, 2H), 7.12-7.04 (m, 2H), 4.28 (m, 1H), 3.46 (br s, 4H), 2.56 (br s, 5H), 2.49 (m, 1H), 2.29 (q, 2H), 2.06 (d, J= 6.4, 2H), 2.0 (d, J = 9, 2H), 1.52 (m, 1H), 1.47 (s. 9H).
Step 4: A stirred solution of 0.52 g of trans -1 ,3-dihydro-1 -{4-[4-(tert -butyloxycarbonyl)piperazin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one in 15 mL of 1N HCl was heated to reflux for 1 h, cooled, basified to pH 10 with 6N NaOH and extracted 2 × 50 mL of CHCl3. The combined extracts were dried over MgSO4 and concentrated under reduced pressure. After drying overnight under vacuum, there was obtained 0.28 g of trans -1 ,3-dihydro-1 -{4-( 1 -piperazinyl)-1 -cyclohexyl] -2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 7.14 (m, 1H), 7.11 (m, 1H), 7.07 (m, 2H), 4.28 (m, 1H), 2.61 (s, 4H), 2.45 (t, 1H), 2.26 (q, 2H), 2.10 (d, J= 12.2, 2H), 2.0 (d. J = 10.8. 2H), 1.53 (q, 2H).
Step 5: To a stirred solution of 0.044 g of trans -1,3-dihydro-1 -{4-(1 -piperazinyl)-1 -cyclohexyl }-2H-benzimidazol-2-one and 20 mL of triethylamine in 3 mL of dichloromethane was added 0.03 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 5 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two addtional 20 mL portions of chloroform and the combined organic extracts dried over MgSO4 and concentrated under reduced pressure. Chromatography over silica gel eluting with 90: 10 EtOAc: MeOH gave 0.030 g of trans -1 ,3-dihydro-1 -{ 4-[4-(5-pyrimidinecarbonyl)piperazin- 1-yl]-1 -cyclohexyl } -2H-benzimidazol-2-one as a white solid: mp >250°C; 1H NMR (400 MHz, CDCl3 ) 9.76 (bs 1H), 9.27 (s, 1H), 8.83 (s. 2H). 7.27-7.04 (m, 4H). 4.27 (br t, 1H), 3.84 (br s, 2H), 3.43 (br s, 2H), 2.73 (br s, 1H), 2.61 (br s, 2H), 2.54 (d, 1H), 2.34 (q, 2H), 2.02 (br t, 3H), 1.97 (br s, 1H), 1.52 (q, 2H).
The dihydrochloride salt was recystallized from ethanol: Analysis calculated for C22H26N6O2●2HCl●0.65 CHCl3 C: 48.84, H: 5.18, N: 15.09; found C: 48.85, H: 5.36, N: 14.72.
EXAMPLE 7 1,3-dihydro-1 -{trans-4-[4-(5-pyridinecarbonylamino)piperidin-1 -y I]-1 -cyclohexyl}-2H-benzimidazol-2-one
Step 1 : To a stirred solution of 2.0 g of ethyl 4-amino- 1 -piperidinecarboxylate and 2 mL of triethylamine in 50 mL of
chloroform was added 2.07 g of nicotinoyl chloride hydrochloride.
After 12 h, the mixture was washed with 50 mL of satutrated sodium bicarbonate, dried over MgSO4 and concentrated under reduced pressure. Drying under vacuum gave 2.2 g of 4-(3-pyridinecarbonylamino)-1 -piperidinecarboxylate as a white solid. Step 2: A mixture of 1.2 g of the ethylene ketal of 4-(3-pyridinecarbonylamino)- 1 -piperidinecarboxylate and 20 mL of 6N HCl was heated under reflux for 6 h. The mixture was cooled, extracted with 20 mL of dichloromethane, then basified with 6N NaOH and extracted with 3 X 50 mL of chloroform. The combined chloroform extracts were dried over MgSO4 and concentrated under reduced pressure. Drying under vacuum gave 0.6 g of 4-(3-pyridinecarbonylamino)piperidine as an oil: 1H NMR (400 MHz, CDCl3) 8.96 (d, J = 2 Hz, 1H), 8.72 (m, 1H), 8.10 (m, 1H), 7.40 (m, 2H).
Step 3: A mixture of 0.13 g of 1 ,3-dihydro-1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 0.12 g of 4-(3-pyridinecarbonylamino)piperidine, 5 mL of 1 ,2-dichloroethane, 0.04 mL of glacial acetic acid and 0.161 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 25 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated under reduced pressure. Chromatography of the crude product on silica gel, eluting with 10% methanol in choroform gave 0.015 g of 1 ,3-dihydro- 1-{ trans-4-[4-(5-pyridinecarbonylamino)piperidin-l -yl]-1 -cyclohexyl}-2H-benzimidazol-2-one: 1H NMR (400 MHz, CDCI3) 9.01 (d, J = 2 Hz, 1H), 8.75 (dd, J = 2 and 4.5 Hz, 1H), 8.40 (br s. 1H), 8.16 (dd. J = 2 and 8 Hz, 1H), 7.43 (m, 2H), 7.08 (m, 3H), 6.16 (br m, 1H), 4.47 (m, 1H), 4.12 (m, 2H), 3.1 (br s, 2H), 2.8 (m, 1H), 2.5 (m, 1H), 2.2 (br m, 4H), 1.60 (br m, 8H). The dihydrochloride salt was precipitated from ether: Analysis calculated for C24H29N5O2●2HCl●0.75 CHCl3● 1.0 H2O C: 49.54. H: 5.67, N: 1 1.67 found C: 49.55, H: 5.85, N: 1 1.88. EXAMPLE 8
1,3-dihydro-1-{1 -[1 -(3-pyridinemethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
A mixture of 0.10 g of 1,3-dihydro-1-{ 1 -[ 1-piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one, 0.037 mL of 3-pyridinecarboxaldehyde, 15 mL of 1 ,2-dichloroethane, 0.10 mL of glacial acetic acid and 0.106 g of sodium triacetoxyborohydride was stirred at room temperature for 24 h. The reaction mixture was poured into 10 mL dichloromethane and 10 mL saturated aqueous NaHCO3 and the layers separated. The aqueous layer was extracted with 2 X 10 mL of dichloromethane and the combined organic layers dried over MgSCM and concentrated under reduced pressure. Preparative thin layer chromatography on silica gel, eluting with 10% methanol in chloroform gave 0.050 g of 1 ,3-dihydro-1 -{ 4 -[ 1 -(3-pyridinemethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.9 (s, 1H), 8.55 (m, 2H), 7.65 (m, 1H), 7.35-7.25 (m, 2H), 7.15-7.05 (m, 3H), 4.38 (br m, 1H), 3.5 (s, 2H), 3.1 (br m, 2H), 2.88 (br m, 2H), 2.44 (m, 4H), 2.2 (m, 1H), 2.05 (br t, 2H), 1.83 (br m, 4H), 1.62 (br m, 2H): Analysis calculated for C23H29N5O●0.45 CHCl3 C: 63.25, H: 6.67, N: 15.73 found C: 62.96, H: 6.74, N: 15.54.
EXAMPLE 9
1,3-dihydro-1-{1 -[1 -(3-pyridylmethylaminocarbonyl)piperidin-4-yl]piperidin-4-yI}-2H-benzimidazol-2-one
Step 1 : To a stirred solution of 0.108 g of 3-aminomethylpyridine and 0.280 g of di-2-pyridylcarbonate in 5 mL of dichloromethane was added 0.209 mL of triethylamine. After 12 h, the mixture was diluted with 50 mL of dichloromethane and washed with 50 mL of satutrated sodium bicarbonate, dried over MgSO4 and concentrated under reduced pressure. The residue was filtered through a short column of silica gel , eluting with ethyl acetate ( 100 mL) and the eluate concentrated to dryness. Drying under vacuum gave 0.20 g of N-(3-pyridylmethyl)-O-2-pyridylurethane as a white solid. Step 2: A mixture of 0.108 g of 1 ,3-dihydro- 1-{ 1-[ 1-piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 0.070 g of N-(3-pyridylmethyl)-O-2-pyridylurethane and 0.062 mL of triethylamine in 5 mL of dichloromethane was added 2.07 g of nicotinoyl chloride hydrochloride. After 12 h, the mixture was washed with 10 mL of satutrated sodium bicarbonate, dried over MgSO4 and concentrated under reduced pressure. Preparative thin layer chromatography on silica gel, eluting with 5% methanol in chloroform containing 2% cone. NH4OH gave 0.113 g of 1,3-dihydro-1-{ 1-[ 1-(3-pyridylmethylaminocarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one: 1H NMR (400 MHz, CDCI3) 9.85 (s. 1H), 8.58 (d, 1H), 8.55 (dd, 1H), 7.7 (m, 1H), 7.27 (m, 1H), 7.15-7.05 (m, 3H), 4.98 (m, 1H), 4.45 (m, 2H). 4.38 (m, 1H), 4.05 (br d, 2H), 3.15 (d, 2H), 2.85 (t, 2H), 2.55 (br m, 1H), 2.42 (br m, 4H), 2.22 (m, 4H), 1.55 (m, 2H): Analysis calculated for C24H30N6O2●0.65 CHCl3 C: 57.81 , H: 6.03, N: 16.41 found C: 57.56, H: 6.08, N: 16.75.
EXAMPLE 10 1,3-dihydro-1-{1-[1-(3-pyridyImethyloxycarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
A mixture of 2.0 g of 1,3-dihydro-1-{ 1-[1-piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one dihydrochloride, 1.48 g of 3-pyridylmethyl 4-nitrophenyl carbonate and 4.45 mL of triethylamine in 20 mL of tetrahydrofuran was stirred for 12 h. The mixture was diluted with 100 mL of chloroform, washed with 20 mL of 1N NaOH, dried over MgSO4 and concentrated under reduced pressure. Drying under vacuum gave 0.20 g of 1 ,3-dihydro-1-{ 1-[1-(3-pyridylmethyloxycarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-oneas a white solid: 1H NMR (400 MHz, CDCI3) 9.12 (s, 1H), 8.64 (m, 1H), 8.58 (m, 1H), 7.7 (m, 1H), 7.27 (m, 1H), 7.15-7.05 (m, 3H), 5.2 (s, 1H), 4.3 (m, 3H), 3.06 (m, 2H), 2.80 (br s, 2H), 2.5 (m, 1H). 2.45 (m, 4H), 1.84 (m, 4H), 1.5 (m, 2H). The
dihydrochloride salt was crystallized from isopropanol: Analysis calculated for C24H30N6O2●2HCl●1.5 H2O.0.6(CH3)2CHOH C: 57.81 , H: 6.03, N: 16.41 found C: 57.56, H: 6.08, N: 16.75.
EXAMPLE 11
1,3-dihydro-1 -{trans -4-[4-(5-pyri midinecarbonyI)piperazin-1 -yl]-1 -cyclohexyl}-2H-benzimidazol-2-one
Step 1 : A mixture of 1.5 g of 1 ,3-dihydro-1 -(4-oxocyclohexyl)- 2H-benzimidazol-2-one, 1.21 g of tert-butyl 1 -piperazinecarboxylate, 20 mL of 1 ,2-dichloroethane, 0.40 mL of glacial acetic acid and 1.79 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 25 mL of chloroform and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Chromatography of the crude product on silica gel, eluting with 10% methanol in choroform gave, firstly, 0.63 g of 1 ,3-dihydro-1 -{ cis -4-[4-(tert -butylcarbonyl)piperazin-1 -yl]-1-cyclohexyl }-2H-benzimidazol-2-one: 1H NMR (400 MHz, CDCl3) 7.47 (m, 1H), 7.25 (m, 1H), 7.05 (m, 2H), 4.55 (m, 1H), 3.54 (m, 4H), 2.49 (m, 6H), 2.27 (s, 0.8H), 2.15 (d, 2H), 1.97 (m, 0.2H), 1.57 (m, 4H), 1.49 (s, 9H). Later fractions gave 1,3-dihydro-1 -{ trans -4-[4-(tert -butylcarbonyl)piperazin-1 -yl]-1 -cyclohexyl }-2H-benzimidazol-2-one: 1 H NMR (400 MHz, CDCI3) 7.15 (m, 2H), 7.06 (m, 2H), 4.28 (m. 1H), 3.46 (m, 4H), 2.56 (m, 4H), 2.5 (m, 1H), 2.26 (m, 2H), 2.03 (m, 6H). 1.47 (s, 9H).
Step 2: A stirred solution of 0.52 g of 1 ,3-dihydro-l -{ trans -4-[4-(tert -butylcarbonyl)piperazin-1 -yl]-1 -cyclohexyl }-2H-benzimidazol-2-one in 15 mL of 1N HCl was heated to reflux for 1 h, cooled and basified with 6N NaOH. The basic mixture was extracted with 2 X 50 mL portions of chloroform. The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. After drying overnight under vacuum, there was obtained 0.28 g of 1,3-dihydro-1 -[trans -4-[1 -piperazinyl]-1-cyclohexyl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz. CDCI3) 7.16-7.03 (m, 4H), 4.27 (m. 1H), 2.94 (m, 4H), 2.61 (m, 4H), 2.25 (m, 2H), 2.1 (d, 2H), 1.97 (d, 2H), 1.54 (m, 2H).
Step 3: To a stirred solution of 0.044 g of 1,3-dihydro-1-[trans-4-[ 1-piperazinyl]-1 -cyclohexyl }-2H-benzimidazol-2-one and 0.2 mL of triethylamine in 3 mL of dichloromethane was added 0.030 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 5 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two addtional 20 mL portions of chloroform and the combined organic extracts dried over MgSCλt and concentrated under reduced pressure. Chromatography over silica gel eluting with 10% methanol in ethyl acetate gave 0.030 g of 1,3-dihydro-1-{trans -4-[4-(5-pyrimidinecarbonyl)piperazin-1 -yl]-1 -cyclohexyl } -2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.76 (s, 1H), 9.29 (s, 1H), 8.83 (s, 2H), 7.16-7.04 (m, 4H), 4.27 (m, 1H), 3.84 (s, 2H), 3.48 (s, 2H), 2.72 (s, 2H), 2.61 (s, 2H), 2.56 (m, 1H), 2.30 (q, 2H), 2.05 (m, 4H), 1.86 (br s, 1H), 1.5 (q, 2H). The dihydrochloride salt was precipitated from chloroform/ethyl acetate: Analysis calculated for C22H26N6O2●2HCl●0.65 CHCl3 C: 48.84, H: 5.18, N: 15.09 found C: 48.85, H: 5.36, N: 14.72.
EXAMPLE 12
1 ,3-dihydro-1-{trans -4-[4-(3-pyridinecarbonyl)piperazin-1 -yl]-1 -cyclohexyl}-2H-benzimidazoI-2-one
From 1,3-dihydro-1-{trans -4-[1-piperazinyl]-1-cyclohexyl }-2H-benzimidazol-2-one and nicotinoylchloride hydrochloride using the procedure described for Example 1 1, Step 3 there was obtained 1 ,3-dihydro-1 -{ trans -4-[4-(3-pyridinecarbonyl)piperazin-1 -yl]-1 - cyclohexyl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 9.51 (s, 1H), 8.68 (s, 2H), 7.77 (m, 1H), 7.38 (m, 1H), 7.12-7.04 (m, 4H), 4.26 (m, 1H), 3.83 (s, 2H), 3.47 (s, 2H), 2.71 (s, 2H), 2.58 (s, 2H), 2.53 (m, 2H), 2.30 (q, 2H), 2.0 (q, 4H), 1.53 (m, 2H), 1.26 (m, 2H). The hydrochloride salt was precipitated from
chloroform/toluene: Analysis calculated for C23H27N5O2●HCl●0.20 CHCl3●0.45 CH3C6H5 C: 57.99, H: 6.43, N: 12.83 found C: 58.04, H:
6.36, N: 12.75.
EXAMPLE 13
1 ,3-dihydro-1 -{trans -4-[1 -(3-pyridinecarbonyl)-4-piperidinylamino]-1-cyclohexyI}-2H-benzimidazol-2-one
Step 1 : A mixture of 1.5 g of 1,3-dihydro- 1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 1.12 g of ethyl 4-amino-1 -piperidinecarboxylate, 20 mL of 1 ,2-dichloroethane, 0.40 mL of glacial acetic acid and 1.79 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 25 mL of chloroform and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Chromatography of the crude product on silica gel, eluting with 10% methanol in ethyl acetate gave 1.3 g of 1 ,3-dihydro-1 -{ trans -4-[ 1-ethoxycarbonyl-4-piperidinylamino]-1-cyclohexyl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 9.8-9.9 (br m, 1H), 7.30 (m, 1H), 7.1 1 -7.02 (m, 4H), 4.37 (m, 1H), 4.17-4.06 (m, 4H), 3.15 (m, 1H), 2.88 (t, 2H), 2.7 (m, 1H), 2.55 (m, 2H), 1.97 (d, 2H), 1.86 (d, 2H), 1.65 (q, 4H), 1.25 (m, 5H). Analysis calculated for C21H30N4O3 C: 65.26, H: 7.82, N: 14.46 found C: 65.20, H: 7.57, N: 14.15.
Step 2: A stirred solution of 1.2 g of 1,3-dihydro-1 -{trans -4-[ 1-ethoxycarbonyl-4-piperidinylamino]-1-cyclohexyl }-2H-benzimidazol-2- one in 20 mL of 6N HCl was heated to reflux for 12 h, cooled and basified with 6N NaOH. The basic mixture was extracted with 2 X 50 mL portions of chloroform. The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. After drying overnight under vacuum, there was obtained 0.5 l g of 1,3-dihydro-1 -{trans -4-[4-piperidinylamino]-1-cyclohexyl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 7.33 (m, 1H), 7.1 1 (m, 1H), 7.04 (m, 2H), 4.37 (m, 1H). 3.16 (m, 3H). 2.61 -2.52 (m, 5H), 2.0 (d, 2H), 1.86 (d, 2H). 1.64 (m, 4H). 1.3 (m, 2H). Step 3: To a stirred solution of 0.050 g of 1,3-dihydro-1-{trans-4-[4-piperidinylamino]-1-cyclohexyl}-2H-benzimidazol-2-one and 0.023 mL of triethylamine in 1.5mL of dichloromethane was added 0.024 g of nicotinoyl chloride hydrochloride. After 12 h, 20 mL of saturated sodium carbonate was added, the organic layer was separated, and the aqueous layer extracted with two addtional 20 mL portions of chloroform. The combined organic extracts dried over MgSO4 and concentrated under reduced pressure. Chromatography over silica gel eluting with 10% methanol/10% cone. NH4OH in chloroform gave 0.024 g of 1 ,3-dihydro-1-{trans -4-[ 1 -(3-pyridinecarbonyl)-4-piperidinylamino]-1 -cyclohexyl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 9.04 (s, 1H), 8.68 (dd, 2H), 7.77 (m, 1H), 7.38 (m, 1H), 7.26 (m, 1H), 7.06 (m, 3H), 4.67 (br s, 1H), 3.75 (br s, 1H), 3.18 (br s, 2H), 2.99 (br s, 1H), 2.87 (br s, 1H), 2.55 (q, 2H), 2.13-1.9 (m, 4 H), 1.72- 1.3 (m, 7H). The dihydrochloride salt was precipitated from chloroform/ethyl acetate: Analysis calculated for C24H29N5O2●2HCl●0.90 CHCl3●0.25 CH3CO2CH2CH3 C: 50.02, H: 5.95, N: 1 1.26 found C: 51.28, H: 5.49, N: 1 1.53. EXAMPLE 14
1 ,3-Dihydro-1-{1 -[trans-4-(3-pyridinecarbonylamino)cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one and
1,3-Dihydro-1 -{1-[cis-4-(3-pyridinecarbonylamino)
cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one
Step 1 : A mixture of trans -4-aminocyclohexanol hydrochloride
(3.0 g), saturated aqueous Na2CO3 (24 mL) and water (40 mL) was adjusted to pH 11.5 with 1 N aqueous NaOH, and di-tert
-butyldicarbonate (4.75 g) in tetrahydrofuran (30 mL) was added dropwise. The resulting mixture was stirred at room temperature for 3 h, then extracted with ethyl acetate (2 × 90 mL). The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. Drying under vacuum gave the desired product, N-tert -butyloxycarbonyl-trans -4-aminocyclohexanol (4.2 g) as a colorless solid. Step 2: To a stirred solution of oxalyl chloride (0.83 g) in dry dichloromethane (15 mL) at -60 °C was added dimethylsulfoxide (1.0 mL) in dichloromethane (3 mL) dropwise. The reaction mixture was stirred at -60 °C for 10 min, then N-tert -butyloxycarbonyl-trans -4- aminocyclohexanol (1.28 g) in dichloromethane (70 mL) was added over 15 min. The resulting mixture was stirred at -60 °C for a further 15 min, then triethylamine (4.2 mL) was added and the solution was allowed to warm to room temperature. The mixture was washed with water (20 mL) and this aqueous layer was extracted once with dichloromethane (20 mL). The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. Drying under vacuum gave N-tert -butyloxycarbonyl-4-aminocyclohexanone (1.25 g) as a colorless solid.
Step 3: A mixture of N-tert -butyloxycarbonyl-4-aminocyclohexanone (1.32 g), 4-(2-keto-1-benzimidazolinyl)piperidine ( 1.48 g), sodium triacetoxyborohydride (1.97 g), acetic acid (0.35 mL), 1 ,2-dichloroethane (50 mL) and tetrahydrofuran (60 mL) was stirred at room temperature for 3 days. Saturated aqueous Na2CO3 (30 mL) and H2O (30 mL) were added and the mixture was extracted with
dichloromethane (2 × 100 mL). The combined organic extracts were concentrated to dryness under reduced pressure. Column
chromatography on silica gel, eluting with dichloromethane-10% methanol- 1%NH4OH gave a mixture of the expected product isomers: 1 ,3-dihydro-1-{ 1-[trans-4-(tert
-butyloxycarbonylamino)cyclohexyl]piperidin-4-yl }-2H-benzimidazol-2-one and 1 ,3-dihydro-1-{ 1-[cis -4-(tert
-butyloxycarbonylamino)cyclohexyl] piperidin-4-yl}-2H-benzimidazol-2-one as a colorless solid (1.9 g).
Step 4: The mixture of cis and trans isomers isolated in Step 3 (0.85 g) was stirred in ethyl acetate (100 mL) at 0 °C and gaseous HCl was bubbled in until the mixture was saturated with the acid. Stirring was continued for 20 min, then the reaction mixture was concentrated in vacuo. The residue was dissolved in chloroform, washed with saturated aqueous Na2CO3, and the organic layer was dried over MgSO4 and evaporated under reduced pressure. The residue was a crude sample of the two isomers: 1 ,3-dihydro-1-{ 1-[trans -4-aminocyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one and 1,3-dihydro-1-{ 1-[cis -4-aminocyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one (ratio≈ 4:1 from 1H NMR spectrum) (0.40 g).
Step 5: To the mixture of cis and trans isomers isolated in Step 4 (90 mg) was added tetrahydrofuran (3 mL), dimethylformamide (2 mL), triethylamine (0.12 mL) and nicotinoyl chloride hydrochloride (76 mg). The reaction mixture was stirred at room temperature for 18 h then concentrated to dryness under reduced pressure. Preparative thin layer chromatography on silica gel, eluting with dichloromethane-10% methanol- 1% NH4OH gave the desired product, 1,3-dihydro-1-{ 1-[trans -4-(3-pyridinecarbonylamino)cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one (72 mg): 1H NMR (400 MHz, CDCl3/CD3OD) 8.99 (m, 1H), 8.65 (d, J = 5 Hz, 1H), 8.23 (d, J = 8 Hz, 1H), 7.47 (dd, J = 8,5 Hz, 1H), 7.42 (m, 1H), 7.07 (m, 3H), 4.35 (br m, 1H), 3.92 (tt, J = 1 1 ,4 Hz, 1H), 3.13 (d, J = 7 Hz, 2H), 2.51 (m, 5H), 2.16 (d, J = 12 Hz, 2H), 2.05 (d, J = 12 Hz, 2H), 1.85 (br m, 2H), 1.49 (m, 4H). HPLC purity (214 nm) = 99%. The dihydrochloride salt was recrystallized from ethanol/chloroform; analysis calculated for C24H29N5O2●2HCl●0.35 C2H6O●0.20 CHCl3: C:56.17, H:6.30, N: 13.15, found: C.56.36, H.6.18, N: 13.14.
Also obtained was the cis isomer, 1,3-dihydro-1-{ 1-[cis-4-(3-pyridinecarbonylamino)cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one (13 mg): 1H NMR (400 MHz, CDCl3/CD3OD) 8.99 (m, 1H), 8.67 (d, J = 5 Hz, 1H), 8.22 (d, J = 8 Hz, 1H), 7.47 (dd, J = 8,5 Hz, 1H), 7.36 (br m, 1H), 7.08 (m, 3H), 4.34 (tt, J = 12,4 Hz, 1H), 4.25 (br m, 1H), 3.30 (d, J = 1 1 Hz, 2H), 2.60-2.35 (br m, 5H), 2.03 (br m, 2H), 1.88 (br m, 4H), 1.73 (br m, 4H). HPLC purity (214 nm) = 98%. FABMS 420 (MH+). EXAMPLE 15
1,3-dihydro-1 -{1 -[1 -(6-chloro-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 1 ,3-dihydro-1-{ 1 -[1-piperidin-4-yl]piperidin-4-y1]-2H-benzimidazol-2-one dihydrochloride salt and 6-chloro-2-pyrazinoic acid using the procedure described for Example 3, there was obtained 1,3-dihydro-1 -{ 1 -[1-(6-chloro-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.58 (s, 1H), 8.82 (m, 2H), 8.66 (s, 1H), 7.31 (m, 1H), 7.08 (m, 3H), 4.79 (s, 1H), 4.01 (d, 1H), 3.1 (m, 4H), 2.88 (t, 1H), 2.74 (s, 1H), 2.5 (m, 4H), 2.1 -1.87 (m, 4H), 1.7 (m, 2H). The dihydrochloride salt was precipitated from ethanol/chloroform: Analysis calculated for C22H25ClN6O2●0.55 CHCl3●0.85 CH3CH2OH: C: 47.08, H: 5.32, N: 13.58 found C: 47.05, H: 5.35, N: 13.57.
EXAMPLE 16
1,3-dihydro-1 -{ 1 -[1 -(6-methoxy-2-pyrazinecarbonyl)piperidin-4-yI]piperidin-4-yl}-2H-benzimidazol-2-one
From 1,3-dihydro-1 -{ 1 -[1-piperidin-4-yl]piperidin-4-yl]-2H-benzimidazol-2-one dihydrochloride salt and 6-methoxy-2-pyrazinoic acid using the procedure described for Example 3, there was obtained 1,3-dihydro-1-{ 1-[1-(6-methoxy-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 8.84 (s, 1H), 8.43 (s, 1H), 8.29 (s, 1H), 7.27-7.07 (m, 4H), 4.84 (br s, 1H), 4.4 (br s, 1H), 4.0 (s, 3H), 3.1 (br s, 2H), 2.82 (m, 1H), 2.47 (m, 1H), 2.1-1.9 (br m, 4H), 1.7 (m, 2H). The dihydrochloride salt was precipitated from ethanol/ether: Analysis calculated for C23H28N6O3●0.30 CH3CH2OH: C: 54.17, H: 6.13, N: 16.06 found C: 54.21 , H: 6.29, N: 16.05. EXAMPLE 17
1,3-dihydro-1-{1-[1-(6-benzyloxy-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
Step 1 : To 1 mL of benzyl alcohol cooled in an ice bath was added 0.1 g of 60% sodium hydride oil dispersion. After 15 min., 0.1 g of 6-chloro-2-pyrazinoic acid was added. The mixture was stirred at room temperature forl h, then acidified with 2 mL of 1 N HCl. The mixture was cooled in an ice bath and the white precipitate collected by filtration. Drying under vacuum gave 0.132 g of 6-benzyloxy-2-pyrazinoic acid: mp 160-162°C; 1H NMR (400 MHz, CDCl3) 9.00 (s, 1H), 8.56 (s, 1H), 7.49-7.36 (m, 5H), 5.46 (s, 2H).
Step 2: From 1,3-dihydro-1-{ 1-[1 -piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one dihydrochloride salt and 6-benzyloxy-2- pyrazinoic acid using the procedure described for Example 3, there was obtained 1 ,3-dihydro-1-{ 1-[ 1-(6-benzyloxy-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 9.98 (s, 1H), 8.46 (m, 1H), 8.36 (m, 1H), 7.47-7.05 (m, 9H), 5.43 (m, 2H), 4.81 (br s, 1H), 4.39 (br s, 1H), 3.9 (br s, 1H), 2.85 (m, 1H), 2.65 (m, 1H), 2.46 (m, 4H), 2.02 (br s, 1H), 1.89 (br s, 2H), 1.76-1.2 (m, 4H). The
dihydrochloride salt was precipitated from ethanol: Analysis calculated for C29H32N6O3●0.75 CH3CH2OH.0.45 H2O: C: 61.91, H: 6.54, N: 14.20 found C: 61.92, H: 6.20, N: 14.18.
EXAMPLE 18
1,3-dihydro-1-{1 -[1-(6-amino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
Step 1: A mixture of 0.15 g of 1,3-dihydro-1-{ 1-[1-(6-chloro-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 0.26 g of sodium azide and 5 mL of anhydrous N,N-dimethylformamide was stirred for 24 h, then concentrated to dryness under reduced pressure. The residue was partitioned between 50 mL of chloroform and 5 mL of saturated sodium carbonate and the organic extracts dried over MgSO4. Removal of solvents under reduced pressure and drying under vacuum gave 0.16 g of crude 1,3-dihydro-1-{ 1 -[1-(6-azido-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one.
Step 2: The crude 1 ,3-dihydro-1-{ 1 -[1-(6-azido-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one was hydrogenated under 1 atm. of hydrogen in 20 mL of ethanol over 0.05 g of 5% palladium on carbon. The catalyst was removed by filtration and the filtrate concentrated to dryness under reduced pressure. Preparative thin layer chromatography using 20%
methanol/10% cone. NH4OH/70% chloroform gave 35 mg of 1 ,3-dihydro-1-{ 1-[1 -(6-amino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one as a solid: 1H NMR (400 MHz, CDCl3) 8.12 (s, 1H), 8.02 (s, 1H), 7.85 (br s, 1H), 7.19-7.04 (m, 4H), 4.95 (br s, 1H), 4.62 (br s, 1H), 4.2 (br s, 1H), 3.65 (br s, 1H), 3.6-3.2 (m, 4H), 3.15 (m, 2H), 3.03 (m, 1H), 2.82 (m, 1H), 2.45-2.25 (m, 2H), 2.1-1.8 (m, 4H). The dihydrochloride salt was precipitated from
chloroform/methanol: Analysis calculated for C21H27N7O2●0.45
CHCl3●0.65 NH4CI: C: 46.25, H: 5.54, N: 18.38 found C: 46.28, H: 5.92, N: 18.48.
EX AMPLE 19
1,3-dihydro-1-{1-[1-(3-amino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-y l}-2H-benzimidazol-2-one
From 1,3-dihydro-1 -{ 1 -[1-piperidin-4-yl]piperidin-4-yl]-2H-benzimidazol-2-one dihydrochloride salt and 3-amino-2-pyrazinoic acid using the procedure described for Example 3, there was obtained 1,3-dihydro-1 -{ 1 -[1 -(3-amino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 10.1 (s, 1H), 8.05 (s, 1H), 7.88 (s, 1H), 7.27 (s, 1H), 7.15-7.05 (m, 3H), 5.75 (s, 2H), 4.77 (d, 1H), 4.36 (s, 1H), 4.27 (d, 1H), 2.87 (m, 1H), 2.67 (m, 2H), 2.48 (m, 3H), 2.01 (m, 1H), 1.85 (s, 3H), 1.64 (m, 2H). The dihydrochloride salt was precipitated from ethanol: Analysis calculated for C22H27N7O2●0.35 CH3CH2OH●1.45 H2O : C: 50.80, H: 6.39, N: 18.27 found C: 50.78, H: 6.25, N: 18.27.
EXAMPLE 20
1,3-dihydro-1 -{1 -[1 -(3-pyridyloxyacetyI)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 1,3-dihydro-1 -{ 1 -[1-piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one dihydrochloride salt and 3-pyridyloxyacetic acid acid using the procedure described for Example 3, there was obtained 1 ,3-dihydro-1 -{ 1-[1 -(3-pyridyloxyacetyl)piperidin-4-yl]piperidin-4-yl } -2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 8.97 (s, 1H), 8.53 (d, 1H), 8.37 (d, 1H), 8.28 (d, 1H), 8.2 (d, 1H), 7.4 (m, 1H), 7.23 (m, 1H), 7.07 (m, 3H), 5.6-4.7 (m, 3H), 4.37 (m, 1H), 3.9 (m, 1H), 3.5-3.0 (m, 4H), 2.75 (br s, 1H), 2.45 (m, 4H), 2.2-1.5 (br m, 4H). The dihydrochloride salt was precipitated from
chloroform/toluene: Analysis calculated for C24H29N5O3●0.75
CHCl3●0.35 CH3C6H5: C: 51.67, H: 5.83, N: 11.08 found C: 51.49, H: 5.93, N: 10.81.
EXAMPLE 21 1,3-dihydro-1 -{1-[1 -(4-pyrimidinecarbonyI)piperidin-4-yI]piperidin-4-yl}-2H-benzimidazol-2-one
From 1,3-dihydro-1 -{ 1 -[1-piperidin-4-yl]piperidin-4-yl} -2H-benzimidazol-2-one dihydrochloride salt and 4-pyrimidinecarboxylic acid using the procedure described for Example 3, there was obtained 1,3-dihydro-1 -{ 1-[ 1-(4-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl ]-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz,
CDCI3) 9.25 (s, 1H), 8.90 (s, 2H), 7.98 (s, 1H), 7.61 (s, 1H), 7.3 (m, 1H), 7.1 -7.05 (m, 3H), 4.8 (m, 1H), 4.4 (m, 1H), 4.1 (m, 1H), 3.1 (m, 2H), 2.9 (m, 2H), 2.77-2.35 (m, 4H), 2.0-1.5 (m, 7H). The dihydrochloride salt was precipitated from ethanol/toluene: Analysis calculated for C22H26N6O2●0.4 CH3CH2OH●0.5 CH3C6H5: C: 58.08, H: 6.38, N: 15.45 found C: 58.07, H: 6.51, N: 15.49. EXAMPLE 22
1,3-dihydro-1-{1-[1-(4-pyridazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 1,3-dihydro-1-{ 1-[1-piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one dihydrochloride salt and 4-pyridazinecarboxylic acid using the procedure described for Example 3, there was obtained 1,3-dihydro-1-{ 1-[1 -(4-pyridazinecarbonyl)piperidin-4-yl]piperidin-4-yl} -2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz,
CDCI3) 9.52 (s, 1H), 9.33 (s, 1H), 9.22 (m, 1H), 7.5 (m, 1H), 7.27 (m, 1H), 7.12-7.04 (m, 3H), 4.77 (m, 1H), 4.35 (br s, 1H), 3.6 (m, 1H), 3.1 (m. 2H), 2.9 (m, 1H), 2.65 (m, 1H), 2.44 (m, 4H), 2.1 (br s, 1H), 1.87 (m, 4H), 1.6 (m, 2H). The dihydrochloride salt was precipitated from ethanol/ether: Analysis calculated for C22H26N6O2●0.62
CH3CH2OH●0.35 (CH3CH2)2O: C: 55.44, H: 6.64, N: 15.77; found C: 55.46, H: 6.92, N: 15.77.
EXAMPLE 23
1,3-dihydro-1-{1-[1 -(4-imidazolecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 1,3-dihydro-1 -{ 1-[ 1-piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one dihydrochloride salt and 4-imidazolecarboxylic acid using the procedure described for Example 3, there was obtained 1 ,3-dihydro-1-{ 1 -[ 1-(4-imidazolecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 10.85 (br s, 0.5H), 9.9 (br s, 0.5H), 8.78 (s, 1H), 7.73 (s, 0.5H), 7.63 (d, 1H), 7.4 (s, 0.5H), 7.27 (m, 1H), 7.06 (m, 3H), 4.6 (br s, 1H), 4.33 (br s, 1H), 3.08 (m, 4H), 2.67 (m, 1H), 2.44 (m, 4H), 2.0-1.8 (m, 4H), 1.6 (br m, 3 nH). The dihydrochloride salt was precipitated from ethanol/ether: Analysis calculated for C21H26N6O2●1.0 CH3CH2OH●0.5 H2O: C: 52.87, H: 6.75, N: 16.09; found C: 53.03, H: 6.53, N: 15.73.
EXAMPLE 24
1,3-dihydro-1 -{ 1 -[1 -(4-amino-5-pyrim idinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 1,3-dihydro-1-{ 1-[1-piperidin-4-yl]piperidin-4-yl ]-2H-benzimidazol-2-one dihydrochloride salt and 4-amino-5-pyrimidinecarboxylic acid using the procedure described for Example 3, there was obtained 1 ,3-dihydro-1-{ 1-[1 -(4-amino-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 10.0 (br s, 1H), 8.57 (s, 1H), 8.23 (s, 1H), 7.27 (s, 1H), 7.13-7.03 (m, 3H), 6.98 (br s, 2H), 4.34 (br s, 2H), 3.4-1.5 (complex m, 17H). The dihydrochloride salt was precipitated from ethanol/ether: Analysis calculated for
C22H27N7O2●1.25 CH3CH2OH: C: 53.31, H: 6.66, N: 17.76; found C: 53.37, H: 6.49, N: 17.73.
EXAMPLE 25
5-ethyl-1,3-dihydro-1-{1 -[1 -(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 4-bromo-3-nitro-ethylbenzene using the procedures described for Example 2, there was obtained 5-ethyl-1 ,3-dihydro-1-{ 1 -[ 1 -(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 9.81 (s, 1H), 9.29 (s, 1H), 8.84 (s, 2H), 7.19 (d, 1H), 6.98 (s, 1H), 6.89 (d, 1H), 4.8 (br s, 1H), 4.3 (br s, 1H), 3.8 (br s, 1H), 3.1 (br m, 4H), 2.84 (br m, 1H), 2.65 (q, 2H), 2.4 (br m, 4H), 2.3-1.4 (br m, 6H), 1.22 (t, 3H). The dihydrochloride salt was precipitated from ethanol/toluene: Analysis calculated for C24H30N6O2●1.6 H2O●0.4 CH3C6H5: C: 56.16, H: 6.77, N: 14.66; found C: 56.18, H: 6.37, N: 14.69.
EXAMPLE 26
5-methoxy-1,3-dihydro-1 -{1 -[1 -(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yI}-2H-benzimidazol-2-one
From 4-chloro-3-nitro-anisole using the procedures described for Example 2, there was obtained 5-methoxy-1,3-dihydro-1-{ 1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 9.79 (s, 1H), 9.29 (s, 1H), 8.84 (s, 2H), 7.18 (br m, 1H), 6.73 (s, 1H), 6.63 (d, 1H), 4.8 (br s, 1H), 4.3 (br s, 1H), 3.8 (s, 4H), 3.1 (br m, 4H), 2.84 (br m, 1H), 2.65 (br m, 2H), 2.4 (br m, 4H), 2.1 -1.8 (br m, 4H), 1.6 (br m, 1H). The dihydrochloride salt was precipitated from ethanol/toluene: Analysis calculated for C23H28N6O3●0.3 CH3C6H5: C: 56.13, H: 6.08, N: 15.65; found C: 56.13, H: 6.39, N: 15.57. EXAMPLE 27
5-chloro-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yI]piperidin-4-yl}-2H-benzimidazol-2-one
From 2,5-dichloronitrobenzene using the procedures described for Example 2, there was obtained 5-chloro-1,3-dihydro-1 -{ 1 -[ 1 -(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCI3 + d6-DMSO) 9.3 (s, 1H), 8.83 (s, 2H), 8.2 (s, 1H), 7.20-7.05 (m, 3H), 4.5 (br m, 2H), 3.4-2.3 (br m, 12H), 2.0-1.4 (br m, 6H). The dihydrochloride salt was precipitated from ethanol/chloroform: Analysis calculated for
C22H25CIN6O2●0.3 CHCl3●0.95 H2O: C: 46.87, H: 5.15, N: 14.67; found C: 46.84, H: 5.54, N: 14.62. EXAMPLE 28
5-fluoro-1,3-dihydro-1 -{1 -[1 -(5-pyrimidinecarbonyl) piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 2-chloro-5-fluoronitrobenzene using the procedures described for Example 2, there was obtained 5-fluoro- 1 ,3-dihydro-1 -{ 1 -[ 1 -(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl } -2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.43 (s, 1H), 9.30 (s, 1H), 8.83 (s, 2H), 7.2 (m, 1H), 6.86-6.77 (m, 2H), 4.8 (br s, 1H), 4.4 (br m, 1H), 3.8 (br m. 1H), 3.1 (br m, 4H), 2.88 (br m, 1H), 2.74 (br m, 1H), 2.44 (br m, 4H), 2.0 (br m, 1H), 1.88 (br m, 2H), 1.58 (br m, 2H). The dihydrochloride salt was precipitated from ethanol/toluene: Analysis calculated for C23H28N6O3●0.3 CH3C6H5: C: 56.13, H: 6.08, N: 15.65; found C: 56.13, H: 6.39, N: 15.57.
EXAMPLE 29
1 ,3-Dihydro- 1 -{1 -[ 1 -(5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yI}-1 H-3,4-dihydroquinazolin-2-one
Step 1 : A mixture of 45 g of 2-aminomethylaniline, 60 g of di-tert -butyldicarbonate, 1000 mL of dichloromethane was stirred for 18 h and washed with 500 mL of 2N NaOH. The organic extract was dried over MgSO4 and concentrated under reduced pressure. Drying under vacuum gave 47 g of 2-(tert -butoxycarbonylaminomethyl)aniline as a white crystalline solid. 1H NMR (400 MHz, CDCl3) 7.1 (t, 1H), 7.05 (d, 1H), 6.65 (dd, 2H), 4.8 (br s, 1H), 4.2 (br m, 4H), 1.44 (s. 9H).
Step 2: A mixture of 15.5 g of 1-{tert -butoxycarbonyl
aminomethyl)aniline, 15 g of N-t-butyloxycarbonyl-4-piperidone, 250 mL of 1 ,2-dichloroethane, 4.2 mL of glacial acetic acid and 25 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na2CO 3 and the layers separated. The aqueous laver was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Drying overnight under vacuum gave 30.1 g of tert -butyl (2-(tert -butoxycarbonyl aminomethyl)anilino)piperidine carboxylate as a solid: 1H NMR (400 MHz, CDCl3) 7.19 (t, 1H), 7.0 (d, 1H), 6.6 (dd, 2H), 4.94 (br s, 1H), 4.75 (br s, 1H). 4.23 (br m, 2H), 4.0 (br m, 2H), 3.45 (br m, 1H), 3.0 (br m, 2H), 2.0 (br m, 2H), 1.82 (br m, 1H), 1.46 (s, 9H), 1.44 (s, 9H).
Step 3: To a stirred solution of 27.1 g of tert -butyl 4-(2-tert-butoxycarbonylaminomethylanilino)-1 -piperidinecarboxylate and 30 mL of triethylamine in 400 mL of dichloromethane was added dropwise 60 mL of a 1.93 M solution of phosgene in toluene. After stirring for 12 h, 200 mL of 1N NaOH was added. The mixture was shaken, and the organic layer separated, dried over MgSO4 and concentrated under reduced pressure. Chromatography on silica gel, eluting with 25% ethyl acetate in hexane gave, after drying ovemight under vacuum, 25 g of 1 ,3-dihydro-1-[ 1-tert -butoxycarbonylpiperidin-4-yl]-3-tert
-butoxycarbonyl-1H-3,4-dihydroquinazolin-2-one carboxylate as a clear glass: 1H NMR (400 MHz, CDCI3) 7.52 (d, 1H), 7.45 (t, 1H), 7.36 (m, 1H), 7.10 (d, 1H), 4.2-4.0 (br m, 5H), 3.65-3.25 (br m, 2H), 2.75 (br m, 2H), 2.28 (br d, 1H), 1.8 (br d, 1H), 1.5 (s, 9H), 1.49 (s, 9H).
Step 4: A stirred solution of 25 g of 1 ,3-dihydro-1 -[1 -tert
-butoxycarbonylpiperidin-4-yl]-3-tert -butoxycarbonyl-1H-3,4-dihydroquinazolin-2-one carboxylate in 1 L of ethyl acetate cooled to -50°C was saturated with hydrogen chloride gas for 15 min. The resulting mixture was allowed to warm to room temperature and stir for 4 h. The white solid precipitate was collected by filtration. Drying under vacuum gave 13.1 of 1 ,3-dihydro-1-[piperidin-4-yl]-3-tert
-butoxycarbonyl-1H-3,4-dihydroquinazolin-2-one hydrochloride salt as a white solid. The salt (0.8 g) was converted to the free base by partitioning between chloroform and saturated sodium carbonate.
Drying under vacuum gave 0.68 g of 1 ,3-dihydro-1-[piperidin-4-yl]- 1H-3,4-dihydroquinazolin-2-one as a white solid: 1H NMR (400 MHz, CDCI3) 7.25 (dd, 1H), 7.12 (d, 1H), 7.06 (d. 1H), 6.98 (t, 1H), 5.2 (br s. 1H), 4.28 (s, 2H), 4.10 (m, 1H), 3.22 (d, 2H), 2.73 (m, 2H), 2.59 (m, 2H), 2.05 (br s, 1H), 1.82 (br d, 2H).
Step 5: A mixture of 0.52 g of 1 ,3-dihydro-1-[piperidin-4-yl]-1H-3,4-dihydroquinazolin-2-one, 0.65 g of N-t-butyloxycarbonyl-4-piperidone, 10 mL of 1 ,2-dichloroethane, 0.3 mL of glacial acetic acid and 1 g of sodium triacetoxyborohydride was stirred at room
temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 25 mL of chloroform and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Chromatography over silica gel using 15% methanol in ethyl acetate gave 0.9 g of 1 ,3-dihydro-1 -{ 1 -[ 1 -(tert -butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl } -1H-3,4-dihydroquinazolin-2-one as a solid: 1H NMR (400 MHz, CDCl3) 7.22 (t, 1H), 7.14 (d, 1H), 7.05 (d, 1H), 6.97 (t, 1H), 5.57 (br s, 1H), 4.27 (s, 2H), 4.1 (br m, 4H), 3.07 (d, 2H), 2.68 (br m, 4H), 2.5 (br t, 1H), 2.36 (br t, 2H), 1.8 (br d, 4H), 1.82 (br m, 1H), 1.46 (s, 9H).
Step 6: A stirred solution of 0.9 g of 1 ,3-dihydro- 1 -{ 1 -[1-(tert-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl }- 1 H-3,4-dihydroquinazolin-2-one in 40 mL of 1N HCl was heated to reflux for 6 h, cooled and concentrated to dryness. After drying overnight under vacuum, there was obtained 0.58 g of 1,3-dihydro-1 -{ 1-[piperidin-4-yl]piperidin-4-yl }-1H-3,4-dihydroquinazolin-2-one dihydrochloride salt as a white solid.
Step 7: To a stirred solution of 0.58 g of 1 ,3-dihydro-1-{ 1- [piperidin-4-yl]piperidin-4-yl }-1H-3,4-dihydroquinazolin-2-one dihydrochloride salt and lmL of triethylamine in 50 mL of
dichloromethane was added 0.3 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 50 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two additional 50 mL portions of chloroform and the combined organic extracts dried over MgSO4 and concentrated under reduced pressure. Chromatography over silica gel using 15% methanol in ethyl acetate gave 0.45 g of 1,3- dihydro-1 -{ 1 -[ 1-(5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-1H-3,4-dihydroquinazolin-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.26 (s, 1H), 8.82 (s, 2H), 7.22 (m, 1H), 7.1 1 (m, 1H), 7.05 (m, 1H), 6.95, (m, 1H), 6.16 (br s, 1H), 4.72 (br s, 1H), 4.27 (s. 2H), 4.04 (br m, 1H), 3.74 (br s, 1H), 3.06 (br m, 2H), 2.87 (br m, 1H), 2.7 (br m, 4H), 2.36 (m, 2H), 2.05 (br m, 1H), 1.99 (br m. 1H), 1.81 (br m, 2H), 1.58 (br m, 2H). The dihydrochloride salt was recystallized from ethanol/ethyl acetate: Analysis calculated for C23H28N6O2●1.95HCl C: 56.19, H: 6.14, N: 17.10 found C: 56.57, H: 6.54, N: 16.70.
EXAMPLE 30
(±)-1,3-Dihydro-1 -{1 -[1 -( 1 -(5-pyrimidinyI)-ethyl)piperidin-4-yl]piperidin-4-yl} -2H-benzimidazol-2-one
Step 1 : To a stirred mixture of 1.1 g of 5-(1 -aminoethyl)pyrimidine (O. Cervinska and P. Malon, Coll. Czechoslov. Chem. Commun. 1977, 42 , 3464-72.), 17 mL of ethanol and 1.36 g of K2CO3 heated to reflux was added dropwise over 30 min, a solution of 4 g of 1 ,1 -dimethyl-4oxopiperidinium iodide in 70 mL of water. When the addition was complete, the mixture was heated under reflux for an additional 2 h, cooled, basified to pH 9 with K2CO3 and extracted with 5 times with 50 mL portions of methylene chloride. The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure.
Chromatography over silica gel, eluting with 90:10 CH3CN:MeOH gave 0.48 g of 1-(1 -(5-pyrimidinyl)-ethyl)-4-oxopiperidine as an oil: 1 H NMR (400 MHz, CDCl3 ) 9.14 (s, 1H). 8.78 (s, 2H), 3.8 (q, J = 7 Hz, 1H). 2.7-2.9 (m. 4H), 2.45 (m, 4H), 1.5 (d, J = 7 Hz, 3H).
Step 2: A mixture of 0.24 g of 1 -( 1-(5-pyrimidinyl)-ethyl)-4-oxopiperidine, 0.24 g of 1-(4-piperidinyl) benzimidazol-2H-one, 4 mL of 1 ,2-dichloroethane, 0.12 mL of glacial acetic acid and 0.45 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 100 mL dichloromethane and 25 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 25 mL of dichloromethane and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Trituration of the residue with 10 mL of ethyl acetate gave 90 mg of (±)-1 ,3-dihydro-1 -{ 1 -[1 -(1 -(5-pyrimidinyl)-1 -ethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one as a white solid. Purification of the filtrate by chromatography on silica gel eluting with 220:60:20 CHCl3:MeOH:conc. NH4OH gave an additional 220 mg of product: 1H NMR (400 MHz, CDCl3 ) 9.7 (s, 1H), 9.12 (s, 1H), 8.71 (s, 2H), 7.26 (br m, 1H), 7.0-7.1 (br m, 3H), 4.35 (br m, 1H), 3.55 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.05 (br t, 2H), 1.86 (br m, 4H), 1.6 (br m, 2H), 1.4 (d, J = 7 Hz, 3H). Analysis calculated for C23H30N6O●0.5 H2O●0.15 CH3CO2CH2CH3 : C: 66.1 1 , H: 7.57, N: 19.60 found C: 66.22. H: 7.29, N: 19.23.
EXAMPLE 31
(1 '''S) 1,3-Dihydro-1 -{1 '-[1 "-(1 ,"-(5""-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yI}-2H-benzimidazol-2-one From (S)-(-)- 5-(1 -aminoethyl)pyrimidine (O. Cervinska and P. Malon, Coll. Czechoslov. Chem. Commun. 1977, 42 , 3464-72.) using the procedures described in Example 30 there was obtained (1"'S) 1,3-dihydro- 1 -{ 1 '-[ 1''-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl }-2H-benzimidazol-2-one as a white solid: mp 126-7°C; 1H NMR (400 MHz, CDCl3 ) 9.7 (s, 1H), 9.12 (s, 1H), 8.71 (s,
2H), 7.26 (br m, 1H), 7.0-7.1 (br m. 3H), 4.35 (br m, 1H), 3.55 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.05 (br t, 2H), 1.86 (br m, 4H), 1.6 (br m, 2H), 1.4 (d, J = 7 Hz, 3H).
The bis-maleate salt: Analysis calculated for C23H30N6O●2 C4H4O4: C:58.29, H: 6.00, N: 13.16 found C: 58.29. H: 6.00, N: 13.25. EXAMPLE 32
(1''',R) 1,3-Dihydro-1-{1,-[1"-(1''',-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2- one
From (R)-(+)-5-(1-aminoethyl)pyrimidine (from D-tartaric acid using procedure of O. Cervinska and P. Malon, Coll. Czechoslov. Chem. Commun. 1977, 42, 3464-72.) using the procedures described in Example 30 there was obtained (1'"R) 1,3-dihydro-1-{1'-[1''-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one as a white solid: mp 126-7°C; 1H NMR (400 MHz, CDCl3) 9.7 (s, 1H), 9.12 (s.1H), 8.71 (s, 2H), 7.26 (br m, 1H), 7.0-7.1 (br m, 3H), 4.35 (br m, 1H), 3.55 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.05 (br t, 2H), 1.86 (br m, 4H), 1.6 (brm, 2H), 1.4 (d, J = 7 Hz, 3H).
The bis-maleate salt: Analysis calculated for C23H30N6O-2
C4H4O4●0.5 H2O: C.57.88, H: 6.03, N: 13.07; found C: 57.78, H: 5.91, N: 13.01.
EXAMPLE 33
(1'''S) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyrimidinyl)-ethyl)piperidin-4''-yI]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one
From (S)-(-)-5-(1-aminoethyl)pyrimidine (O. Cervinska and P. Malon. Coll. Czechoslov. Chem. Commun. 1977,42, 3464-72.) using the procedures described in Example 30, but substituting 5-chloro-1-(4-piperidinyl)benzimidazol-2H-one for 1 -(4-piperidinyl)benzimidazol-2H-one, there was obtained (1'''S) 1,3-dihydro-1-{1'-[1''-(1'''-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one as a white solid: mp 203-5°C; 1H NMR (400 MHz, CDCl3) 9.12 (s.1H), 8.95 (br s, 1H), 8.71 (s, 2H). 7.18 (d, 1H), 7.07 (d, 1H), 7.01 (dd, 1H), 4.3 (br m, 1H), 3.55 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.05 (br t, 2H), 1.85 (br m, 4H), 1.6 (br m, 2H), 1.4 (d, J = 7 Hz, 3H).
The bis-maleate salt: Analysis calculated for C23H29ClN6O●2 C4H4O4: C:55.31, H: 5.54, N: 12.49; found C: 55.41, H: 5.54, N: 12.60.
EXAMPLE 34
(1"'R) 1,3-Dihydro-1-{1'-[1''-(1'''-(5""-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazoI-2-one
From (R)-(+)-5-(1-aminoethyl)pyrimidine (from D-tartaric acid using procedure of O. Cervinska and P. Malon, Coll. Czechoslov. Chem.
Commun. 1977, 42, 3464-72.) using the procedures described in Example 30, but substituting 5-chloro-1-(4-piperidinyl) benzimidazol-2H-one for 1-(4-piperidinyl)benzimidazol-2H-one, there was obtained (1'"R) 1,3-dihydro-1-{1'-[1''-(1"'-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one as a white solid: mp 202-4°C; 1H NMR (400 MHz, CDCl3) 9.12 (s, 1H), 8.95 (br s, 1H), 8.71 (s, 2H), 7.18 (d, 1H), 7.07 (d, 1H), 7.01 (dd, 1H), 4.3 (br m, 1H), 3.55 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.05 (br t, 2H), 1.85 (br m, 4H), 1.6 (br m.2H), 1.4 (d, J = 7 Hz, 3H). The bis-maleate salt: Analysis calculated for C23H29ClN6O●2
C4H4O4●0.25CH3CH2OH●1.0H2O: C:53.68, H: 5.90, N: 11.81;
found C: 53.68, H: 5.51, N: 11.59. EXAMPLE 35
(1"'S) 1,3-Dihydro-1-{1'-[1''-(1''' -(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one
From (S)-(-)-5-(1-aminoethyl)pyrimidine (O. Cervinska and P. Malon, Coll. Czechoslov. Chem. Commun. 1977,42, 3464-72.) using the procedures described in Example 30, but substituting 5-methyl-1-(4-piperidinyl)benzimidazol-2H-one for 1 -(4-piperidinyl)benzimidazol-2H-one, there was obtained (1"'S) 1,3-dihydro-1-{1'-[1''-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one as a white solid: mp 179-180°C; 1H NMR (400 MHz, CDCl3) 9.12 (s, 1H), 8.70 (s, 2H), 8.16 (br s, 1H), 7.17 (d, 1H), 6.87 (br s, 1H), 6.85 (d, 1H), 4.3 (br m, 1H), 3.55 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H).2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.36 (s, 3H), 2.05 (br t, 2H), 1.85 (br m, 4H), 1.6 (br m, 2H).1.4 (d, J = 7 Hz, 3H).
The bis-maleate salt: Analysis calculated for C24H32N6O●2
C4H4O4●0.5 H2O: C:58.08, H: 6.25. N: 12.70; found C: 58.28, H: 6.13, N: 12.47.
EXAMPLE 36
(1''' R) 1,3-Dihydro-1-{1'-[1"-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one
From (R)-(+)-5-(1-aminoethyl)pyrimidine (from D-tartaric acid using procedure of O. Cervinska and P. Malon, Coll. Czechoslov. Chem.
Commun. 1977, 42 , 3464-72.) using the procedures described in Example 30, but substituting 5-methyl-1-(4-piperidinyl)benzimidazol-2H-one for 1-(4-piperidinyl)benzimidazol-2H-one, there was obtained ( 1'''R) 1,3-dihydro-1-{1'-[1''-(1"'-(5"''-pyrimidinyl)-ethyl)piperidin- 4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one as a white solid: mp 170-172°C; 1H NMR (400 MHz, CDCl3 ) 9.12 (s, 1H), 8.70 (s, 2H), 8.16 (br s, 1H), 7.17 (d, 1H), 6.87 (br s, 1H), 6.85 (d, 1H), 4.3 (br m, 1H), 3.55 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.36 (s, 3H), 2.05 (br t, 2H), 1.85 (br m, 4H), 1.6 (br m, 2H), 1.4 (d, J = 7 Hz, 3H).
The bis-maleate salt: Analysis calculated for C24H32N6O●2
C4H4O4●0.5 H2O: C58.08, H: 6.25, N: 12.70; found C: 58.28, H: 6.13, N: 12.47. EXAMPLE 37
1,3-Dihydro-1 -{1 -[4-oxocyclohex-1 -yl]piperidin-4-yl}-2H-benzimidazol-2-one Step 1 : A mixture of 5 g of 1 ,4-cyclohexanedione mono-ethyleneketal, 4.3 g of 1 ,3-dihydro-1 -(4-piperidinyl)-benzimidazol-2H-one, 75 mL of 1 ,2-dichloroethane, 1.2 mL of acetic acid and 5.45 g of sodium
triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Trituration of the crude product with 200 mL of ethyl ether gave 7.0 g of the ethylene ketal of 1 ,3-dihydro-1-{ 1-[4-oxocyclohex-1 -yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: mp = 208-210°C; 1H NMR (400 MHz, CDCl3 ) 9.14 (br s, 1H), 7.3 (m, 1H), 7.1 (m, 1H), 7.05 (m, 2H), 4.35 (br s, 1H), 3.96 (s, 4H), 3.05 (br d, J= 6.6, 2H), 2.45 (m, 4H), 1.84 (br d, J = 2.8, 5H), 1.72-1.55 (m, 6H).
Step 2: A mixture of 7.0 g of the ethylene ketal of 1 ,3-dihydro-1 -{ 1 -[4-oxocyclohex-1-yl]piperidin-4-yl} -2H-benzimidazol-2-one, 80 mL of glacial acetic acid, 80 mL of water and 20 mL of cone. HCl was heated under reflux for 2 h, then allowed to cool ovemight. The mixture was concentrated under reduced pressure, diluted with 100 mL of saturated Na2CO3 and extracted into 3 X 200 mL of CHCl3. The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. Trituration with ether-ethyl acetate and drying under vacuum gave 5 g of 1 ,3-dihydro-1 -{ 1 -[4-oxocyclohex-1 -yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: mp = 221 -223°C; 1H NMR (400 MHz, CDCl3) 8.68 (br s, 1H), 7.28 (m, 2H), 7.07 (m, 2H), 4.35 (br s, 1H), 3.12 (br d, J= 8.7, 2H), 2.82 (br t, J = 9.74, 2H), 2.50 (br t, J = 13.76, 2H), 2.44-2.32 (m, 6H), 2.06 (br s, 2H), 1.87 (br d, J = 10.9, 4H). Analysis calculated for C18H23N3O2●0.4 H2O: C: 67.44, H: 7.48, N: 13.1 1. found C: 67.44, H: 7.41 , N: 12.86.
EXAMPLE 38 cis -1,3-D'hydro-1 -{ 1 -[1 -(5-pyrimidiny lamino)cyclohex-4-yl]piperidin-4-yI}-2H-benzimidazol-2-one and
trans -1,3-Dihydro-1 -{1 -[1 -(5-pyrimidinylamino)cyclohex-4-yI]piperidin-4-yI}-2H-benzimidazoI-2-one
A mixture of 0.25 g of 1 ,3-dihydro- 1 -{ 1 -[4-oxocyclohex-1 -yl]piperidin-4-yl }-2H-benzimidazol-2-one, 0.25 g of 5-aminopyrimidine (H. Bredereck, F. Effenberger and E. H. Schweizer, Chem. Ber. 1962 95, 803-9), 2 mL of 1 ,2-dichloroethane, 0.5 mL of acetic acid and 0.35 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 200 mL chloroform and 20 mL saturated aqueous Na2CO3 and the layers separated. The aqueous layer was extracted with 2 X 25 mL of CHCl3 and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Preparative TLC on silica gel, eluting with 85: 15:5
Et2O:MeOH:conc. NH4OH gave 85 mg of trans -1 ,3-dihydro- 1 -{ 1 -[ 1 -(5-pyrimidinylamino)cyclohex-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one: 1 H NMR (400 MHz. CDCl3 + 5% CD3OD) 8.44 (s, 1H), 8.12 (m, 2H), 7.36 (m, 1H), 7.09 (m. 3H), 4.3 (br m, 1H), 3.65 (br m, 2H), 3.2 (br m, 2H), 2.45 (m, 5H), 2.0 (m, 2H), 1.85 (br m, 4H), 1.65 (m, 4H): Analysis calculated for C22H28N6O●1.05 H2O●0.25 CHCl3: C: 60.56, H: 7.17, N: 18.68: found C: 60.81. H: 7.17, N: 18.68. and 75 mg of cis -1,3-dihydro-1 -{ 1-[1-(5-pyrimidinylamino)cyclohex-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one: 1H NMR (400 MHz, CDCl3 + 5% CD3OD) 8.43 (s, 1H), 8.08 (m, 2H), 7.65 (m, 1H), 7.1 (m, 3H), 4.6 (br m, 1H), 3.6 (br m, 2H), 3.25 (br m, 2H), 3.0 (br m, 5H), 2.3 (m, 4H), 2.0 (m, 2H), 1.75 (br m, 2H), 1.35 (m, 2H): Analysis calculated for C22H28N6O●0.25 H2O-0.75 CHCl3: C: 55.90, H: 5.97, N: 17.16; found C: 56.19, H: 5.96, N: 17.14.
EXAMPLE 39 trans-1,3-Dihydro-1 -{4-[4-(3-pyridinylmethyl)piperazin-1 -yl]-1 -cyclohexyl}-2H-benzimidazol-2-one
Step 1 : A mixture of 0.10 g of trans -1 ,3-dihydro-1 -{4-(1 - piperazinyl)-1 -cyclohexyl }-2H-benzimidazol-2-one, 0.037 mL of 3-pyridinecarboxaldehyde, 15 mL of 1 ,2-dichloroethane, 0.10 mL of glacial acetic acid and 0.1 1 g of sodium triacetoxyborohydride was stirred at room temperature for 24 h. The reaction mixture was poured into 10 mL dichloromethane and 10 mL saturated aqueous NaHCO3 and the layers separated. The aqueous layer was extracted with 2 X 10 mL of dichloromethane and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Preparative thin layer chromatography on silica gel, eluting with 90:10:2 chloroform:
methanol: cone. NH4OH gave 0.050 g of trans -1,3-dihydro-1 -{4-[4-(3-pyridinylmethyl)piperazin-1 -yl]-1 -cyclohexyl }-2H-benzimidazol-2-one as a white solid: mp = 250°C; 1H NMR (400 MHz, CDCl3 ) 9.71 (br s, 1H), 8.54 (dd. 2H), 7.68 (d, J = 7.9, 1H), 7.26 (t, 1H), 7.15-7.02 (m, 4H), 4.26 (m, 1H), 3.54 (s, 2H), 2.66 (br dd, 4H). 2.27 (q, 2H), 2.10 (d, 2H), 1.97 (d, 2H), 1.92 (q, 2H): Analysis calculated for
C23H29N5O●0.45 CHCl3 C: 63.25, H: 6.67, N: 15.73 found C: 62.96, H: 6.74, N: 15.54. EXAMPLE 40
1,3-Dihydro-1 -{1 -[1 -(2-pyrazinylmethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazoI-2-one
From the procedure in Example 8, substituting pyrazine-2-carboxaldehyde for 3-pyridinecarboxaldehyde there was obtained 1 ,3-dihydro-1 -{ 1 -[ 1 -(2-pyrazinylmethyl)piperidin-4-yl]piperidin-4-yl } -2H- benzimidazol-2-one as white solid: 1H NMR (400 MHz, CDCl3 ) 10.40 (br s, 1H), 8.69 (d, 1H), 8.54 (dd, 1H), 8.47 (d, 1H), 7.31 (m, 1H), 7.10 (m, 1H), 7.06-7.00 (m, 2H), 4.37 (m, 1H). 3.70 (s. 2H), 3.12 (d, 2H), 2.99 (d, 2H), 2.54-2.40 (m. 5H), 2.15 (t, 2H), 1.85 (d, 4H), 1.70 (qd, 2H).
EXAMPLE 41
(±)- cis-1 ,3-Dihydro-1 -( 1 -{4-[(5-pyrimidinyl)hydroxymethyl]cyclohex-1 -yl}piperidin-4-yl)- 2H-benzimidazol-2-one and
(±)-trans-1,3-Dihydro-1-(1 -{4-[(5-pyrimidinyl)hydroxymethyl]cyclohex-1 -yI}piperidin-4-yl)-2H-benzimidazol-2-one
Step 1 : A mixture of ethyl 4-oxocyclohexanecarboxylate (1.86 g), 4-(2-oxo-1 -benzimidazolinyl)piperidine ( 1.98 g), 1 ,2-dichloroethane (40 mL), glacial acetic acid (0.52 mL) and sodium triacetoxyborohydride (3.47 g) was stirred at room temperature for 72 h. The reaction mixture was poured into dichloromethane (50 mL) and saturated
Na2CO3 (50 mL) and the layers separated. The aqueous layer was extracted with 2 X 50 mL of dichloromethane and the combined organic layers dried over MgSO4 and concentrated to dryness under reduced pressure. The crude product was purified by flash column
chromatography on silica, eluting with a gradient of ethyl acetate; 0-8% methanol to yield the cis and trans isomers of ethyl 1 -[4-(2-keto- 1 - benzimidazolinyl)piperidin-1-yl]cyclohexane-4-carboxylate as a colorless solid (2.23 g).
Step 2: To a stirred solution of the cis and trans isomers of ethyl 1-[4-(2-keto-1 -benzimidazolinyl)piperidin- 1-yl]cyclohexane-4-carboxylate (2.16 g) in dry toluene (150 mL) at -90 °C under argon, was added diisobutylaluminum hydride (1 1.6 mL of a 1.5 M solution in toluene). The reaction mixture was stirred at -90 °C for 1h, then quenched with methanol (1 mL) followed by saturated sodium potassium tartrate (50 mL). The layers were separated, the aqueous layer was extracted with 2 X 100 mL of ethyl acetate, and the combined organic layers were dried over MgSO4 and concentrated to dryness under reduced pressure to give the cis and trans isomers of 1-[4-(2-keto-1-benzimidazolinyl)piperidin-1 -yl]cyclohexane-4-carboxaldehyde as a colorless foam (1.82 g).
Step 3: To a stirred solution of 5-bromopyrimidine (3.98 g) in 1 : 1 diethyl ether; tetrahydrofuran (120 mL) at -1 10 °C under argon, was added n-butyllithium (10.4 mL of a 1.6 M solution in hexanes) at such a rate that the temperature was maintained at -1 10 °C. After stirring for an additional 10 min at this temperature, a solution of the cis and trans isomers of 1 -[4-(2-keto-1-benzimidazolinyl)piperidin-1-yl]cyclohexane-4-carboxaldehyde (0.91 g) in tetrahydrofuran (50 mL) was slowly added. The reaction mixture was allowed to warm gradually to room temperature, quenched with 1 N NaHCO3 (100 mL), and extracted with
3 X 150 mL ethyl acetate. The combined extracts were dried over MgSO4 and concentrated under reduced pressure. The residue was taken up in chloroform (200 mL) and extracted with H2O (100 mL) at pH 6. The aqueous layer was then adjusted to pH 1 1 and extracted with
4 X 100 mL chloroform and these extracts were dried over Na2SO4 and concentrated under reduced pressure. Silica chromatography, eluting with acetonitrile; 5% NH4OH, yielded 1.0 g of the desired cis and trans isomers. A 100 mg sample of the isomers was purified by normal phase HPLC, eluting with butyl chloride; 19% ethanol; 0.1% triethylamine, gave: 54 mg of (±)-cis -1 ,3-dihydro-1-( 1 -{ 4-[(5-pyrimidinyl)hydroxymethyl]cyclohex- 1 -yl}piperidin-4-yl)-2H- benzimidazol-2-one as a colorless solid: 1H NMR (400 MHz, CDCl3 ) 9.71 (br s, 1H), 9.14 (s, 1H), 8.75 (s, 2H), 7.25 (m, 1H), 7.11-7.02 (m, 3H), 4.71 (d, 1H), 4.32 (tt, 1H), 3.20 (m, 2H), 3.15 (br s, 1H), 2.44 (m, 2H), 2.34 (m, 1H), 2.17 (t. 2H), 1.98-1.75 (m, 6H), 1.64-1.49 (m, 3H), 1.42 (m, 1H), 1.30 (m, 1H). The hydrochloride salt was precipitated from ethanol/toluene: analysis calculated for C23H29N5O2●HCl●1.65 H2O●0.20 C6H5CH3 C: 59.55, H: 7.15, N: 14.23; found C: 59.53, H: 6.85, N: 14.32; and 29 mg of (±)-trans -1 ,3-dihydro-1 -(1 -{4-[(5-pyrimidinyl)hydroxymethyl]cyclohex-1 -yl }piperidin-4-yl)-2H-benzimidazol-2-one as a colorless solid: 1H NMR (400 MHz, CDCl3 ) 9.28 (br s, 1H), 9.14 (s, 1H), 8.70 (s, 2H), 7.34 (m. 1H), 7.10-7.01 (m, 3H), 4.54 (d, 1H), 4.33 (tt, 1H), 3.05 (m, 2H), 2.68 (br s, 1H), 2.53-2.35 (m, 5H), 2.07-1.93 (m, 3H), 1.88- 1.82 (m, 2H), 1.68-1.58 (m, 2H), 1.37-1.25 (m, 2H), 1.13 (m, 2H). The hydrochloride salt was
precipitated from ethanol/toluene: analysis calculated for
C23H29N5O2●1.8 HCl C: 58.39, H: 6.56, N: 14.80; found C: 58.27, H: 6.63, N: 14.98.
EXAMPLE 42 trans -1,3-Dihydro-1 -{ 1 -[4-(5-pyrimidinylcarbon yl)cyclohex-1 -yI]piperidin-4-yl}-2H-benzimidazoI-2-one
Step 1 : To a stirred solution of oxalyl chloride (68 mg) in dry
dichloromethane (4 mL) at -60 °C, under argon, was added dry dimethyl sulfoxide (0.107 mL) dropwise. The resulting mixture was stirred for 5 min, then added to a solution of (±)-cis-1 ,3-dihydro-1 -( 1 -{4-[(5-pyrimidinyl)hydroxymethyl]cyclohex-1 -yl }piperidin-4-yl)-2H-benzimidazol-2-one (1 12 mg) in dichloromethane (5 mL) at -60 °C. The reaction mixture was stirred for 20 min at -60 °C, then
triethylamine (0.54 mL) was added and the solution was allowed to warm to room temperature. Water was added and the mixture stirred for a further 10 min, after which saturated sodium carbonate was added and the mixture was extracted with dichloromethane (3 X 20 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo. Purification by preparative TLC on silica eluting with chloroform; 7% methanol; 1 % NH4OH, followed by a second purification eluting with dichloromethane; 10% methanol; 1 % NH4OH yielded trans -1,3-dihydro-1 -{ 1 -[4-(5-pyrimidinylcarbonyl)cyclohex-1 -yl]piperidin-4-yl }-2H-benzimidazol-2-one: 1H NMR (400 MHz, CDCl3 ; CD3OD) 9.34 (s, 1H), 9.30 (s, 2H), 7.43 (m, 1H), 7.1 1 -7.04 (m, 3H), 4.40 (tt, 1H), 3.36 (m, 1H), 3.28 (d, 2H), 2.73-2.57 (m, 5H), 2.24-2.10 (m, 4H), 1.90 (m, 2H), 1.633 (m, 4H). m/z (FAB): 406 (MH+). The hydrochloride salt was precipitated from ethanol/chloroform: analysis calculated for C23H27N5O2●2 HCl●0.75 H2O●0.35 C2H5OH C: 56.03, H: 6.47, N: 13.78; found C: 56.03, H: 6.14, N: 13.76.
EXAMPLE 43 cis -1,3-Dihydro-1 -{1 -[1 -(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one and
trans -1,3-Dihydro-1-{1 -[1 -(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
Step 1 : A mixture of 1 ,3-dihydro-1 -{ 1 -[4-oxocyclohex-1 -yl]piperidin-4-yl }-2H-benzimidazol-2-one (200 mg), 3-aminopyridine (29 mg), 1 ,2-dichloroethane (1.5 mL), acetic acid (0.087 mL) and sodium
triacetoxyborohydride (180 mg) was stirred at room temperature for 20 h. The reaction mixture was poured into saturated aqueous Na2CO3 (10 mL) and extracted with dichloromethane (3 X 30 mL). The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. Column chromatography on silica gel, eluting with a gradient of dichloromethane; 0.5% NH4OH; 3-10% methanol gave 83 mg of the desired cis and trans isomers, which were separated by normal phase HPLC (eluting with butyl chloride; 7% methanol;
0.2% triethylamine): cis -1 ,3-dihydro-1 -{ 1-[1-(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one (34 mg): 1H NMR (400 MHz, CDCl3 ) 10.03 (br s, 1H), 8.05 (d, 1H), 7.94 (d, 1H), 7.29 (dd, 1H), 7.14-7.01 (m, 4H), 6.88 (dd, 1H), 4.37 (tt, 1H), 3.86 (d, 1H), 3.61 (m, 1H), 3.17 (d, 2H), 2.53-2.30 (m, 5H), 2.01 -1.84 (m, 4H), 1.78-1.59 (m, 6H). The hydrochloride salt was precipitated from ethanol/toluene and triturated with diethyl ether: analysis
calculated for C23H29N5O●3 HCl●0.30 (C2H5)2O C: 55.56, H: 6.74, N: 13.39; found C: 55.59, H: 6.73, N: 13.41 ; trans -1 ,3-dihydro-1 -{ 1-[ 1 -(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one (10 mg): 1H NMR (400 MHz. CDCl3 ) 9.28 (br s, 1H), 8.01 (d, 1H), 7.93 (d, 1H), 7.32 (m, 1H). 7.09-7.03 (m, 4H), 6.86 (ddd, 1H), 4.36 (tt, 1H), 3.22 (tt, 1H), 3.09 (d. 2H), 2.50-2.39 (m. 5H), 2.23 (d, 2H), 2.00 (d, 2H), 1.86 (m, 2H), 1.47 (q, 2H), 1.21 (q, 2H). The hydrochloride salt was precipitated from methanol/diethyl ether: analysis calculated for C23H29N5O●3 HCl●0.65 CH3OH C: 54.45, H: 6.68, N: 13.42; found C: 54.44, H: 6.60, N: 13.29.
EXAMPLE 44
(±)-1 ,3-Dihydro-1 -(1-{1 -[1-(2-pyrazinyl)-ethyl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one
Step 1 : Sodium borohydride (0.69 g) was added in portions to a stirred solution of acetylpyrazine (1.49 g) in ethanol (300 mL) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 20 min, then water (100 mL) was added and the mixture adjusted to pH 7 with 1 N hydrochloric acid. The neutralized solution was concentrated in vacua to a volume of 200 mL, saturated with sodium chloride, and extracted with ethyl acetate (3 X 500 mL). The organic extracts were dried (Na2SO4) and concentrated to give a solid which was washed with dichloromethane (4 X 100 mL). The dichloromethane washings were concentrated to give 2-(1 -hydroxyethyl)pyrazine (1.38 g) as a colorless oil.
Step 2: To a stirred solution of 2-( 1 -hydroxyethyl)pyrazine (0.859 g) and diphenylphosphoryl azide (2.48 g) in dry toluene (12 mL) at 0 °C, under argon, was added 1 ,8-diazabicyclo[5.4.0]undec-7-ene ( 1.35 mL) dropwise. The resulting mixture was allowed to warm slowly to room temperature and stirred for 22 h then quenched with water (8 mL). The organic layer was removed and the aqueous phase extracted with 10 mL ethyl acetate. The combined extracts were concentrated, and the crude product was purified by flash column chromatography, eluting with hexane; 25% ethyl acetate to give 2-(1-azidoethyl)pyrazine (0.88 g) as a colorless oil.
Step 3: 2-(1-Azidoethyl)pyrazine (0.77 g) and 10% palladium on carbon (0.075 g) were stirred in ethanol (40 mL) under an atmosphere of hydrogen at room temperature for 2 h. The mixture was filtered through a pad of celite and the filtrate concentrated under reduced pressure to yield 2-(1-aminoethyl)pyrazine (0.56 g) as a pale oil
Step 4: To a stirred mixture of 2-(1 -aminoethyl)pyrazine (225 mg), ethanol (10 mL) and K2CO3 (72 mg) heated to reflux was added dropwise over 30 min, a solution of 4 g of 1 ,1 -dimethyl-4-oxopiperidinium iodide (2.1 g) in water (36 mL). When the addition was complete, the mixture was heated under reflux for an additional 2 h, cooled, basified to pH 10 with Na2CO3 and extracted with ethyl acetate (3 X 100 mL). The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. Column
chromatography over silica gel, eluting with a gradient of ethyl acetate; 0-5% methanol gave 300 mg of 1 -(1 -(2-pyrazinyl)-ethyl)-4-oxopiperidine as an oil: 1H NMR (400 MHz, CDCl3 ) 8.74 (d, 1H), 8.54 (dd, 1H), 8.48 (d, 1H), 3.94 (q, 1H), 2.89-2.75 (m, 4H). 2.46 (t, 4H), 1.50 (d, 3H).
Step 5: A mixture of 1 -(1-(2-pyrazinyl)-ethyl)-4-oxopiperidine (37 mg), 4-(2-oxo-1 -benzimidazolinyl)piperidine (41 mg), 1 ,2-dichloroethane (0.75 mL), glacial acetic acid (0.01 1 mL) and sodium triacetoxyborohydride (60 mg) was stirred at room temperature for 48 h. The reaction mixture was poured into dichloromethane (5 mL) and saturated aqueous Na2CO3 (3 mL) and the layers separated. The aqueous layer was extracted with dichloromethane (2 X 5 mL) and the combined organic layers dried over Na2SO4 and concentrated under reduced pressure. Purification by preparative TLC. eluting with chloroform; 10% methanol; 1% NH4OH, followed by trituration with diethyl ether gave 35 mg of (±)-1,3-dihydro-1-(1-{1-[1-(2-pyrazinyl)-1-ethyl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one as a colorless solid: 1H NMR (400 MHz, CDCl3) 9.77 (br s, 1H), 8.69 (d, 1H), 8.54 (dd, 1H), 8.46 (d, 1H). 7.35 (m, 1H), 7.11-7.03 (m, 3H), 4.39 (m, 1H), 3.73 (q, 1H), 3.11 (m, 3H), 2.90 (m, 1H), 2.35-2.55 (m, 5H), 2.11 (m, 2H), 1.92-1.61 (m, 6H), 1.44 (d, 3H). Analysis calculated for C23H30N6O●0.1 H2O●0.3 CHCl3: C: 63.01, H: 6.92, N: 18.92 found C: 63.07, H: 6.96, N: 18.76.
EXAMPLE 45
(±) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)- ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one
From 3-(1-aminoethyl)pyridine using the procedures described in Example 30 there was obtained 1,3-dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)-)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz. CDCl3) 8.7 (d, 1H), 8.5 (dd, 1H), 8.2 (br s, 1H), 7.65 (dt, 1H), 7.25-7.32 (br m.3H), 7.02-7.08 (m.3H), 4.35 (br m, 1H), 3.55 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.05 (br t, 2H), 1.86 (br m.4H).1.6 (br m, 2H), 1.4 (d, J = 7 Hz, 3H).
The trihydrochloride salt: Analysis calculated for C24H31N5O●3 HCl●2 H2O● 0.25 CH3CH2OH: C.52.31, H: 7.20, N: 12.20 ; found C: 52.61. H:6.87,N: 11.93. EXAMPLE 46
(1 ' ''R) 1 ,3-Dihydrc-1 -{1 '-[1 ''-(1 ' ''-(5'' ''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one
Step 1 : Sodium borohydride (1.75 g) was added in portions to a stirred solution of ace tylpyri dine (12.1 g) in ethanol (100 mL) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 20 min, then concentrated under reduced pressure to remove ethanol. The thick residue was diluted with 300 mL of dichloromethane, 25 mL of water and 5 mL of 20% NaOH. Thed aqueous layer was saturated with sodium chloride,and extracted with ethyl acetate (4 X 150 mL). The combined organic extracts were dried (MgSO4) and concentrated.
Evaporative distillation of the crude oily product (14.0 g) at 1mm, oven temperature 85-95°C gave 1 1.4 g of 3-(1 -hydroxyethyl)pyridine as a colorless oil.
Step 2: A mixture of 5 g of 3-( 1-hydroxyethyl)pyridine, 80 mL of t-butylmethylether, 0.85 g of lipase from Pseudomυnas fluorescens on Celite® (30 wt%, prepared as described by D. Bianchi, P. Cesti and E. Battistel, J. Org. Chem. 1988, 53 , 5531 -34) and 2.0 mL of acetic anhydride was allowed to stir in a stoppered flask for 24 h. The mixture was filtered and concentrated under reduced pressure. Low pressure chromatography on silica gel eluting with a gradient of 100% ethyl acetate to 95:5 ethyl acetate: methanol gave 3.5 g of the acetate of 3-(1'R-hydroxyethyl)pyridine followed by 2.4 g of 3-(1 'S-hydroxyethyl)pyridine. The enantiomeric purity assessed by HPLC on Chiracel OD (250×4.6 mm, 0.3% diethylamine in n-butyl chloride, isochratic) was 99%.
Step 3: To a stirred solution of 1.7 g of 3-(1 'S-hydroxyethyl)pyridine and 4.7 g of diphenylphosphoryl azide 20 mL of dry tetrahydrofuran cooled to 0 °C, was added 3.4 g of 1 ,8-diazabicyclo[5.4.0]undec-7-ene. The resulting mixture was allowed to warm to room temperature for 48 h., then loaded on a 10× 15 cm column of silica gel. Elution with ether give 1.7 g of 3-(1 'R-azidoethyl)pyridine as a colorless oil: [α]D25= + 78.6° (c = 5.75, MeOH); 1 H NMR (400 MHz, CDCl3 ) 8.59 (d, 1H), 8.58 (dd, 1H), 7.68 (dt, 1H), 7.33 (dd, 1H), 4.65 (q, 1H), 1.6 (d, 3H). Step 4: A mixture of 1.7 g of 3-( 1 'R-azidoethyl)pyridine, 0.25 g of 5% palladium on carbon and 150 mL of ethanol was stirred under an atmosphere of hydrogen at room temperature for 4 h. The mixture was filtered through a pad of celite and the filtrate concentrated under reduced pressure to yield 1.5 g of 3-( 1'R-aminoethyl)pyridine as a pale oil.
Step 5: To a stirred mixture of 1.5 g of 3-( 1 'R-aminoethyl)pyridine, 50 mL of ethanol and 1.54 g of K2CO3 heated to reflux was added dropwise over 40 min a solution of 4.5 g of 1 -ethyl-1 -methyl-4-oxopiperidinium iodide in water (80 mL). When the addition was complete, the mixture was heated under reflux for an additional 30 min, cooled and extracted with 3 X 100 mL portions of chloroform. The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. Column chromatography over silica gel, eluting with 50:50 ethyl acetate tetrahydrofuran gave 1.9 g of 1 -(1'R-(3"-pyridinyl)-ethyl)-4-oxopiperidine as an oil: 1H NMR (400 MHz, CDCl3) 8.61 (d, 1H), 8.52 (dd, 1H), 7.7 (dt, 1H), 7.28 (dd, 1H), 3.7 (q, 1H), 2.89-2.75 (m, 4H), 2.44 (t. 4H), 1.44 (d, 3H).
Step 6: A mixture of 1 -( 1'R-(3"-pyridinyl)-ethyl)-4-oxopiperidine (250 mg), 4-(2-oxo-1 -benzimidazolinyl)piperidine (530 mg), 1 ,2-dichloroethane (7 mL), glacial acetic acid (0.2 mL) and sodium
triacetoxyborohydride (450 mg) was stirred at room temperature for 48 h. The reaction mixture was partitioned between chloroform (3 × 50 mL) and saturated aqueous Na2CO3 (5 mL) and the combined organic layers dried over MgSO4 and concentrated under reduced pressure. Chromatography over silica gel, eluting with 95% tetrahydrofuran; 5% cone. NH4OH, followed by trituration with ethyl acetate gave 280 mg of ( 1'''R) 1,3-dihydro- 1 - { 1'-[ 1 ''-( 1 '''-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3 ) 8.54 (d, 1H), 8.49 (dd, 1H), 8.2 (br s, 1H), 7.65 (dt, 1H), 7.25-7.32 (br m. 3H). 7.02-7.08 (m. 3H), 4.35 (br m, 1H), 3.5 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.05 (br t, 2H), 1.86 (br m, 4H), 1.6 (br m, 2H), 1.39 (d, 3H).
The citrate salt: Analysis calculated for C24H31N5O● 1.5 C6H8O7: C: 57.13, H: 6.25, N: 10.10 found C: 57.48, H: 6.39, N: 10.35.
EXAMPLE 47
(1'',R) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one
From 1-(1'R-(3"-pyridinyl)-ethyl)-4-oxopiperidine using the procedure described in Example 46, but substituting 5-chloro-1-(4-piperidinyl) benzimidazol-2H-one for 1-(4-piperidinyl)benzimidazol-2H-one, there was obtained (1'''R) 1,3-dihydro-1-{1'-[1''-(1'''-(5'''' pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one as a white solid: mp 162-3°C; 1H NMR (400 MHz, CDCl3) 9.2 (br s, 1H), 8.56 (d, 1H), 8.51 (dd, 1H), 7.67 (dt, 1H), 7.28 (dd, 1H), 7.21 (d, 1H), 7.09 (d, 1H), 7.02 (dd, 1H), 4.35 (br m, 1H), 3.5 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.3-2.5 (m, 5H), 2.05 (br t, 2H), 1.86 (br m, 4H), 1.6 (br m, 2H), 1.4 (d.3H). The citrate salt: Analysis calculated for C25H33N5O●1.0 C6H8O7●1.0 CH3CO2CH2CH3O.5 H2O: C: 56.00, H: 6.50, N: 9.60 found C: 55.97, H: 6.42, N: 9.61. EXAMPLE 48
(1"'R) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one
From 1-(1'R-(3"-pyridinyl)-ethyl)-4-oxopiperidine using the procedure described in Example 46, but substituting 5-methyl-1-(4-piperidinyl) benzimidazol-2H-one for 1-(4-piperidinyl)benzimidazol-2H-one, there was obtained (1'''R) 1,3-dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)- ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one as a white solid: mp 176-8°C; 1H NMR (400 MHz, CDCl3) 8.54 (d, 1H), 8.49 (dd, 1H), 8.5 (br s, 1H), 7.65 (dt, 1H), 7.25 (dd, 1H), 7.17 (d, 1H), 6.88 (s, 1H), 6.84 (d, 1H), 4.35 (br m, 1H), 3.5 (q, J = 7 Hz, 1H), 3.0-3.1 (m, 3H), 2.85 (m, 1H), 2.5-2.3 (m, 5H), 2.36 (s, 3H), 2.05 (br t, 2H), 1.86 (br m, 4H), 1.6 (br m, 2H), 1.4 (d, 3H). The citrate salt:
Analysis calculated for C25H33N5O●1.0 C6H8O7●1.0 H2O: C: 59.12, H: 6.88, N: 11.12 found C: 59.47, H: 6.78, N: 10.78.
EXAMPLE 49
(±)-1,3-Dihydro-1-(1-{1-[1-(2-pyrazinyl)-1-ethyl]piperidin-4-yl}piperidin-4-yl)-5-methyl-2H-benzimidazol-2-one
From 1-(1-(2-pyrazinyl)-ethyl)-4-oxopiperidine using the procedure described in Example 44, but substituting 5-methyl-1-(4-piperidinyl)benzimidazol-2H-one for 1-(4-piperidinyl)benzimidazol-2H-one, there was obtained (1"'R) 1,3-dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 8.68 (m, 1H), 8.53 (m, 1H), 8.46 (m, 1H), 7.80 (br s, 1H), 7.17 (d, 1H), 6.86 (m, 2H), 4.31 (m, 1H), 3.73 (q, 1H), 3.12-3.03 (m, 3H), 2.87 (d, 1H), 2.43-2.26 (m, 5H), 2.36 (s, 3H), 2.08 (q, 2H), 1.86-1.75 (m, 4H), 1.70-1.52 (m, 2H), 1.43 (d.3H).
EXAMPLE 50
(±)-1,3-Dihydro-1-(1-{1-[1-(2-pyrazinyl)-1-ethyI]piperidin-4-yl}piperidin-4-yl)-5-chloro-2H-benzimidazol-2-one
From 1-(1-(2-pyrazinyl)-ethyl)-4-oxopi-eridine using the procedure described in Example 44, but substituting 5-chloro-1-(4-piperidinyl) benzimidazol-2H-one for 1-(4-piperidinyl)benzimidazol-2H-one, there was obtained (1"'R) 1,3-dihydro-1-{1"-[1''-(1",-(5''''-pyridinyl)- ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3 ) 10.60 (br s, 1H), 8.69 (d, 1H), 8.54 (dd, 1H), 8.46 (d, 1H), 7.21 (d, 1H), 7.12 (d, 1H), 7.00 (dd, 1H), 4.34 (m, 1H), 3.72 (q, 1H), 3.14-3.05 (m, 3H), 2.89 (d, 1H), 2.472.33 (m, 5H), 2.10 (m, 2H), 1.90-1.77 (m, 4H), 1.74-1.57 (m, 2H), 1.44 (d, 3H).
EXAMPLE 51
1 ,3-dihydro-1 -( 1 -{1 -[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one
Step 1 : To a stirred solution of 4.06 g of 5-pyrimidineacetic acid (F. Zymalkowski and E. Reimann, Arch. Pharm. 1966 299 362-7) and triethylamine (6.55 g) in methylene chloride (150 mL) at 0 °C was added ethyl chloroformate (6.38 g) followed by 4-dimethylaminopyridine (0.72 g). The mixture was stirred at 0 °C for 1 h, then the solution was diluted with methylene chloride (200 mL) and saturated ammonium chloride ( 150 mL) was added. After removal of the organic phase, the aqueous layer was extracted with methylene chloride (2 X 200 mL) and the combined organic extracts were dried over MgSO4 and concentrated to give 7.33 g of a crude oil.
Purification by column chromatography, eluting with hexane; 50% ethyl acetate gave ethyl 5-pyrimidinylacetate (3.98 g) as a colorless oil. Step 2: A solution of ethyl 5-pyrimidinylacetate (3.98 g) and
iodomethane (17.0 g) in dry THF (200 mL) was added to a solution of lithium bis(trimethylsilyl)amide (60 mmol) in dry THF (200 mL) at -70 °C at such a rate that the temperature did not rise above -65 °C. The reaction mixture was stirred under argon at -70 °C for 2 h, then allowed to warm to room temperature overnight and quenched with sulfuric acid (2.94 g) in water (100 mL). Saturated ammonium chloride (100 mL) was added, the THF layer was removed, and the aqueous phase was extracted with ethyl acetate (200 mL). The combined organic extracts were dried over MgSO4 and concentrated to give 4.64 g of ethyl 2-methyl-2-(5-pyrimidinyl)propionate as a colorless oil.
Step 3: A mixture of ethyl 2-methyl-2-(5-pyrimidinyl)propionate (4.64 g), 1.0 N lithium hydroxide (26 mL) and THF ( 100 mL) was heated to reflux under argon for 26 h. The mixture was allowed to cool, adjusted to pH 7 with acetic acid, and concentrated to dryness to give 4.1 1 g of lithium 2-methyl-2-(5-pyrimidinyl)propionate as a pale solid.
Step 4: A mixture of lithium 2-methyl-2-(5-pyrimidinyl)propionate (4.1 1 g), diphenylphosphoryl azide (13.2 g), triethylamine (4.86 g) and anhydrous tert-butyl alcohol (100 mL) was heated to reflux for 6 h, then allowed to cool and concentrated in vacuo. The residue was partitioned between chloroform (250 mL) and water ( 100 mL), and the chloroform was extracted, dried (MgSO4) and evaporated under reduced pressure. Chromatography on silica gel, eluting with
chloroform; 5% methanol gave a partially purified sample of 2-(5-pyrimidinyl)-2-propylisocyanate as a colorless oil.
Step 5: The crude 2-(5-pyrimidinyl)-2-propylisocyanate was treated with a mixture of 1.0 N sodium hydroxide (26 mL), water (20 mL) and THF ( 100 mL) at 0 °C for 30 min, then the mixture was poured into ethyl acetate (200 mL) and water (100 mL). The aqueous layer was acidified to pH 5 with 10% citric acid, extracted twice with ethyl acetate, and then adjusted to pH 1 1 , saturated with sodium chloride, and extracted with methylene chloride (3 X 250 mL). The combined methylene chloride extracts were dried (Na2SO4) and concentrated in vacuo to give 2-(5-pyrimidinyl)-2-propylamine (950 mg) as a colorless oil.
Step 6: To a stirred mixture of 2-(5-pyrimidinyl)-2-propylamine (660 mg), ethanol (9 mL) and K2CO3 (665 mg) heated to reflux was added dropwise over 30 min, a solution of 1 ,1-dimethyl-4-oxopiperidinium iodide (1.9 g) in water (36 mL). When the addition was complete, the mixture was heated under reflux for an additional 2 h, cooled, basified to pH 10 with Na2CO3 and extracted with ethyl acetate (3 ¥ 100 mL). The combined organic extracts were dried over MgSO4 and
concentrated under reduced pressure. Column chromatography over silica gel, eluting with a methylene chloride; 5% methanol gave 360 mg of 1 -(2-(5-pyrimidinyl)-prop-2-yl)-4-oxopiperidine as an oil: 1 H NMR (400 MHz, CDCl3) 9.13 (s, 1H), 8.95 (s, 2H), 2.79 (t, 4H), 2.44 (t, 4H), 1.47 (s, 6H).
Step 7: A mixture of 1 -(2-(5-pyrimidinyl)-prop-2-yl)-4-oxopiperidine ( 1 17 mg), 4-(2-oxo-1 -benzimidazolinyl)piperidine ( 128 mg), 1 ,2-dichloroethane (2.5 mL), glacial acetic acid (0.031 mL) and sodium triacetoxyborohydride ( 170 mg) was stirred at room temperature for 48 h. The reaction mixture was poured into dichloromethane (15 mL) and saturated aqueous Na2CO3 (8 mL) and the layers separated. The aqueous layer was extracted with dichloromethane (2 X 15 mL) and the combined organic layers dried over Na2SO4 and concentrated under reduced pressure. Purification by column chromatography, eluting with a gradient of methylene chloride: 0-6% methanol; 1 % NH4OH, followed by trituration with diethyl ether gave 104 mg of 1,3-dihydro-1 -( 1 -{ 1 -[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl }piperidin-4-yl)-2H-benzimidazol-2-one as a colorless solid: 1H NMR (400 MHz, CDCl3 ) 10.37 (br s, 1H), 9.10 (s, 1H), 8.88 (s, 2H), 7.30 (m, 1H), 7.12-7.01 (m, 3H), 4.37 (m, 1H), 3.1 1 (d, 2H), 2.86 (d, 2H), 2.53-2.30 (m, 5H), 2.18 (t, 2H), 1.85 (m, 4H), 1.57 (m, 2H), 1.40 (s, 6H). Treatment with citric acid in ethanol yielded the citrate salt, analysis calculated for C24H32N6O●0.1 H2O●1.5 C6H8O7: C: 55.78, H: 6.27, N: 1 1.83 found C: 55.82, H: 6.56, N: 11.68. EXAMPLE 52
1 ,3-dihydro-1 -(1 -{ 1 -[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-5-methyl-2H-benzimidazol-2-one From 1 -(1 -(2-pyrazinyl)-ethyl)-4-oxopiperidine using the procedure described in Example 51 , Step 7, but substituting 5-methyl-1 -(4-piperidinyl) benzimidazol-2H-one for 1 -(4-piperidinyl) benzimidazol-2H-one, there was obtained 1 ,3-dihydro-1-( 1 -{ 1 -[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl }piperidin-4-yl)-5-methyl-2H-benzimidazol-2- one as a colorless solid: 1H NMR (400 MHz, CDCl3 ) 10.64 (br s, 1H), 9.10 (s, 1H), 8.89 (s, 2H), 7.17 (d, 1H), 6.95 (s, 1H), 6.82 (d, 1H), 4.35 (m, 1H), 3.1 1 (d, 2H), 2.85 (d, 2H), 2.51-2.30 (m, 5H), 2.35 (s, 3H), 2.18 (t, 2H), 1.84 (m, 4H), 1.57 (m, 2H), 1.39 (s, 6H).
EXAMPLE 53
1 ,3-dihydro-1 -(1 -{1 -[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yI}piperidin-4-yl)-5-chloro-2H-benzimidazol-2-one
From 1 -( 1-(2-pyrazinyl)-ethyl)-4-oxopiperidine using the procedure described in Example 51 , Step 7, but substituting 5-chloro- 1-(4-piperidinyl) benzimidazol-2H-one for 1 -(4-piperidinyl) benzimidazol-2H-one, there was obtained 1,3-dihydro-1-(1-{ 1-[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl }piperidin-4-yl)-5-chloro-2H-benzimidazol-2-one as a colorless solid: 1H NMR (400 MHz, CDCl3 ) 10.70 (br s, 1H), 9.10 (s, 1H), 8.89 (s, 2H), 7.20 (d, 1H), 7.12 (d, 1H), 6.99 (dd, 1H), 4.33 (m, 1H), 3.1 1 (m, 2H), 2.86 (d, 2H), 2.46-2.31 (m, 5H), 2.35 (s, 3H), 2.18 (t, 2H), 1.84 (m, 4H), 1.56 (m, 2H), 1.40 (s, 6H).
EXAMPLE 54
1,3-dihydro-5-methyl-1 -( 1 -{1 -[2-(3-pyridyl)-prop-2-yl]piperidin-4-yl} piperidin-4-yl)-2H-benzimidazol-2-one
Using the procedures described in Example 51, but substituting 3-pyridineacetic acid for 5-pyrimidineacetic acid and 5-methyl-1 -(4-piperidinyl) benzimidazol-2H-one for 1 -(4-piperidinyl) benzimidazol-2H-one, there was obtained 1 ,3-dihydro-1 -( 1 -{ 1 -[2-(3-pyridinyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-5-methyl-2H-benzimidazol-2-one as a colorless solid: 1H NMR (400 MHz, CDCl3 ) 10.11 (br s, 1H), 8.76 (d, 1H), 8.46 (dd, 1H), 7.86 (dt, 1H), 7.25-7.17 (m, 2H), 6.93 (s, 1H), 6.84 (d, 1H), 4.35 (m, 1H), 3.12 (d, 2H), 2.87 (d. 2H), 2.51 -2.32 (m, 5H), 2.35 (s, 3H), 2.14 (t, 2H), 1.83 (m, 4H), 1.56 (m, 2H), 1.37 (s, 6H).
EXAMPLE 55
1,3-dihydro-(1-{1 -[2-(3-pyridyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one
Using the procedures described in Example 51 , but substituting 3-pyridineacetic acid for 5-pyrimidineacetic acid there was obtained 1 ,3-dihydro-1 -(1 -{ 1 -[2-(3-pyridinyl)-prop-2-yl]piperidin-4-yl }piperidin-4-yl)-2H-benzimidazol-2-one as a colorless solid: 1H NMR (400 MHz, CDCl3) 10.35 (br s, 1H), 8.76 (d, 1H), 8.46 (dd, 1H), 7.86 (dt, 1H), 7.32 (m, 1H), 7.23 (dd, 1H), 7.10 (m, 1H), 7.02 (m, 2H), 4.38 (m, 1H), 3.13 (d, 2H), 2.87 (d, 2H), 2.54-2.32 (m, 5H), 2.14 (t, 2H), 1.84 (m, 4H), 1.56 (m, 2H), 1.37 (s, 6H).
EXAMPLE 56 1,3-dihydro-1 -{1 -[1 -(2-phenyl-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 1,3-dihydro-1 -{ 1 -[ 1-piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one dihydrochloride salt and 2-phenyl-5-pyrimidinecarboxylic acid (P. Schenone, L. Sansebastiano and L. Mosti, J. Heterocychc Chem., 1990, 27 , 295-305) using the procedure described for Example 3, there was obtained 1 ,3-dihydro-1 -{ 1 -[ 1 -(2-phenyl-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a solid: 1H NMR (400 MHz, CDCl3) 8.88 (s, 2H). 8.49 (m, 2H), 8.05 (s. 1H), 7.52 (m. 2H), 7.27 (m. 3H), 7.06 (m, 2H), 4.79 (br s, 1H), 4.34 (m, 1H), 3.90 (s, 1H), 3.09 (d, 4H), 2.66 (t, 1H), 2.43 (m, 1H), 1.87 (m, 5H). The dihydrochloride salt: Analysis calculated for C28H30N6O2●2 HCl● 0.20 CHCl3● 0.65 CH3CH2OH: C: 61.85, H: 6.18, N: 14.67 found C: 61.90. H: 6.32, N: 14.68. EXAMPLE 57
1,3-Dihydro-1-{1-[1-(3-pyridinesulfonyI)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From 1,3-dihydro-1-{1-[1-piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one dihydrochloride salt and pyridine-3-sulfonylchloride (B. I. Alo, O. B. Familoni, F. Marsais and G.
Queguiner, J. Hetcrocyd. Chem.19922961-4.) using the procedure described for Example 1, Step 4 there was obtained 1,3-dihydro-1-{1-[1-(3-pyridinesulfonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.01 (s, 1H), 8.84 (m, 1H), 8.18 (s, 1H), 8.07 (m, 1H), 7.50 (m, 1H), 7.25 (m, 2H), 7.06 (m, 2H), 4.26 (m, 1H), 3.92 (m, 2H), 3.00 (m, 3H), 2.39 (m, 5H), 1..79 (m, 4H), 1.30 (m, 2H), 0.88 (m, 1H). The dihydrochloride salt: Analysis calculated for C22H29CI2N5O3S● 2 HCl● 0.8 C7H8● 2.0 H2O C: 53.10, H: 6.36, N: 11.22 found C: 53.02, H: 6.40, N: 11.15.
EXAMPLE 58
1,3-dihydro-1-{1-[1-(2-methyI-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one From 1,3-dihydro-1-{1-[1-piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one dihydrochloride salt and 2-methyl-5-pyrimidinecarboxylic acid (P. Schenone, L. Sansebastiano and L. Mosti, J. Heterocyclic Chem., 1990, 27 , 295-305) using the procedure described for Example 3, there was obtained 1,3-dihydro-1-{1-[1-(2-methyl-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one dihydrochloride salt as a solid: 1H NMR (400 MHz, d6-DMSO) 8.80 (m, 2H), 7.79 (d, 1H).7.25 (m, 2H), 7.16 (m, 2H), 4.68 (m, 1H), 4.47 (m, 1H), 4.16 (m, 1H), 2.93 (m, 4H), 2.68 (m, 1H), 2.31 (m, 5H), 1.88 (m, 5H), 1.21 (s, 3H). Analysis calculated for C23H28N6O2● 2 HCl● 1.55 CH3CO2CH2CH3●2.5 CH3CH2OH: C:
57.96, H: 8.02, N: 11.86; found C: 57.56, H: 8.11, N: 12.24.
EXAMPLE 59
1,3-Dihydro-1 -{1 -[1 -(5-pyrimidinylmethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
From the procedure in Example 8, substituting pyrimidine-5-carboxaldehyde for 3-pyridinecarboxaldehyde (H. Bredereck, G.
Simchen, H. Wagner and S. Santos, Liebigs Ann. Chem. 1971 766 73-88.) there was obtained 1 ,3-dihydro-1-{ 1-[ 1-(5-pyrimidinylmethyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3 ) 9.06 (s, 1H), 8.62 (s, 2H), 8.44 (s, 1H), 7.27 (s, 2H), 7.06 (s, 2H), 6.36 (s, 2H), 3.05 (m, 3H), 2.24 (m, 3H), 2.04 (m, 2H), 1.92 (m, 2H), 1.67 (m, 3H), 1.26 (m, 2H), 0.94 (m, 3H).The dihydrochloride salt: Analysis calculated for
C22H28N6O● 2HCl●1.3 C7H8● 2.0 H2O: C: 60.03, H: 7.35, N: 13.51 ; found C: 60.07, H: 7.46, N: 13.46.
EXAMPLE 60
1,3-Dihydro-1 -{1 -[1 -(4-imidazolylmethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one From the procedure in Example 8. substituting imidazole-4-carboxaldehyde for 3-pyridinecarboxaldehyde there was obtained 1 ,3-dihydro-1 -{ 1-[1-(4-imidazolylmethyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3 ) 8.98 (s, 1H), 7.63 (s, 1H), 7.28 (s, 2H), 7.05 (s, 2H), 6.97 (s, 1H), 3.08 (m, 3H), 2.40 (m, 5H), 2.17 (t, 2H), 2.05 (s, 2H), 1.85 (m, 2H), 1.70 (m, 2H), 1.27 (m, 2H), 0.89 (m, 1H).The trihydrochloride salt: Analysis calculated for C21H28N6O● 3HCl● 1.7 C7H8●0.1 H2O: C: 49.1 1 , H:
6.88, N: 15.84: found C: 48.93, H: 6.48, N: 15.48. EXAMPLE 61
1,3-dihydro-1 -{1 -[1 -(2-amino-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one
Step 1 : A mixture of 0.65 g of ethyl 2-amino-5-pyrimidinecarboxylate (P. Schenone, L. Sansebastiano and L. Mosti, J. Heterocyclic Chem., 1990, 27 , 295-305) , 1.7 g of di-tert-butyldicarbonate and 50 mL of dichloromethane was allowed to stir overnight then concentrated under reduced pressure. After drying under vacuum, there was obtained 0.75 g of ethyl 2-tert-butoxycarbonylamino-5-pyrimidinecarboxylate as a solid: 1H NMR (400 MHz, CDCl3 ) 9.23 (s, 2H), 4.42 (q, 2H), 1.5 (s, 9H), 1.45 (t, 3H).
Step 2: A mixture of 200 mg of ethyl 2-tert-butoxycarbonylamino-5-pyrimidinecarboxylate, 125 mg of potassium hydroxide and 15 mL of ethanol was heated to 70°C for 3 h, cooled and concentrated under reduced pressure. The residue was dissolved in 50 mL of ice water, washed with 50 mL of ether, acidified to pH= 3 with cone. HCl and extracted with 3 X 50 mL of chloroform. The combined organic extracts were dried (MgSO4) and concentrated under reduced pressure. Drying under vacuum gave 156 mg of 2-tert-butoxycarbonylamino-5-pyrimidinecarboxylic acid as a white solid.
Step 3 : From 1,3-dihydro-1 -{ 1 -[ 1-piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one dihydrochloride salt and 2-tert-butoxycarbonylamino-5-pyrimidinecarboxylic acid using the procedure described for Example 3, there was obtained 1 ,3-dihydro- 1 -{ 1 -[ 1 -(2-tert-butoxycarbonylamino-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl }-2H-benzimidazol-2-one as a solid: 1H NMR (400 MHz, CDCl3 ) 9.95 (m, 1H), 8.81 (s, 2H), 7.28 (m, 2H), 7.08 (m, 2H), 4.77 (s, 1H), 4.35 (m, 1H), 3.80 (s, 1H), 3.12 (m, 4H). 2.88 (m, 1H), 2.68 (m, 1H), 2.45 (m, 5H), 1.92 (m, 5H), 1.50 (s, 3H).
Step 4: The 1 ,3-dihydro-1-{ 1 -[ 1 -(2-tert-butoxycarbonylamino-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl } -2H-benzimidazol-2-one was dissolved in ethyl acetate, cooled to -50°C and treated with a stream of HCl gas for 2 min. The reaction mixture was allowed to warm to room temperature and stir for several hours, and then concentrated to dryness under reduced pressure. The product 1 ,3-dihydro-1-{1-[1-(2-amino-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one dihydrochloride salt, was obtained as white solid: Analysis calculated for C22H25N7O2● 2 HCl●1.0 C7H8●3.0 H2O: C: 54.38, H: 6.77, N: 15.31; found C: 54.31, H: 6.48, N: 15.23. EXAMPLE 62
(1'''R)-1,3-Dihydro-1-{1'-[1''-(1'''-phenylethyI)piperidin-4"-yl]piperidin-4'-yI}-2H-benzimidazol-2-one From (R)-(+)-1-phenethylamine using the procedures described in Example 30 there was obtained (1'"R)-1,3-dihydro-1-{1'-[1''-(1'''-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.4 (br s, 1H), 7.65 (dt, 1H), 7.25-7.32 (m, 6H).7.02-7.08 (m, 3H), 4.35 (br m, 1H), 3.42 (q, 1H), 3.18 (d, 1H), 3.10 (d, 2H), 2.90 (d, 1H), 2.45-2.30 (m, 5H), 1.98 (t.1H), 1.86 (br m, 4H), 1.8-1.5 (m, 3H), 1.4 (d, 3H). Analysis calculated for C25H32N4O●0.5 H2O: C: 72.60, H: 8.04, N: 13.55 ; found C: 72.54, H: 7.88. N: 13.17. EXAMPLE 63
(1'''S)-1,3-Dihydro-1-{1'-[1''-(1'''-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one From (S)-(-)-1-phenethylamine using the procedures described in Example 30 there was obtained (1'''S)-1,3-dihydro-1-{1'-[1''-(1"'-phenylethyl)piperidin-4"-yl]piperidin-4-yl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3) 9.4 (br s, 1H), 7.65 (dt, 1H), 7.25-7.32 (m.6H), 7.02-7.08 (m, 3H), 4.35 (br m, 1H), 3.42 (q, 1H), 3.18 (d, 1H), 3.10 (d, 2H), 2.90 (d, 1H), 2.45-2.30 (m, 5H), 1.98 (t, 1H), 1.86 (br m, 4H), 1.8-1.5 (m, 3H), 1.4 (d, 3H). Analysis calculated for C25H32N4O●0.5 H2O●0.25 CH3CH2OH: C: 72.82, H:
8.15, N: 13.32 ; found C: 72.72 H: 7.85, N: 12.97.
EXAMPLE 64
(1'''R)-1,3-Dihydro-1-{1'-[1''-(2'''-hydroxy-1'''-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one
From (R)-(-)-2-amino-2-phenylethanol using the procedures described in Example 30 there was obtained (1'"R)-1,3-dihydro-1-{1'-[1''-(2'''-hydroxy-1'"-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3 + CD3OD) 7.35 (m, 5H), 7.25 (d, 2H), 7.05 (m, 3H), 4.35 (br m, 1H), 4.0 (dd, 1H), 3.70 (m, 2H), 3.60 (s, 3H), 3.08 (m, 3H), 2.95 (d, 1H), 2.5-2.2 (m, 5H), 1.98-1.7 (m, 5H), 1.55 (m.1H). Analysis calculated for C25H32N4O●0.25 H2O: C: 70.64, H: 7.71, N: 13.18 ; found C: 70.43, H: 7.57, N: 12.99.
EXAMPLE 65
(1'''S)-1,3-Dihydro-1-{1'-[1''-(2''',-hydroxy-1'''-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one
From (S)-(+)-2-amino-2-phenylethanol using the procedures described in Example 30 there was obtained (1'"R)-1,3-dihydro-1-{1'-[1''-(2'"-hydroxy-1'''-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one as a white solid: 1H NMR (400 MHz, CDCl3+ CD3OD) 7.35 (m, 5H), 7.25 (d, 2H), 7.05 (m, 3H), 4.35 (br m, 1H), 4.0 (dd, 1H).3.70 (m, 2H), 3.60 (s.3H), 3.08 (m, 3H), 2.95 (d, 1H), 2.5-2.2 (m, 5H), 1.98-1.7 (m, 5H).1.55 (m, 1H). Analysis calculated for C25H32N4O●0.25 H2O: C: 70.64, H: 7.71, N: 13.18 ; found C: 70.76, H: 7.62, N: 12.96.
EXAMPLE 66
1,3-Dihydro-1-{1-[trans -4-hydroxycyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one
Step 1: To a stirred solution of 1,3-dihydro-1-{1-[4-oxocyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one (100 mg) in methanol (4 mL) at 0°C, under nitrogen, was added tert-butylamine-borane (28 mg). The reaction mixture was stirred at 0°C for 1 h, then quenched with water (2 mL) and concentrated to remove the methanol. The resulting oil was dissolved in ethyl acetate (50 mL) and the organic solution was washed with saturated sodium carbonate (10 mL), then water (10 mL), then brine (10 mL) and then dried over sodium sulfate. Concentration under reduced pressure yielded trans-1,3-dihydro-1-{1-[4-hydroxycyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one (75 mg) as a colorless solid: 1H NMR (400 MHz, CD3OD) 7.42 (m, 1H), 7.04 (m, 3H), 4.28 (m, 1H), 3.50 (m, 1H), 3.09 (m, 2H), 2.45 (m, 5H), 2.031.94 (m, 4H), 1.78-1.75 (m, 2H), 1.44-1.26 (m, 4H). The
hydrochloride salt was precipitated from diethyl ether/chloroform:
analysis calculated for C18H25N3O2●HCl●0.50 H2O●0.70 CHCl3
C: 50.54, H: 6.28, N: 9.45; found C: 50.54, H: 6.19, N: 9.64.
EXAMPLE 67 cis -1,3-Dihydro-1-{1-[4-hydroxycyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one
Step 1: To a stirred solution of 1,3-dihydro-1-{1-[4-oxocyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one (100 mg) in dry
tetrahydrofuran (25 mL) at -78°C, under nitrogen, was added L-Selectride (0.385 mL of a 1.0 M solution in tetrahydrofuran). The reaction mixture was stirred at -78 °C for 30 min, then quenched with water (3 mL). The solution was allowed to warm to room temperature and ethyl acetate (50 mL) was added. The organic layer was washed with saturated sodium carbonate (10 mL), then water (10 mL), then brine (10 mL) and then dried over sodium sulfate. Concentration under reduced pressure yielded cis-1 ,3-dihydro-1 -{ 1-[4-hydroxycyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one (43 mg) as a colorless solid: 1H NMR (400 MHz, CD3OD) 7.42 (m, 1H), 7.05 (m, 3H), 4.32 (m, 1H), 3.94 (m, 1H), 3.17 (m, 2H), 2.53 (m, 5H), 1.88- 1.71 (m, 8H), 1.59-1.53 (m, 2H). The hydrochloride salt was precipitated from diethyl ether/methylene chloride: analysis calculated for
C1 8H25N3O2●HCl●0.70 H2O
C: 59.48, H: 7.32, N: 1 1.56; found C: 59.46, H: 7.28, N: 1 1.23. EXAMPLE 68
Radioligand Binding Studies
The affinity of muscarinic antagonists for ml-m5
receptors expressed in Chinese hamster ovary cells (CHO) were determined using the technique described by Dorje et al., J.
Pharmacol. Exp. Ther. 256: 727-733 (1991).
When 80- 100% confluent, CHO cells were harvested, and transferred to centrifuge tubes containing CHO buffer (20 mM HEPES at pH 7.4 containing 5mM MgCl2). The cells were
homogenized using a Brinkman Polytron homogenizer for 30
seconds at a setting of 5, on ice. The homogenate was centrifuged at 40,000 × g for 15 minutes at 4°C in a Beckman J2-21 M centrifuge.
The supernatant was discarded and the
homogenization/centrifugation step repeated once. Pelleted
membranes were resuspended in CHO buffer to a concentration of one flask harvested (75 cm2) per mL of buffer, mixed well and aliquoted in cryovials ( 1mL/vial). The vials were stored at -70°C until used in the assay. The binding incubation was done in
polypropylene macrowell tube strips in a final volume of 0.5 mL of HEPES buffer (20 mM; pH 7.4 containing 5 mM MgCl2) containing 0.1 mL of cell membrane suspension, 3H-N-methylscopolamine (NEN Corporation, NET-636, 70-87 Ci/mmole) at a final
concentration of approximately 0.2 nM and the competing drug in a varying range of concentrations or vehicle. After the addition of the cell homogenate the tubes were agitated on a vortex mixer and then placed in a water bath at 32°C. After 90 minutes of incubation, the membranes were harvested on a Skatron filtermat (#1 1734) or a Wallac filtermat (#205-404) using three washes of HEPES buffer (4°C). The radioactivity on the filters was counted in a Packard 2200CA scintillation counter or in a Wallac 1205 Betaplate scintillation counter. Specific binding was defined as the difference in binding observed in the presence and absence of 10 micromolar atropine and accounted for at least 80% of total binding. Ki values were calculated using the program LIGAND. Compounds displayed Ki values at m1 , m2 and m4 in the range of InM to 5,000 nM. All compounds described herein displayed typically greater than 300-fold less potency at the m3 receptor subtype, in the range of 300 nM to 1 14,000 nM. EXAMPLE 69 ml receptor antagonist activity on the rabbit vas deferens
The technique described by Feifel et al., Brit. J.
Pharmacol. 99: 455-460 (1990) was used as follows: Male Hazelton New Zealand White rabbits weighing 1.5-3 kg, are euthanized
(phenobarbital sodium, 85 mg/kg. i. v.). An abdominal incision is made and the vas deferens are removed. The tissues are placed in a Petri dish containing oxygenated Krebs solution [NaCl, 1 18 mM; KCl, 4.7 mM; CaCl2, 2.5 mM; KH2PO4, 1.2 mM; MgSO4, 1.2 mM; NaHCO3, 25 mM; dextrose, 1 1 mM] warmed to 30°C. Each tissue is cut into three 2-cm segments: proximal to the prostate, a middle section, and distal to the prostate. Only the first two segments are used.Tissue segments are attached to platinum electrodes with 4-0 surgical silk and placed in a 10 mL jacketed tissue bath containing Krebs buffer at 30°C, bubbled with 5% CO2 / 95% O2. The tissues are connected to a Statham-Gould force transducer; 0.75 gram of tension is applied and the tissues are electrically stimulated. [EFS parameters are 0.05 Hz; 0.5 ms duration; voltage is set to 30% of 50 V at 25 ohms and increased until a supramaximal voltage is achieved.] The contractions are recorded on a Gould strip chart recorder. The tissues are washed every 20 minutes and allowed to equilibrate. A concentration response curve to the selective ml receptor agonist McN-A-343 is determined. Tissues are washed every 20 minutes for 60 minutes. The vehicle or compound is added to the bath and the tissues are incubated for 30 minutes, then the McN-A-343 concentration response is repeated. EC50 values are determined for both vehicle and tissues treated with the compound before and after treatment. Antagonist dissociation constants (Kb) are calculated by the dose-ratio method. Compounds displayed Kb values at m l generally consistent with the radioligand binding assay described in Example 30 in the range of 5 to 100 nM.
EX AMPLE 70 m2 receptor antagonist activity on the guinea pig left atria
The technique described by Feifel et al., Brit. J.
Pharmacol. 99: 455-460 ( 1990) was used as follows: Duncan-Hartley guinea pigs (Hazelton) weighing 300-600 g, are asphyxiated with CO2. The abdomen is opened and the left atria is rapidly removed. The tissues are placed in a Petri dish containing
oxygenated Krebs solution [NaCl, 1 18 mM; KCl, 4.7 mM; CaCl2, 2.5 mM; KH2PO4, 1.2 mM; MgSO4 , 1.2 mM; NaHCO3, 25 mM;
dextrose, 1 1 mM] warmed to 37°C. Each atria is attached to platinum electrodes with 4-0 surgical silk and placed in a 10 mL jacketed tissue bath containing Krebs buffer at 37°C, bubbled with 5% CO2 / 95% O2. The tissues are connected to a Statham-Gould force transducer; 0.75 gram of tension is applied and the tissues are electrically stimulated. [EFS parameters are 3 Hz; 4 ms duration; voltage is set to 5 V.] The contractions are recorded on a Gould strip chart recorder. The tissues are washed every 20 minutes and allowed to equilibrate. A concentration response curve to the agonist carbachol is determined. Tissues are washed every 20 minutes for 60 minutes. The vehicle or compound is added to the bath and the tissues are incubated for 30 minutes, then the carbachol
concentration response is repeated. EC50 values are determined for both vehicle and compound treated tissues before and after
treatment. Antagonist dissociation constants (Kb) are calculated by the dose-ratio method. Compounds displayed Kb values at M2 generally consistent with the radioligand binding assay described in Example 30 in the range of 5 to 100 nM.
EX AMPLE 71
M3 receptor antagonist activity on the guinea pig ileum longitudinal muscle
The technique described by Feifel et al., Brit. J.
Pharmacol. 99: 455-460 (1990) was used as follows: Duncan-Hartley guinea pigs (Hazelton) weighing 300-600 g, are asphyxiated with CO2. The abdomen is opened and the caecum and the distal end of the ileum are identified. The ileum is removed and 5 cm of the terminal end (proximal to the caecum) is discarded. The lumen of the remainder is flushed with oxygenated Krebs solution [NaCl, 1 18 mM; KCl, 4.7 mM; CaCl2, 2.5 mM: KH2PO4, 1.2 mM; MgSO4 , 1.2 mM; NaHCO3, 25 mM; dextrose, 1 1 mM] warmed to 30°C. The ileum is cut into 2.5 cm segments and each segment is mounted on a glass pipette. A scalpel is used to lightly cut the surface of the tissue and a cotton swab used to tease the longitudinal muscle free from the underlying circular muscle. Longitudinal muscle segments are attached to glass tissue holders with 4-0 surgical silk and placed in a 10 mL jacketed tissue bath containing Krebs buffer at 30°C, bubbled with 5% CO2 / 95% O2. The tissues are connected to a Statham-Gould force transducer. One gram of tension is applied and the contractions are recorded on a Gould strip chart recorder. The tissues are washed every 20 minutes and allowed to equilibrate. A concentration response curve to the agonist carbachol is determined. Tissues are washed every 20 minutes for 60 minutes. The vehicle or compound is added to the bath and the tissues are incubated for 30 minutes, then the carbachol concentration response is repeated. EC50 values are determined for both vehicle and tissues treated with the compound before and after treatment. Antagonist dissociation constants (Kb) are calculated by the dose-ratio method. Compounds displayed Kb values at M3 generally consistent with the radioligand binding assay described in Example 30 in the range of 3900 to 24000 nM.
EXAMPLE 72 ml and m3 receptor antagonist activity on the human muscarinic receptors expressed in CHO cells
Preconfluent CHO cells were labeled for 24 hours with 4 μCi/mL of [3H] myo-inositol (specific activity 15-20 Ci /mmole). The cells were detached from flasks using 1 mM EDTA in phosphate buffer saline, centrifuged for 5 minutes at 200x g, and resuspended in assay buffer (1 16 mM NaCl; 10 mM LiCl; 4.7 mM KCl; 1.2 mM MgSO4 ; 2.5 mM CaCl2; 1.2 mM KH2PO4; 5 mM NaHCO3; 1 1 mM dextrose, 20 mM HEPES; pH 7.4 at 37°C) to the desired volume. Four hundred microliters of the cell suspension (approximately 2 X 106 cells) was added to tubes containing buffer or compound and left at room temperature for 30 minutes. Muscarinic agonist (carbachol) was then added and the cells incubated for 30 minutes at 37°C. The reaction was stopped using an acid solution (12% perchloric acid / 3 mM EDTA / 1 mM diethylenetriamine pentaacetic acid) and the tubes placed on ice for 15 minutes. The samples were then
neutralized with 3M KOH / 0.25 M 2-(N-morpholino)ethane sulfonic acid / 0.25 M 3-(N-morpholino) propane sulfonic acid and
centrifuged at 3000x g for 15 minutes. Five hundred microliters of each supernatant was diluted to 5.5 mL with water and the entire tube contents applied to anion exchange columns. The columns are sequentially washed with 5 mL of H2O, 15 mL of 60 mM ammonium formate / 5 mM borax and 8 mL of 200 mM ammonium formate / 5 mM borax. The radioactivity in the last eluate was determined by liquid scintillation counting and taken as the amount of [3H]-inositol monophosphate formed during the incubation. Two different types of experiments were performed: IC50 values for compounds where calculated using a fixed concentration of carbachol , or Kb values were generated by performing carbachol concentration-response curves in the absence and presence of a fixed concentration of compound. Compounds displayed Kb values at ml and m3 generally consistent with the radioligand binding assay described in Example 30 in the range of 1 to 100 nM at m 1 and 4,000 to 20,000 at m3.
EXAMPLE 73 m2 receptor antagonist activity on the human muscarinic receptors expressed in CHO cells
Preconfluent CHO cells were harvested using 1 mM
EDTA in phosphate buffer saline and washed one time by
centrifugation in a HEPES buffered physiological salt solution. The cell concentration was adjusted to 3.3 X 106 cells / mL in the HEPES buffer containing 1.3 micromolar isobutylmethylxanthine. Three hundred microliters of the cell suspension was added to tubes containing compound and incubated for 15 minutes at room
temperature. Muscarinic agonist (50 microliters of carbachol; 1 micromolar final concentration) was then added followed by 20 microliters of 200 μM forskolin and the tubes were incubated at 30°C for an additional 15 minutes. The reaction was stopped by placing the tubes in boiling water for 5 minutes. The tubes were cooled on ice and then centrifuged at 12,000 xg for 10 minutes. Fifty microliters of each supernatant was then analyzed for cAMP using a commercially available radioimmunoassay kit following the manufacturer's instructions. Two different types of experiments were performed: IC50 values for compounds where calculated using a fixed concentration of carbachol , or Kb values were generated by performing carbachol concentration-response curves in the absence and presence of a fixed concentration of compound. Compounds displayed Kb values at m2 generally consistent with the radioligand binding assay described in Example 30 in the range of 1 to 100 nM.

Claims

WHAT IS CLAIMED IS:
1.
Figure imgf000105_0001
wherein:
C is carbon
H is hydrogen
N is nitrogen
O is oxygen
S is sulfur
P is phosphorus
X, Y, and Z are independently = N, or CH;
J is independently = NB or CB2;
K is independently = NB, CB2, O, carbonyl,
thiocarbonyl, sulfonyl, phosphonyl, NBCO, NBCO2, NBCB2, COCB2, CONB, CO2, CO2B, NB2,
NBCONB2, CB2COCB2, CB2CONB, NBCOCB2, or OB;
W is O or H2;
A is (CH2 )n, (CBH)n, (CB2)n, C=O, or C=S, wherein n is 0, 1 or 2: m, o & k are 0, 1 or 2;
B is H, Me, Et, Pr, iPr, CH2OH, CO2Me, CO2Et,
CH2CH2OH, CONH2, OH, NH2. NHMe,
NMe2, OMe, OEt, CONHMe, or CONMe2
Q is phenyl or heterocycle ring unsubstituted or
substituted with Me, Et, Pr, Bu, hydroxyl, alkoxy, F, Cl, Br, I, alkylsulfonyl, phenyl or
heterocyclic;
D, E, F & G are chosen from:
Figure imgf000106_0001
Figure imgf000107_0001
where:
R is ind ependent ly taken from H, small alkyl , branch
alkyl, halo, alkoxy, OH, amino, dialkylamino, or
alkylamino.
2. Compounds of Claim 1, wherein X=N, Y=CH, m=0, A is not present, B=H, and D,E,F and G are CR where R is defined as above.
3. The compound of Claim 1 which is
1,3-dihydro-1-{1-[1-(4-nitrobenzoyl)piperidin-4-yl]piperidin-4-y1}-2H- benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-nitrobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H- benzimidazol-2-one, 1,3-dihydro-1-{1-[1-benzyl-4-piperidinyl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(2-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-benzoylpiperidin-4-yl]piperidin-4-y1}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridinecarbonyl)-4-piperidinylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyridinecarbonyl)-4-piperidinylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-furoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]piperidin-4-yl]-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2,3,4,5,6-pentafluorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1 ,3-dihydro-1-{1-[1-(3-benzo[b]thiophenecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5,6-dichloro-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1 ,3-dihydro-1-{1-[1-(2-benzofurancarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[trans-1-benzyloxycarbonylamino-4-cyclohexylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[trans-1-phthalimido-4-cyclohexylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[trans-4-phthalimidomethyl-1-cyclohexyl]piperidin-4-yl]-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-napthyl)piperidin-4-yl]piperidin-4-y1}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-methoxybenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(3-chloro-2-benzo[b]thiophenecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2,4,6-trichlorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-isoxazolyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3,5-dimethyl-4-isoxazolyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[trans-1-(4-nitrobenzamido)-4-cyclohexylmethyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[trans-4-ethoxycarbonyl-1-cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-nitrobenzyl)-4-piperidinyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(benzyloxycarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one. 1,3-dihydro-1-{1-[trans-4-hydroxymethyl-1-cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-fluorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-bromobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-iodobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3,4-dimethoxybenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-nitro-2-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[trans-1-phthalimido-4-cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-methoxy-4-amino-5-chlorobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-dimethylaminobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-nitrobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-cyanobenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-methoxycarbonylbenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-(3-pyridyl)acrylyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-nitro-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-methyl-2-pyrazolin-1-yl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-quinolinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-acetylbenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-methoxybenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-phenylbenzoyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(2-methyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-amino-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-quinolinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-phenyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-methyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-(4-morpholinyl)-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridylmethyloxycarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridylacetyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one. 1,3-dihydro-1-{1-[1-(4-methyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyridylacetyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-methyl-3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl]-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridylmethylaminocarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2R-(1,1-dimethylethoxycarbonylamino)-3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2S-(1,1-dimethylethoxycarbonylamino)-3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyridylthioacetyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, (4'''R,5'''S) and (4'''S,5"'R) 1,3-dihydro-1-(1'-(1''-(1'''-methyl-2'''-oxo-5'''-(3""-pyridyl)-4'"-pyrrolidinecarbonyl)piperidin-4"-yl)piperidin-4'-yl)-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(2S-amino-3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-yl]-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2R-amino-3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(3-pyridyloxyacetyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-(3-pyridyl)propionyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{trans-4-[4-(3-pyridinecarbonyl)piperazin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yI]piperidin-4-yl}-1H-3,4-dihydroquinazolin-2-one, 1,3-dihydro-1-{1-[1-(4-pyridylsulfonyl)acetyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-amino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1 ,3-dihydro-1-{1-[1-(4-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-imidazolecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{trans-4-[4-(4-nitrobenzoyl)piperazin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{trans-4-[1-(3-pyridinecarbonyl)-4-piperidinylamino]-1-cyclohexyl}-2H-benzimidazol-2-one,
5-methyl-1,3-dihydro-1-{1-[1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{trans-4-[4-(5-pyrimidinecarbonyl)piperazin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-amino-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridinemethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{ 1-[1 -(6-methoxy-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-methyl-1,3-dihydro-1-{ 1-[ 1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-fluoro-1,3-dihydro-1-{ 1 -[1 -(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-chloro- 1 ,3-dihydro-1-{ 1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
4-fluoro- 1,3-dihydro-1-[ 1-[ 1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl]-2H-benzimidazol-2-one,
6-fluoro-1,3-dihydro-1-{ 1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
7-fluoro- 1,3-dihydro-1 -{ 1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
6-methyl-1,3-dihydro-1 -{ 1 -[ 1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1 ,3-dihydro-1 -{ 1 -[ 1-(2-amino-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{ 1-[ 1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{ 1-[1-(6-methylamino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{ 1-[ 1-(6-dimethylamino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{ 1-[1-(6-piperidino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{ 1-[ 1-(6-pyrrolidinyl-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 5-methyl-1,3-dihydro-1-{1-[1-(5-pyrimidinemethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{trans-4-[4-(5-pyridinecarbonylamino)piperidin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(4-pyridazinecarbonyl)piperidin-4-yl]piperidin-4-yl]-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-benzyloxy-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-chloro-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
4-methyl-1,3-dihydro-1-{1-[1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-ethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-methoxy-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-hydroxy-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-ethoxy-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-(2-hydroxyethoxy)-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(6-amino-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-3-{1-[1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-2-oxo-imidazo[4,5-b]pyridine, 1,3-dihydro-1-{1-[trans-4-(3-pyridinecarbonylamino)cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[4-(1,3-dihydro-2-oxo-2H-benzimidazolin-1-yl)cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[cis-4-(3-pyridinecarbonylamino)cyclohexyl]piperidin-4-yl}-2H-benzimidazol-2-one, 5-propyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-butyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 5-(1-methylethyl)-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-(1-hydroxyethyl)-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
4-methyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
4-ethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5,6-dimethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
4,5-dimethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[1-(5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-1H-3,4-dihydroquinazolin-2-one, (±)-1,3-Dihydro-1-{1-[1-(1-(5-pyrimidinyl)-ethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
(1'''S) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'"R) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'''S) 1,3-Dihydro-1-{1'-[1''-(1"'-(5''"-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one,
(1'''R) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one, (1'''S) 1,3-Dihydro-1-{1'-[1''(1'''-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one,
(1'''R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[4-oxocyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one, cis-1,3-Dihydro-1-{1-[1-(5-pyrimidinylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[1-(5-pyrimidinylamino)cyclohex-4-yl]piperidin-4-yl]-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{4-[4-(3-pyridinylmethyl)piperazin-1-yl]-1-cyclohexyl}-2H-benzimidazol-2-one,
1 ,3-Dihydro-1-{1-[1-(2-pyrazinylmethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, (±)-cis-1,3-Dihydro-1-(1-{4-[(5-pyrimidinyl)hydroxymethyl]cyclohex-1-yl}piperidin-4-yl)-2H-benzimidazol-2-one,
(±)-trans-1,3-Dihydro-1-(1-{4-[(5-pyrimidinyl)hydroxymethyl]cyclohex-1-yl}piperidin-4-yl)-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[4-(5-pyrimidinylcarbonyl)cyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one, cis-1,3-Dihydro-1-{1-[1-(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[1-(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
(±)-1,3-Dihydro-1-(1-{1-[1-(2-pyrazinyl)-ethyl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one,
(±) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)-ethyl)piperidin-4''-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'''R) 1,3-Dihydro-1-{1'-[1''-(1'''-(5,m-pyridinyl)-ethyl)piperidin-4''-yl]piperidin-4'-yl}-2H-benzimidazol-2-one, (1"'R) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyridinyl)-ethyl)piperidin-4''-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one,
( 1'"R) 1,3-Dihydro-1-{1'-[1"-(1'"-(5''''-pyridinyl)-ethyl)piperidin-4''-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one,
(±)-1,3-Dihydro-1-(1-{1-[1-(2-pyrazinyl)-1-ethyl]piperidin-4-yl}piperidin-4-yl)-5-methyl-2H-benzimidazol-2-one,
(±)-1,3-Dihydro-1-(1-{1-[1-(2-pyrazinyl)-1-ethyl]piperidin-4-yl}piperidin-4-yl)-5-chloro-2H-benzimidazol-2-one, 1,3-dihydro-1-(1-{1-[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one,
1,3-dihydro-1-(1-{1-[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-5-methyl-2H-benzimidazol-2-one,
1,3-dihydro-1-(1-{1-[2-(5-pyrimidinyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-5-chloro-2H-benzimidazol-2-one,
1,3-dihydro-5-methyl-1-(1-{1-[2-(3-pyridyl)-prop-2-yl]piperidin-4-yl}piperidin-4-yl)-2H-benzimidazol-2-one,
1,3-dihydro-(1-{1-[2-(3-pyridyl)-prop-2-yl]piperidin-4-yl]piperidin-4-yl)-2H-benzimidazol-2-one,
1,3-dihydro-1-{1-[1-(2-phenyl-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[1-(3-pyridinesulfonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-methyl-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
1,3-Dihydro-1-{1-[1-(5-pyrimidinylmethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[1-(4-imidazolylmethyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-amino-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, (1 '''R)-1,3-Dihydro-1-{1'-[1"-(1"'-phenylethyl)piperidin-4''-yl]piperidin-4'-yl}-2H-benzimidazol-2-one, (1'''S)-1,3-Dihydro-1-{1'-[1"-(1'"-phenylethyl)piperidin-4''-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'"R)-1,3-Dihydro-1-{1'-[1"-(2"'-hydroxy-1"'-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'"S)-1,3-Dihydro-1-{1'-[1"-(2"'-hydroxy-1'"-phenylethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[4-hydroxycyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one, or cis-1,3-Dihydro-1-{1-[4-hydroxycyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one.
4. The compound of Claim 2 which is
5-methyl-1,3-dihydro-1-{1-[1-(3-pyridinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, 1,3-dihydro-1-{1-[1-(3-pyridinemethyl)piperidin-4-yl]piperidin-4-yl}- 2H-benzimidazol-2-one,
5-methoxy-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one. 5-methyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
5-ethyl-1,3-dihydro-1-{1-[1-(5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, (1'"R) 1,3-Dihydro-1-{1'-[1''-(1'''-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'''R) 1,3-Dihydro-1-{1'-[1''-(1"'-(5"''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one,
(1'"R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyrimidinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one, 1,3-Dihydro-1-{1-[4-oxocyclohex-1-yl]piperidin-4-yl}-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[1-(5-pyrimidinylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one, trans-1,3-Dihydro-1-{1-[1-(3-pyridylamino)cyclohex-4-yl]piperidin-4-yl}-2H-benzimidazol-2-one,
(1'"R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyridinyl)-ethyl)piperidin-4''-yl]piperidin-4'-yl}-2H-benzimidazol-2-one,
(1'"R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-chloro-2H-benzimidazol-2-one, or
(1'''R) 1,3-Dihydro-1-{1'-[1''-(1'"-(5''''-pyridinyl)-ethyl)piperidin-4"-yl]piperidin-4'-yl}-5-methyl-2H-benzimidazol-2-one.
5. A method for the treatment or prevention of abnormal increase in eye axial length in an animal in need thereof, which comprises the step of ocularly administering to said animal a pharmacologically effective amount of a muscarinic pharmacological agent known to be selective for m1, m2 and m4 receptors, but less active at m3 receptors.
6. A method for the treatment or prevention of abnormal increase in eye axial length in an animal in need thereof, which comprises the step of ocularly administering to said animal a pharmacologically effective amount of a muscarinic pharmacological agent of Claim 1 , known to be selective for m 1 , m2 and m4
receptors, but less active at m3 receptors.
7. A method of alleviating or controlling the development of amblyopia in the eye of an animal in need thereof, which comprises administering to such an animal a
pharmacologically effective amount of a compound of Claim 1.
8. A composition useful for the treatment or prevention of abnormal increase in eye axial length in an animal in need thereof, which comprises a pharmacologically effective amount of a muscarinic pharmacological agent, known to be selective for ml, m2 and m4 receptors, but less active at m3 receptors, in a carrier or diluent buffered to a pH suitable for ocular
administration.
9. A composition useful for the treatment or prevention of abnormal increase in eye axial length in an animal in need thereof, which comprises a pharmacologically effective amount of a muscarinic pharmacological agent of Claim 1 , known to be selective for ml , m2 and m4 receptors, but less active at m3 receptors, in a carrier or diluent buffered to a pH suitable for ocular administration.
PCT/US1995/013710 1994-10-27 1995-10-24 Muscarine antagonists WO1996013262A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU39674/95A AU701127B2 (en) 1994-10-27 1995-10-24 Muscarine antagonists
EP95937615A EP0786997A4 (en) 1994-10-27 1995-10-24 Muscarine antagonists
JP51469196A JP2002515008A (en) 1994-10-27 1995-10-24 Muscarinic antagonist

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/329,757 US5574044A (en) 1994-10-27 1994-10-27 Muscarine antagonists
US08/440,153 US5691323A (en) 1995-05-12 1995-05-12 Muscarine antagonists
US440,153 1995-05-12
US329,757 1995-05-12

Publications (1)

Publication Number Publication Date
WO1996013262A1 true WO1996013262A1 (en) 1996-05-09

Family

ID=26986957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013710 WO1996013262A1 (en) 1994-10-27 1995-10-24 Muscarine antagonists

Country Status (5)

Country Link
EP (1) EP0786997A4 (en)
JP (1) JP2002515008A (en)
AU (1) AU701127B2 (en)
CA (1) CA2200468A1 (en)
WO (1) WO1996013262A1 (en)

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751647A1 (en) * 1996-07-25 1998-01-30 Synthelabo BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATIONS AND THEIR THERAPEUTIC APPLICATIONS
WO1998017646A1 (en) * 1996-10-21 1998-04-30 Dr. Karl Thomae Gmbh 1-(4-piperdinyl)-piperidinylene as aggregation inhibitor
WO1999032479A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
EP0990653A1 (en) * 1997-05-30 2000-04-05 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
WO2001044213A1 (en) * 1999-12-17 2001-06-21 Astrazeneca Ab New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
EP1221443A1 (en) * 1999-10-13 2002-07-10 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
WO2002085890A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
JP2003513088A (en) * 1999-10-29 2003-04-08 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and methods for their preparation
WO2003028650A3 (en) * 2001-10-02 2003-06-19 Acadia Pharm Inc Benzimidazolidinone derivatives as muscarinic agents
WO2003103669A1 (en) * 2002-04-18 2003-12-18 Schering Corporation 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists
WO2003105781A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2004069828A1 (en) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation Piperidine compound and medicinal use thereof
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
US6881754B2 (en) 1999-12-17 2005-04-19 Astrazeneca Ab Adamantane derivatives
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
EP1598339A1 (en) * 2001-04-18 2005-11-23 Euro-Celtique S.A. 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
WO2007007890A1 (en) * 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxoimidazole derivative
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
WO2007036715A3 (en) * 2005-09-30 2007-05-18 Glaxo Group Ltd Compounds which have activity at m1 receptor and their uses in medicine
WO2007107566A1 (en) * 2006-03-22 2007-09-27 Glaxo Group Limited Benzimidazoles which have activity at m1 receptor and their uses in medicine
WO2007107567A1 (en) * 2006-03-22 2007-09-27 Glaxo Group Limited Benzimidazoles which have activity at m1 receptor and their uses in medicine
WO2007107565A1 (en) * 2006-03-22 2007-09-27 Glaxo Group Limited Benzimidazoles which have activity at m1 receptor and their uses in medicine
WO2007142583A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia.
WO2007142585A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
WO2008119721A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119713A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119717A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119715A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119718A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119720A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119719A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
US7501425B1 (en) 1998-05-26 2009-03-10 Warner Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation
WO2009124883A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel 1,3-dihydro-benzoimidazol-2-ones as m1 agonists
WO2009136850A1 (en) * 2008-05-05 2009-11-12 Astrazeneca Ab Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia
US7745623B2 (en) 2004-05-21 2010-06-29 Takeda Pharmaceutical Company Limited Cyclic amide derivative, and its production and use
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US8288413B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
US8288412B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8344000B2 (en) 2007-09-20 2013-01-01 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2013130890A1 (en) * 2012-02-29 2013-09-06 Amgen Inc. Heterobicyclic compounds and their use as phosphodiesterase inhibitors
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
WO2017058805A1 (en) * 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9840516B2 (en) 2013-10-10 2017-12-12 Araxes Pharma Llc Substituted quinazolines as inhibitors of KRAS G12C
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US9926267B2 (en) 2013-03-15 2018-03-27 Araxes Pharma Llc Covalent inhibitors of K-Ras G12C
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2018174149A1 (en) * 2017-03-23 2018-09-27 Singapore Health Services Pte Ltd Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
WO2018174145A1 (en) * 2017-03-23 2018-09-27 Singapore Health Services Pte Ltd Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising umeclidinium as active ingredient
US10111874B2 (en) 2014-09-18 2018-10-30 Araxes Pharma Llc Combination therapies for treatment of cancer
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
CN109996792A (en) * 2016-10-14 2019-07-09 赫普泰雅治疗有限公司 With the active heterocyclic compound in treatment CNS disease and pain as the regulator of muscarinic M 1 and/or M4 receptor
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
US11773090B2 (en) 2018-06-22 2023-10-03 Heptares Therapeutics Limited Pharmaceutical compounds
US11793817B2 (en) 2011-11-18 2023-10-24 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
US11945801B2 (en) 2018-12-07 2024-04-02 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090102810A (en) * 2006-12-26 2009-09-30 큐엘티 플러그 딜리버리, 인코포레이티드 Drug delivery implants for inhibition of optical defects
UY31346A1 (en) * 2007-09-20 2009-04-30 COMPOUNDS THAT HAVE ACTIVITY IN THE RECEIVER M1 AND ITS USES IN MEDICINE
EP2194982A1 (en) * 2007-09-20 2010-06-16 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
JP2017507959A (en) * 2014-03-13 2017-03-23 ボドール ラボラトリーズ， インコーポレイテッド Use of selected anticholinergic zwitterions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5284843A (en) * 1988-06-03 1994-02-08 Trustees Of The University Of Penna. Pharmacological treatment of ocular development
US5322847A (en) * 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
US5284843A (en) * 1988-06-03 1994-02-08 Trustees Of The University Of Penna. Pharmacological treatment of ocular development
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5322847A (en) * 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0786997A4 *

Cited By (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004546A1 (en) * 1996-07-25 1998-02-05 Synthelabo Benzimidazole derivatives, preparation thereof, and therapeutical uses thereof
FR2751647A1 (en) * 1996-07-25 1998-01-30 Synthelabo BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATIONS AND THEIR THERAPEUTIC APPLICATIONS
WO1998017646A1 (en) * 1996-10-21 1998-04-30 Dr. Karl Thomae Gmbh 1-(4-piperdinyl)-piperidinylene as aggregation inhibitor
US6258825B1 (en) 1997-05-30 2001-07-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
EP0990653A1 (en) * 1997-05-30 2000-04-05 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
EP0990653A4 (en) * 1997-05-30 2001-04-11 Banyu Pharma Co Ltd 2-oxoimidazole derivatives
WO1999032479A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
US7501425B1 (en) 1998-05-26 2009-03-10 Warner Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation
US6933319B2 (en) 1999-03-22 2005-08-23 Pfizer Inc. Resorcinol derivatives
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
EP1221443A1 (en) * 1999-10-13 2002-07-10 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
US6699880B1 (en) 1999-10-13 2004-03-02 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
EP1221443A4 (en) * 1999-10-13 2002-11-04 Banyu Pharma Co Ltd Substituted imidazolidinone derivatives
JP2003513088A (en) * 1999-10-29 2003-04-08 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and methods for their preparation
US6881754B2 (en) 1999-12-17 2005-04-19 Astrazeneca Ab Adamantane derivatives
US7132457B2 (en) 1999-12-17 2006-11-07 Astrazeneca Ab Adamantane derivatives
US7297818B2 (en) 1999-12-17 2007-11-20 Astrazeneca Ab Adamantane derivatives
CN1304382C (en) * 1999-12-17 2007-03-14 阿斯特拉曾尼卡有限公司 New p2X7 receptor antagonists for use in the treatment of inflammatory immune or cardiovascular diseases
US6812226B2 (en) 1999-12-17 2004-11-02 Astrazeneca Ab P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular disease
WO2001044213A1 (en) * 1999-12-17 2001-06-21 Astrazeneca Ab New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
EP1598339A1 (en) * 2001-04-18 2005-11-23 Euro-Celtique S.A. 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
WO2002085890A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
US7164024B2 (en) 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
WO2003028650A3 (en) * 2001-10-02 2003-06-19 Acadia Pharm Inc Benzimidazolidinone derivatives as muscarinic agents
KR100809569B1 (en) * 2001-10-02 2008-03-04 아카디아 파마슈티칼스 인코포레이티드 Benzimidazolidinone derivatives as muscarinic agents
US7291611B2 (en) 2001-10-02 2007-11-06 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A3 (en) * 2001-10-02 2004-11-25 Acadia Pharm Inc Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US7087593B2 (en) 2001-10-02 2006-08-08 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US7300928B2 (en) 2001-10-02 2007-11-27 Acadia Pharmaceuticals, Inc. Benzimidazolidinone derivatives as muscarinic agents
US7273857B2 (en) 2001-10-02 2007-09-25 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
JP2006206603A (en) * 2002-04-18 2006-08-10 Schering Plough Corp 1-(4-piperidinyl)benzimidazolone as histamine h3 antagonist
US7220735B2 (en) 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists
JP2005529161A (en) * 2002-04-18 2005-09-29 シェーリング　コーポレイション 1- (4-Piperidinyl) benzimidazolone as a histamine H3 antagonist
WO2003103669A1 (en) * 2002-04-18 2003-12-18 Schering Corporation 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists
WO2003105781A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2005532361A (en) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド Ophthalmic composition for the treatment of ocular hypertension
US7279490B2 (en) 2002-06-17 2007-10-09 Merck & Co, Inc. Ophthalmic compositions for treating ocular hypertension
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
WO2004069828A1 (en) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation Piperidine compound and medicinal use thereof
US8697865B2 (en) 2004-05-21 2014-04-15 Takeda Pharmaceutical Company Limited Cyclic amide derivative, and its production and use
US7745623B2 (en) 2004-05-21 2010-06-29 Takeda Pharmaceutical Company Limited Cyclic amide derivative, and its production and use
WO2007007890A1 (en) * 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxoimidazole derivative
US8288412B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
KR101374458B1 (en) * 2005-09-30 2014-03-17 글락소 그룹 리미티드 Compounds which have activity at m1 receptor and their uses in medicine
US8481566B2 (en) 2005-09-30 2013-07-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
AU2006296369B2 (en) * 2005-09-30 2012-12-20 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8288413B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
EA016286B1 (en) * 2005-09-30 2012-03-30 Глэксо Груп Лимитед Compounds which have activity at mreceptor and their uses in medicine
WO2007036715A3 (en) * 2005-09-30 2007-05-18 Glaxo Group Ltd Compounds which have activity at m1 receptor and their uses in medicine
WO2007107567A1 (en) * 2006-03-22 2007-09-27 Glaxo Group Limited Benzimidazoles which have activity at m1 receptor and their uses in medicine
WO2007107566A1 (en) * 2006-03-22 2007-09-27 Glaxo Group Limited Benzimidazoles which have activity at m1 receptor and their uses in medicine
WO2007107565A1 (en) * 2006-03-22 2007-09-27 Glaxo Group Limited Benzimidazoles which have activity at m1 receptor and their uses in medicine
CN101448495B (en) * 2006-03-22 2013-05-08 葛兰素集团有限公司 Benzimidazoles which have activity at m1 receptor and their uses in medicine
US20120316202A1 (en) * 2006-03-22 2012-12-13 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US20120309789A1 (en) * 2006-03-22 2012-12-06 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2007142583A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia.
WO2007142585A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
US7956069B2 (en) 2006-06-09 2011-06-07 Astrazeneca Ab Compounds
WO2008119720A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119717A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119713A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119715A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119718A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119721A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119719A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US8344000B2 (en) 2007-09-20 2013-01-01 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2009124883A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel 1,3-dihydro-benzoimidazol-2-ones as m1 agonists
WO2009136850A1 (en) * 2008-05-05 2009-11-12 Astrazeneca Ab Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia
CN102083812A (en) * 2008-05-05 2011-06-01 阿斯利康(瑞典)有限公司 Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia
US11793817B2 (en) 2011-11-18 2023-10-24 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
US9174992B2 (en) 2012-02-29 2015-11-03 Amgen Inc. Heterobicyclic compounds
WO2013130890A1 (en) * 2012-02-29 2013-09-06 Amgen Inc. Heterobicyclic compounds and their use as phosphodiesterase inhibitors
US10030012B2 (en) 2013-02-07 2018-07-24 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
US10273207B2 (en) 2013-03-15 2019-04-30 Araxes Pharma Llc Covalent inhibitors of kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US10919850B2 (en) 2013-03-15 2021-02-16 Araxes Pharma Llc Covalent inhibitors of KRas G12C
US9926267B2 (en) 2013-03-15 2018-03-27 Araxes Pharma Llc Covalent inhibitors of K-Ras G12C
US10927125B2 (en) 2013-10-10 2021-02-23 Araxes Pharma Llc Substituted cinnolines as inhibitors of KRAS G12C
US9840516B2 (en) 2013-10-10 2017-12-12 Araxes Pharma Llc Substituted quinazolines as inhibitors of KRAS G12C
US10370386B2 (en) 2013-10-10 2019-08-06 Araxes Pharma Llc Substituted quinolines as inhibitors of KRAS G12C
US11878985B2 (en) 2013-10-10 2024-01-23 Araxes Pharma Llc Substituted quinazolines as inhibitors of KRAS G12C
US10111874B2 (en) 2014-09-18 2018-10-30 Araxes Pharma Llc Combination therapies for treatment of cancer
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10829458B2 (en) 2015-04-10 2020-11-10 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10351550B2 (en) 2015-07-22 2019-07-16 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058805A1 (en) * 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US11021470B2 (en) 2015-11-16 2021-06-01 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10723738B2 (en) 2016-09-29 2020-07-28 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US11834407B2 (en) 2016-10-14 2023-12-05 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US10759751B2 (en) 2016-10-14 2020-09-01 Heptares Therapeutics Limited Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US11014880B2 (en) 2016-10-14 2021-05-25 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
CN109996792A (en) * 2016-10-14 2019-07-09 赫普泰雅治疗有限公司 With the active heterocyclic compound in treatment CNS disease and pain as the regulator of muscarinic M 1 and/or M4 receptor
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
JP7016880B2 (en) 2017-03-23 2022-02-07 シンガポール ヘルス サービシーズ ピーティーイー リミテッド Myopia prophylaxis, myopia treatment and / or myopia progression inhibitor containing tiotropium as an active ingredient
WO2018174145A1 (en) * 2017-03-23 2018-09-27 Singapore Health Services Pte Ltd Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising umeclidinium as active ingredient
WO2018174149A1 (en) * 2017-03-23 2018-09-27 Singapore Health Services Pte Ltd Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
US11642350B2 (en) 2017-03-23 2023-05-09 Singapore Health Services Pte Ltd Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
JP2020514347A (en) * 2017-03-23 2020-05-21 シンガポール ヘルス サービシーズ ピーティーイー リミテッド Myopia prevention, myopia treatment and / or myopia progression inhibitor containing tiotropium as an active ingredient
US11377441B2 (en) 2017-05-25 2022-07-05 Araxes Pharma Llc Covalent inhibitors of KRAS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
US11773090B2 (en) 2018-06-22 2023-10-03 Heptares Therapeutics Limited Pharmaceutical compounds
US11945801B2 (en) 2018-12-07 2024-04-02 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists

Also Published As

Publication number Publication date
AU3967495A (en) 1996-05-23
CA2200468A1 (en) 1996-05-09
EP0786997A1 (en) 1997-08-06
EP0786997A4 (en) 1998-03-11
JP2002515008A (en) 2002-05-21
AU701127B2 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
AU701127B2 (en) Muscarine antagonists
US5574044A (en) Muscarine antagonists
US5691323A (en) Muscarine antagonists
JP5335426B2 (en) Diarylamine-containing compounds and compositions and their use as modulators of C-KIT receptors
AU2005208887B2 (en) Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
AU687017B2 (en) Heterocyclic ether compounds that enhance cognitive function
US20070027118A1 (en) Novel compounds of amino sulfonyl derivatives
US5756508A (en) Muscarine antagonists
AU2011291110B2 (en) Pyrimidine derivatives as FAK inhibitors
CA2315117C (en) Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission
EP1912989A2 (en) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
PL192397B1 (en) Derivatives of piperidine substituted at their position 4 with 1,2-substituted 1-piperidinyl radical a antagonists of tachykinin receptor
CA2607874A1 (en) Quinoline derivatives as neurokinin receptor antagonists
CA2810696A1 (en) Pyrazoloquinoline compound
WO1997016192A1 (en) Muscarine antagonists
JP2012532916A (en) Spiroamino compounds especially suitable for the treatment of sleep disorders and drug addiction
CA3127284A1 (en) Thiazolopyridine derivatives as adenosine receptor antagonists
CA3073333A1 (en) Bezimidazole derivatives as adenosine receptor antagonists
US5852016A (en) Quinoxaline derivatives useful in therapy
WO1997016187A1 (en) Muscarine antagonists
JP2918508B2 (en) Azetidines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US US UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2200468

Country of ref document: CA

Ref country code: CA

Ref document number: 2200468

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995937615

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995937615

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995937615

Country of ref document: EP